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FunCtionAL PeLViC FLoor DisorDers
Symptoms related to the dysfunction of the pelvic floor can disrupt dramatically the 
lives of the men and women who are affected by it. In clinical practice, functional 
disorders are conditions impairing the normal function and are not primarily due to 
a mechanical disorder or anatomical abnormality. Symptoms relating to dysfunction 
of the pelvic floor include involuntary loss of urine, pelvic organ prolapse, inability to 
control the passage of stool or flatus, and sexual dysfunction. 
A few of the most commons symptoms are described:
Urinary incontinence: The loss of bladder control  leading to persistent involuntary 
urine leakage is a symptom caused by underlying physical problems or changes, for 
instance after treatment of prostate cancer; an obstruction (e.g. enlarged prostate or 
tumor) hindering the normal flow of urine; aging of the bladder muscle resulting in 
a decrease of the bladder’s capacity to store urine; damage of the supporting pelvic 
floor muscles (e.g. due to childbirth or surgery); or spinal injury (e.g. spinal cord injury, 
multiple sclerosis) interfering with nerve signals involved in bladder control. Different 
types of urinary incontinence can be distinguished, that is: stress urinary incontinence 
with symptoms of occasionally leaking of urine upon elevated abdominal pressure 
(for instance during coughing or sneezing); urge urinary incontinence with symptoms 
of having suddenly a strong urge to urinate leading to involuntarily urine loss; or a 
variation of both (mixed urinary incontinence). 
Pelvic floor disorders: A weakening of the muscles and ligaments supporting women’s 
pelvic organs – including uterus, vagina, bladder, small bowel or rectum – can lead to 
vaginal bulging due to sliding of these organs (prolapse). Pelvic floor disorders are seen 
usually years after childbirth, hysterectomy, menopause, or any combination of the 
above. Conditions associated with pelvic floor disorders include underactive bladder, 
obstructed urination or urinary incontinence, constipation, obstructed defecation or 
fecal incontinence, and sensation of prolapse (e.g. feeling of heaviness). 
Fecal incontinence: The inability to control bowel movements can cause stool (feces) 
to leak from the rectum unexpectedly. Fecal incontinence ranges from an occasional 
leakage of stool while passing gas to a complete loss of bowel control. Common causes 
include diarrhea, constipation, and muscle or nerve damage of the anal sphincter. The 
muscle or nerve damage may be associated with aging, vaginal child delivery, pelvic 
surgery or spinal trauma. 
Sexual dysfunction: Problems in any phase of the sexual response cycle, which 
consists of  desire, excitement, sensation of orgasm and satisfaction,1 can cause sexual 
dysfunction. In both men and women the origin of sexual dysfunction can be physical 
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General introduction
(e.g. erectile dysfunction or ejaculation problems, pelvic floor disorders), psychologi-
cal (e.g. stress, anxiety, past sexual trauma), or both. 
Although above described functional disorders of the pelvic floor are as a rule not 
life-threatening, they often limit daily activities and may significantly influence physi-
cal, psychological, and social well-being of the affected individuals.2 In the general 
population - depending on age, etiology, and the definition used - urinary inconti-
nence affects approximately 30% to 60% of women and up to 29% of men3,4, prolapse 
approximately 4-15% of women3, and fecal incontinence up to 15% of both men and 
women5. Based on the considerable prevalence and clinical consequences, functional 
disorders of the pelvic floor are a serious health problem. 
ComPonents oF ADequAte PAtient CAre 
Outcomes are fundamental measures of success in health care to provide for adequate 
patient care. When evaluating the efficacy of patient care for those with pelvic floor 
dysfunction, studies focused on measurable (objective of semi-objective) symptoms 
are useful to estimate disease burden and the effect of medical interventions. Examples 
of such traditional outcome measures are parameters obtained from urodynamic stud-
ies, voiding diaries and ultrasound results. Patient reported outcome measures (PROMs) 
are often standardized, validated questionnaires which are completed by patients to 
measure their perception of their functional well-being and health status.6 PROMs 
represent patient’s health-related quality of life (HRQOL), and provide as such another 
dimension of the efficacy of various treatment modalities than traditional outcome 
measures. Moreover, PROMs could assist to manage patient expectation and improve 
patient satisfaction.7 Consequently, PROMs can be used to support shared decision-
making, communication, and appropriate evaluation of individual treatment success. 
As physicians tend to assess superior valuation to traditional outcome measures - 
whereas patients tend to evaluate higher importance to the impact of symptoms on 
quality of life8 -  the use of PROMs has the potential to narrow the gap between the 
clinician’s and patient’s view of clinical reality and help tailor treatment plans to meet 
the patient’s personal preferences and needs9. 
Considering that generic HRQOL measures lack sensitivity to the unique aspects 
of a specific disease10,11,  disease-specific HRQOL measures are regarded to be more 
applicable in capturing the impact of a particular disease. Suitable disease-specific 
PROMs have been developed and are currently recommended by the International 
Continence Society.12 However, these measure tend to be English, and a measure that 
is valid and reliable for a particular language and culture may not prove so when used 




the population of interest can be assessed by testing its psychometric measurement 
properties.14 So far, short, practical, and validated Dutch PROMs evaluating HRQOL of 
men and women with functional disorders of the pelvic floor are lacking. 
Another essential contribution to adequate patient care is evidence based medicine. 
Evidence based medicine is the “conscientious, explicit and judicious use of current 
best evidence in making decisions about the care of individual patients”.15 To address 
a specific research or clinical question, systematic reviews collects all evidence ac-
cording to pre-specified eligibility criteria using systematic methods to minimize bias. 
By integrating individual clinical expertise with the best available external clinical 
evidence from systematic research clinical practice guidelines can be developed. 
To optimize treatment and promote more uniform approaches to specific aspects of 
patient care, evidence based guidelines are required. An example of such evidence 
based guidelines is the European Association of Urology (EAU) Guidelines on Neuro-
Urology.16 
Aims oF this thesis
This thesis focuses on evaluating functional disorders of the urogenital tract in men 
and women, using traditional outcome measures along with PROMs. In this thesis, we 
aim to:
1. Evaluate the urodynamic changes in patients treated with Adjustable Continence 
Therapy for men (ProACT) for post-prostatectomy incontinence and to explore 
the clinical and urodynamic preimplantation parameters as predictors of clinical 
outcome.
2. Develop linguistically adapted and psychometrically adequate PROMs for assess-
ing symptom distress and HRQOL of urogenital functional disorders in Dutch. 
3. Assess the effectiveness of different surgical therapies for the treatment of func-
tional bladder outlet obstruction in adults with neurogenic bladder dysfunction.
4. Compose Dutch multidisciplinary guidelines consisting of guiding decisions and 
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Urodynamic effects of 
volume-adjustable balloons 
for treatment of post-
prostatectomy urinary 
incontinence
Elaine Utomo, Jan Groen, Irene H. Vroom,  






To evaluate the urodynamic changes in patients treated with Adjustable Continence 
Therapy for men (ProACT) for post-prostatectomy incontinence and to explore the 
clinical and urodynamic pre-implantation parameters as predictors of clinical out-
come.
methods
Patients underwent urodynamic studies before and after ProACT implantation. Pro-
ACT was considered successful if patients used none or 1 dry precautionary pad and 
non-successful if the patient reported ≥1 wet pad/day. The pre- and post-implantation 
assessments were retrospectively compared within and between the success and non-
success groups. Multivariate logistic regression analysis was performed to investigate 
the association between the pre-implantation variables and the clinical outcomes of 
ProACT implantation.
results 
A total of 49 patients were included, 37 with successful and 12 with non-successful 
clinical outcome. Post-implantation urodynamic studies were performed a median of 
9 months after ProACT implantation. In the successfully treated patients, maximum 
free flow rate, bladder contractility index, maximum of bladder contractility param-
eter w, and bladder voiding efficiency were significantly lower after implantation. 
The detrusor pressure at maximum flow rate, post void residual urine volume, and 
bladder outlet obstruction index were significantly higher. A longer duration of urinary 
incontinence, the use of >5 pads daily, and a smaller cystometric bladder capacity 
were all independently associated with non-successful clinical outcome after ProACT 
implantation.
Conclusion 
ProACT implantation with successful clinical outcome resulted in greater urethral 
resistance during voiding and reduced bladder contraction strength. A longer duration 
of incontinence, the use of >5 pads daily, and a smaller cystometric bladder capacity 
were independent predictors of unsuccessful clinical outcomes, suggesting ProACT 
implantation should be considered sooner, rather than later, after conservative treat-





Men who have undergone radical prostatectomy (RP) for prostate cancer are at risk of 
stress urinary incontinence (SUI). The prevalence of post-prostatectomy incontinence 
(PPI) has ranged from 2% to nearly 60%.1 PPI is a distressing disorder that affects men’s 
quality of life2 and often requires treatment. Surgical techniques can be considered if 
conservative treatment fails. Implantation of an artificial urinary sphincter (AUS) has 
been the reference standard surgical treatment of PPI; however, recently, less-invasive 
and less-expensive techniques have been introduced as potential alternatives.3
The Adjustable Continence Therapy system for men (ProACT, Uromedica, Min-
neapolis, MN) is a minimally invasive implant, consisting of 2 volume-adjustable 
balloons.4  These balloons are placed paraurethrally just beneath the bladder neck. 
Each balloon is attached by a conduit to a port placed subcutaneously in the scrotum, 
allowing for separate volume adjustments after the initial implantation using an iso-
tonic solution of contrast medium. The balloon volume is adjusted to create bilateral 
urethral compression. The balloons are adjusted until continence is achieved and the 
optimal balance between bladder emptying and continence has been obtained.
The clinical results of ProACT reported during the past few years have shown dry 
or improved rates ranging from 56% to 92%.5-7 Nevertheless, the urodynamic working 
mechanism of ProACT implantation is not fully understood and needs additional elu-
cidation. For instance, it is unknown whether the bilateral compression causes greater 
urethral resistance, and whether this resistance affects bladder contractility.
Various studies have shown acceptable to good reproducibility in diagnosing blad-
der outlet obstruction using urodynamic studies (UDS), varying from same session 
testing8-10 to repeated testing within 6 months.8,10 We, therefore, performed a study 
to evaluate the urodynamic changes in patients treated with ProACT for PPI and to 
explore which clinical and urodynamic pre-implantation parameters are associated 
with the non-successful clinical outcome of ProACT implantation.
methoDs
Since May 2007, ProACT balloons have been used at our department for the treatment 
of male SUI. The ProACT implantation procedure has been previously described.4 In 
brief, using fluoroscopic guidance, 2 balloons were placed immediately adjacent to 
the urethra at the level of the bladder neck by way of 2 small incisions in the perineum. 
Each balloon was then filled with 1 mL of isotonic contrast medium solution. All implan-
tation procedures were performed by the same surgeon. The patients were assessed 
after implantation at regular 3-4-week intervals. If required, we adjusted the balloon 
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volume with a maximum of 1 mL in each balloon per visit by way of the subcutaneous 
port sited in the scrotum.
The local ethical committee approved the retrospective analysis of the data from all 
patients who had undergone Pro-ACT implantation for PPI. All patients who had un-
dergone ProACT implantation for PPI in our clinic until June 2012 with UDS available 
before and after ProACT implantation, were eligible for inclusion in the present analy-
sis. The exclusion criteria for ProACT implantation included external radiotherapy for 
positive margins, salvage radiotherapy for increased prostate-specific antigen levels 
after RP,4,11 and bladder neck sclerosis or urethral stenosis. The data collected from the 
patient medical charts included date of birth, date of RP, previous treatment of SUI, the 
use of anticholinergics, the reported number of incontinence pads used daily (PPD) 
before ProACT implantation, the date of ProACT implantation, the number of ProACT 
balloon adjustments and total ProACT balloon volume after implantation; the reported 
use of PPD after Pro-ACT balloon adjustments, and a non-validated Dutch translation 
of the bother question12 of the International Prostate Symptom Score13 (IPSS-BQ). The 
IPSS-BQ is a single disease-specific quality-of-life question that assesses the degree to 
which patients find their symptoms bothersome. The score of the IPSS-BQ ranges from 
0 to 6, with a greater score indicating more bother from the patient’s urinary condition. 
Patients were defined as having “mild” urinary incontinence if the PPD usage was 1 or 
2, “moderate” if it was >2-5, and “severe” if >5 or if a condom catheter was needed.
After the volume adjustments, ProACT implantation was either “successful” or “non-
successful.” We defined “successful” if the patient was subjectively dry (i.e., if he used 0 
PPD or 1 precautionary PPD). This precautionary pad is the smallest male incontinence 
pad available. “Non-successful” was defined as patients reporting the use of ≥1 wet 
PPD. Patients were excluded if a surgical intervention, other than ProACT implanta-
tion, had occurred between the pre-implantation and post-implantation UDS, such as 
internal urethrotomy, an AUS was in situ, or if the patient had a neurologic disease that 
could affect voiding function.
Before implantation of the ProACT balloons, the UDS was performed to determine 
the bladder and sphincter function. This was repeated after the balloon volume 
adjustments were completed. The latter, post-implantation UDS was a part of the 
standard evaluation protocol in our clinic either to detect bladder outlet obstruction 
in successful patients or to evaluate the persistence of incontinence in non-successful 
patients (e.g., urge incontinence).
Each UDS was performed according to the International Continence Society 
standards14 and included free uroflowmetry, 2 filling cystometries, and subsequent 
pressure-flow studies (PFS). The maximum flow rate (Qmax) and average flow rate were 
measured using a rotating disk flow meter. A 7F double-lumen transurethral catheter 




filled to the maximum cystometric capacity at a medium rate (50 mL/min) using filling 
fluid at room temperature.14 When filling the bladder was not possible because of total 
incontinence, the patient was asked to manually squeeze the urethra. The intravesical 
pressure transducers were placed at the level of the superior edge of the pubic sym-
physis. The pressure was zeroed to the atmospheric pressure.
The outcome variables derived from the cystometric studies were the parameters 
characterizing detrusor overactivity (DO) and compliance. DO was defined as the oc-
currence of involuntary detrusor contractions during the filling phase of the bladder, 
without a lower limit for the amplitude of an involuntary detrusor contraction.15 Com-
pliance was calculated at cystometric capacity15 or at 500 mL if the capacity was >500 
mL. The outcome variables derived from the PFS were Qmax, detrusor pressure at Qmax 
(PdetQmax), and parameters of urethral resistance and bladder contraction strength. The 
parameter for urethral resistance was the bladder outlet obstruction index (BOOI=Pdet.
Qmax–2*Qmax).16 The parameters for bladder contraction strength were the bladder 
contractility index (BCI=PdetQmax+5*Qmax)16 and parameter w17 an approximation of the 
power generated by the detrusor muscle per unit of bladder wall area. The maximum 
of w (wmax) and the value of w at Qmax (wQmax) were used as contractility parameters.17,18 
Additionally, we determined the voided volume, postvoid residual urine (PVR) vol-
ume, cystometric bladder capacity (sum of the voided and PVR volume during PFS), 
and bladder voiding efficiency (BVE=(voided volume/bladder capacity)*100).16 In the 
case of repeated PVR measurements, we used the lowest value measured.
The measurement with the largest cystometric capacity was used to assess the filling 
phase. The PFS with the greatest Qmax was used to assess the voiding phase. Artefacts 
were corrected manually. The urodynamic data were analysed using AUDACT soft-
ware, version 4.50 (Andromeda Medizinische Systeme GmbH, Taufkirchen, Germany).
Statistical analysis was performed using SPSS Statistics, release 20.0.0.1 (IBM, Ar-
monk, NY). Statistical significance was defined as p <.05. The median and interquartile 
range (lower quartile to upper quartile) are reported for continuous data. For discrete 
data, counts and percentages are reported.
To assess the change in outcome before and after ProACT implantation within the 
success and non-success group, the Wilcoxon signed rank test was used for continu-
ous variables and McNemar’s test for categorical variables. The Mann-Whitney U test 
was used to compare the pre-implantation urodynamic parameters between the 
success and non-success groups for continuous variables and the chi-square test for 
categorical variables.
Multivariate logistic regression analysis was conducted using the backward likelihood ra-
tio method. All pre-implantation patient characteristics and pre-implantation urodynamic 
parameters with p <.05 on univariate analysis were considered in building the model to 




From May 2007 to June 2012, 81 patients with PPI received implantation of the ProACT 
balloons (Figure 1.1). At the last follow-up visit, 8 patients were still in the process of post-
implantation balloon adjustments and had not yet undergone the post-implantation 
UDS. Another 8 patients had their ProACT devices removed because of infection (n=2), 
dislocation of the device (n=3), or tissue erosion (n=3). A final 8 patients met an exclu-
sion criterion: 2 had undergone surgical intervention between the pre-implantation and 
post-implantation UDS, 3 had an AUS in situ, and 3 developed a neurologic disease (2 
experienced a stroke and 1 developed Alzheimer’s disease). Thus, 49 of the 57 patients 
(86%) completed the post-implantation UDS and were included in our study.
ProACT was the first surgical SUI therapy after failed pelvic floor muscle training in 38 
of the 49 patients (78%). Of the 49 patients, 15 (31%) had mild, 18 (37%) had moderate, 












ProACT not in situ
n = 8
Success: “dry”
(0 or 1 ‘ security’ PPD)
n = 44
Excluded
- lower urinary tract surgery between 
UDS (n = 2)
- AMS-prothesis in situ (n = 3)












Figure 1.1 Flowchart of inclusion process of ProACT patients




After implantation, none of the 49 included patients had symptoms of persistent 
urinary retention or symptomatic urinary tract infection. ProACT implantation was 
successful in 37 patients and not successful in 12, although 4 of these 12 patients had a 
reduction in PPD of ≥50%. These 12 unsuccessfully treated patients had either received 
the maximal allowed filling volume (n=8) or had noted absolutely no improvement 
after several adjustments (n=4). The success rate was 93% (14 of 15) in patients with mild 
incontinence, 83% (15 of 18) in those with moderate incontinence, and 50% (8 of 16) in 
those with severe incontinence.
The patient characteristics were compared between the success and non-success 
groups (Table 1.1). In the non-success group, the median age was 7.5 years older (p=.001), 
the median duration of urinary incontinence was 7.5 years longer (p=.001), and the 
incontinence was more severe (p=.01). As expected, the patients in the non-success 
group had a greater balloon volume (p<.001) and a greater IPSS-BQ score (p<.001) than 
did the patients in the success group.
The urodynamic outcomes before and after implantation for the successful and 
unsuccessful groups are listed in Table 1.2. The pre-implantation cystometric bladder 
capacity and free flow Qmax were significantly lower in the non-success group than in 
the success group. The other parameters, including BCI (p=.06), were not significantly 
different between the 2 groups.
In the non-success group, only the average flow rate was significantly lower after im-
plantation. We did not find any other significant differences between the urodynamic 
parameters before and after ProACT implantation. In the success group, 8 patients 
(22%) had DO during the pre-implantation UDS, of whom 3 continued to have DO 
during the post implantation UDS. Also, 7 patients showed de novo DO with threshold 
volumes of ≥250 mL. No statistically significant differences were found before and after 
implantation in the proportion of patients with DO, the cystometric bladder capacity, 
or bladder compliance (p=.77, p =.31, and p=.79, respectively). The urethral resistance 
during voiding, as described by BOOI, was significantly greater after implantation (p 
<.001). The BOOI increased in most patients after implantation (Figure 1.2). In 3 patients, 
the BOOI was lower after ProACT implantation. Four patients had a post-implantation 
BOOI >40 but had no clinical symptoms of symptomatic urinary retention or persis-
tent urinary tract infection. The maximum free flow rate and average flow rate were 
significantly lower after implantation, and the PVR volume was significantly greater, 
with a median of 0 mL (interquartile range 0-25). Five patients (14%) had a PVR volume 
>100 mL. Consequently, the bladder voiding efficiency was significantly lower after 
implantation (p<.001). The proportion of patients who had to strain during the PFS 
(35%) was not significantly increased after implantation (32%). The bladder contraction 
strength, characterized by the BCI and wmax, was significantly lower after implantation 
(p<.001 and p=.004, respectively); however, wQmax was not (p=.09).
Chapter 1
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Age, years 68.0 (63.5 – 72.5) 75.5 (69.5 – 79.8) .001
Previous treatment of SUI .22
Only PFMT 29 (78%) 9 (75%)
Bulking agent 0 (0%) 1 (8%)
AUS 2 (5%) 1 (8%)
Unknown 6 (16%) 1 (8%)
Urinary incontinence duration, years 3.0 (1.0 – 6.0) 10.5 (6.0 – 13.5) .001
Incontinence severity .01
Mild (1 or 2 PPD) 14 (38%) 1 (8%)
Moderate (>2 to 5 PPD) 15 (41%) 3 (25%)
Severe (>5 PPD) 8 (22%) 8 (67%)
After implantation and balloon adjustments
Interval between ProACT and UDS, months 7.0 (5.0 – 9.0) 13.5 (10.3 – 22.0) <.001
Interval between last balloon adjustment and UDS, 
months
3.0 (2.0 – 3.0) 2.5 (1.0 – 4.0) .87
Balloon volume, mL 4.0 (2.9 – 6.0) 7.5 (6.5 – 8.9) <.001
Adjustments, number 3.0 (2.0 – 5.5) 6.0 (5.0 – 7.0) .002
Incontinence severity NA
No incontinence (0 or 1 security PPD) 37 (100%) 0
Mild (1 or 2 PPD) 0 4 (33%)
Moderate (>2 to 5 PPD) 0 2 (17%)
Severe (>5 PPD) 0 6 (50%)
IPSS-BQ 
“If you were to spend the rest of your life with your urinary condition just 
the way it is now, how would you feel about that?”
<.001
Delighted 13 (35%) 0 (0%)
Pleased 13 (35%) 0 (0%)
Mostly satisfied 5 (14%) 1 (8%)
Mixed 2 (5%) 5 (42%)
Mostly dissatisfied 1 (3%) 1 (8%)
Unhappy 1 (3%) 4 (33%)
Terrible 1 (3%) 1 (8%)
Missing 1 (3%) 0 (0%)
Abbreviations: AUS artificial urinary sphincter, IPSS-BQ International Prostate Symptom Score bother 
question, NA not applicable, PFMT pelvic floor muscle training, PPD incontinence pads per day, RP 
radical prostatectomy, UDS urodynamic studies
Data in median (lower quartile to upper quartile) or number (%)

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Multivariate logistic regression analysis was performed to explore both the clinical 
and the urodynamic pre-implantation parameters as predictors of outcome. A longer 
duration of urinary incontinence (p=.007), severe incontinence (p=.02), and smaller 
cystometric bladder capacity (p=.05) were all independently associated with a non-
successful outcome of ProACT implantation (Table 1.3). Patient age and free fl ow Qmax 






















obstructed equivocal unobstructed 
Figure 1.2 Graph showing detrusor pressure at maximum fl ow rate (PdetQmax) and maximum fl ow rate 
(Qmax) before (open circles) and after (black circles) implantation of Adjustable Continence Therapy 
for men (ProACT). Bold lines and arrows indicate that bladder outlet obstruction index was lower after 
ProACT implantation.
Table 1.3 Results of multivariate analysis for non-successful outcome
Odds ratio 95% CI p-value
Duration of incontinence, each year 1.83 1.17 – 2.83 .007
Incontinence severity
Mild (1 or 2 PPD) Reference
Moderate (>2-5 PPD) 1.55 0.06 – 39.41 .79
Severe (>5 PPD) 136.42 2.10 – 9075.82 .02
Cystometric bladder capacity, each 10 mL 0.91 0.82 – 1.0 .05
Abbreviations: CI confi dence interval,  PPD incontinence pads per day, RP radical prostatectomy
Candidates for inclusion in the model: age, duration of urinary incontinence, severity of incontinence, 





The present study was designed to describe the urodynamic changes after implanta-
tion of ProACT for PPI. Our results have shown that successful treatment with ProACT 
increased urethral resistance and could affect the parameters of bladder contraction 
strength. In the successfully treated patients, a clear shift could be seen from the unob-
structed area toward the equivocal and—to a lesser extent—to the obstructed area of 
the provisional International Continence Society nomogram (Figure 1.2). Nevertheless, 
no signs of clinical obstruction were found, because the proportion of patients who 
had to strain during voiding did not differ after ProACT implantation, and none of our 
patients had persistent urinary retention or symptomatic urinary tract infections during 
our follow-up period. Also, treatment success was demonstrated by patient-reported 
PPD use and IPSS-BQ, both important for quality of life. In 3 patients, the BOOI was 
lower after implantation, although the absolute differences were small and did not 
result in a clear change in the BOOI category assignments (Figure 1.2).
The BCI and wmax, representing bladder contractility, were significantly lower after 
ProACT implantation with a successful outcome. Several explanations are possible for 
this unexpected observation. First, the bladder can use its muscle contractility to gen-
erate a high pressure at low flow rate or a high flow rate at a low pressure.19 Therefore, 
a contractility parameter should combine these 2 properties in an equation, such that 
when the muscle contractility does not change but the balance between the pressure 
and flow rate changes from external causes (e.g., a change in urethral resistance), the 
contractility parameter would remain constant. It might be that in the equations that 
define wmax and BCI, the decrease in Qmax caused by the balloon volume is not ad-
equately compensated by the accompanying increase in PdetQmax. This would result in a 
decrease in contractility parameter value, which would not represent a true decrease 
in muscle contractility. Second, in patients with urethral obstruction from benign pros-
tatic hyperplasia, the bladder contractions might slowly decline prematurely, leaving 
a PVR volume.20 This decline could cause a lower wmax. It is likely that the decline does 
not affect the value of w at Qmax because the value of w at Qmax is usually attained earlier 
during the course of micturition than is wmax. This was also observed in our group. 
Parameter wQmax was not significantly lower after ProACT implantation. Third, it is 
physiologically plausible that our finding of lower bladder contraction strength could 
be caused by the decreased Qmax owing to the urethrovesical reflex. This reflex is re-
sponsible for the maintenance of the detrusor contraction in the normal bladder.21 The 
reduced urine flow after ProACT implantation could thus lead to reduced stimulation 
of the bladder and, consequently, to a decreased bladder contraction strength. For 
these reasons, the lower bladder contraction strength we found could have resulted 
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from an inadequacy of the equation used to estimate the bladder contractility in 
urinary incontinence or might have a physiologic explanation.
Our second objective was to explore the clinical and urodynamic pre-implantation 
parameters as predictors of a non-successful outcome after ProACT implantation. A 
longer duration of urinary incontinence and severe incontinence (>5 PPD) were in-
dependent clinical predictors of a non-successful outcome. Possibly, scarred tissue 
around the neobladder neck from RP becomes less distensible as it ages. Conse-
quently, inflation of the balloons might not result in sufficient urethral compression. 
Perhaps, ProACT treatment should be considered sooner, rather than later, after 
conservative treatment of PPI has failed. Patients with severe incontinence were more 
likely to have an unsuccessful outcome after Pro-ACT implantation than patients with 
either mild or moderate incontinence. Still, 50% of patients with severe PPI achieved 
continence with ProACT implantation. ProACT implantation has been suggested as a 
part of a “step-up” approach22 before opting for AUS, which can be considered in the 
case of more severe incontinence. Of the urodynamic parameters, only a smaller pre-
implantation cystometric bladder capacity was independently associated with non-
success. This finding is in line with the results from Warner et al23 on the urodynamic 
effects of transobturator male slings in the treatment of SUI. They also found that a 
small bladder capacity might be a predictor of an unsuccessful outcome.23
DO is a urodynamic diagnosis and is not necessarily symptomatic or clinically rel-
evant. Therefore, only patients who experienced urgency in everyday life were treated 
with anticholinergic agents. Of the 3 patients who continued to have DO after implan-
tation, 2 were treated with anticholinergic agents, the third patient had a threshold 
volume of 500 mL and no urge symptoms in daily life. Of the 7 patients had de novo 
DO, only 1 required treatment with anticholinergic agents; the remaining 6 patients 
were asymptomatic and did not need treatment. The “de novo” DO might have been 
already present but missed by the UDS before ProACT implantation.24,25
Various studies on the operative and clinical results of ProACT implantation have 
been published.4,5,22,26,27 These studies were all cohort and/or feasibility studies, and 
our study focused on the urodynamic outcomes. Although some studies have evalu-
ated leak point pressures and uroflowmetry,5,26 important urodynamic outcomes of 
ProACT implantation such as urethral resistance and bladder contraction strength 
have never before been evaluated after implantation.
The limitations of our study included the use of a non-validated IPSS-BQ and the 
lack of a cough stress test as outcome measures. Although other ProACT studies used 
the same classification for incontinence severity,27-30 it might be somewhat arbitrary, 
because it can vary by merely volume intake. The relatively short follow-up and small 




Still, to our knowledge, ours is the first study to review the urodynamic changes after 
ProACT implantation. Our results have provided a clear impression of the increased 
urethral resistance due to the paraurethrally placed balloons to achieve continence. 
Studies with longer follow-up are needed to determine the effects of chronically 
increased urethral resistance on bladder function from ProACT implantation. For now, 
individual follow-up is important to achieve the right balance between patient satis-
faction and urethral resistance.
ConCLusion
Our data have suggested that urethral resistance is increased to achieve continence 
with ProACT implantation without symptoms of clinical bladder outlet obstruc-
tion. We also found a decreased bladder contraction strength after continence was 
achieved with Pro-ACT, which could be either an artefact or part of a physiologic 
phenomenon. A longer incontinence duration, severe incontinence (defined by the 
use of >5 PPD), and a smaller cystometric bladder capacity were important predictors 
of a  non-successful clinical outcome in patients undergoing ProACT implantation. 
Therefore, ProACT treatment should be considered sooner, rather than later, after 
conservative treatment of PPI has failed.
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The Urogenital Distress Inventory (UDI-6) and Incontinence Impact Questionnaire 
(IIQ-7) assess symptom distress and the impact on daily life of urinary incontinence. 
The UDI-6 has not been validated before in males. Our aim was to validate the UDI-6 
and IIQ-7 in Dutch men and women.
methods
The translation to Dutch followed standardized procedures. We validated the IIQ-7 
with and without an additional gender-neutral item (IIQ-SF). Adults with urinary in-
continence for at least three months, completed the measures at inclusion; one week 
after inclusion to evaluate the test-retest reproducibility; and six months after inclusion 
with the addition of the RAND-36 health transition item to assess responsiveness and 
interpretability. To assess the discriminate ability, a reference population was enrolled. 
To assess construct validity, the urodynamic diagnosis was used.
results
Questionnaire data of 160 patients were analysed. Patients reported more symptoms 
and bother than the reference population (p<.001). The internal consistency was good 
in the IIQ-SF baseline scores (Cronbach’s alphas 0.86-0.92); though moderate in the 
UDI-6 (Cronbach’s alphas 0.44-0.66). Both measures showed good reproducibility 
at the test-retest (Intraclass Correlations Coefficients 0.75-0.85). Construct was ad-
equate with 75% confirmed hypotheses of urodynamic data with measure scores. The 
measures were responsive after treatment with smaller measurement errors than the 
minimal important change. No floor or ceiling effects were observed in baseline data. 
Conclusion
The Dutch UDI-6 and IIQ-7 are reliable, valid, and responsive instruments for assess-
ing symptom distress of urinary incontinence and its impact on daily life in both men 
and women.
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introDuCtion
Urinary incontinence (UI) affects approximately 30% to 60% of women and 1% to 39% 
of men, depending on age, aetiology, and the definition of incontinence used.1 Vari-
ous measures are available to assess the impact of UI on health related quality of life 
(HRQOL). Generic HRQOL measures lack sensitivity to the unique aspects of a specific 
disease2,3, therefore disease-specific HRQOL measures can be considered more ap-
plicable in capturing the impact of a specific disease such as UI. These measures may 
also serve to assess the impact of treatment on UI and to facilitate future research in 
incontinence treatment.
The urogenital distress inventory (UDI) and incontinence impact questionnaire (IIQ) 
were both developed to assess the impact of UI on HRQOL.4,5 Short versions of the 
UDI and IIQ, UDI-6 and IIQ-7, were developed to reduce the respondents’ burden.6 
The UDI-6 and IIQ-7 are both “A grade” recommended by the Fourth International 
Consultation on Incontinence.7 A measure that is valid and reliable for a particular lan-
guage and culture may not prove so when used in a different population.8 The UDI and 
IIQ long forms were previously translated and revisited in Dutch9, and are nowadays 
widely used in the Netherlands in urogynecology clinical practice and research.10-12 
An unvalidated Dutch translation of the UDI-6 and IIQ-7 is also commonly used.13,14 
However, by using a questionnaire without the measurement properties tested15, it re-
mains unknown whether a reliable, valid, and responsive measure for the population 
of interest is used. Though not yet in Dutch, the UDI-6 and IIQ-7 have been translated 
and validated in other languages.16-22 Although both measures6 were developed for 
female patients, we aimed to validate these in both sexes. Unlike the UDI-6, the IIQ-7 
has earlier been validated in men.23 The objective of this study was to validate the 
UDI-6 and IIQ-7 in Dutch to provide a useful evaluation tool for the use in both men 
and women suffering from UI. 
methoDs
This observational study was conducted at a tertiary Urology and Gynaecology centre 
as part of a larger validation study of HRQOL pelvic floor measures. The study was 
approved by the Institutional Ethical Committee (MEC-2008-376).
questionnaires
The UDI-6 is a six item symptom inventory, specific to symptoms associated with 
lower urinary tract dysfunction, and combines information on irritative, stress and 
obstructive/discomfort symptoms.6 The IIQ-7 is a seven item life-impact assessment 
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instrument specific to UI, and covers separate domains of physical activity, travel, 
social/relationships, and emotional health.6 Both measures were developed for self-
administration and are intended to be used in combination. Patients rated how much 
they experience impaired function of UI and the extent to which this UI affects their 
daily functioning with four response options per item ((0) “not at all”; (1) “slightly”; (2) 
“moderately”; (3 ) “greatly”). We maintained the scoring procedure as described by 
the original developer: if more than two items are missing, a total score is not to be 
calculated.6 The mean score of items is multiplied by 33 1/3 to convert to a 0–100 
scale.6 Higher scores indicates more symptom distress (UDI-6), or more impact on 
daily life (IIQ-7).
In consultation with the original developer we concluded that the UDI-6 had good 
face validity concerning male patients, i.e. the questions seemed plausible, relevant, 
and to span the domain adequately. In the IIQ-7 however, the item addressing house-
hold chores (“Has urine leakage affected your ability to do household chores (cooking, 
housecleaning, laundry)?”) might be related more to females. Therefore, based on the 
factor loadings of the IIQ long form4 and as suggested by the original developer, we 
added a question about employment (“Has urine leakage affected your employment 
(work) outside the home?”). The addition of this “employment” item resulted in three 
versions of the IIQ-7 completed by both men and women: (1) IIQ-7 original 6; (2) IIQ-
7 adjusted; in which the item addressing “household chores” was substituted by the 
item “employment” (“Has urine leakage affected your employment (work) outside the 
home?”)4 (3) IIQ-8; in which the item “employment” was added to the original IIQ-7. 
We refer to these versions as the IIQ-short forms (IIQ-SF). Referring to the IIQ long 
form4, the “employment” item was part of the “travel” domain while the “household 
chose” item was part of the “physical activity” domain. However, unlike the IIQ long 
form, the IIQ-7 does not contain separate domain scores,6 and therefore only total 
scores of the IIQ-SF are reported.
Linguistic Validation
The translation of the measures to Dutch followed standardized forward-backward 
procedures8: three independent forward translations, and backward translation by a 
native speaker. The Dutch versions of the measures were tested in 10 patients with 
UI, where potential problems were explored and discussed guided by a checklist. UI 
was defined according to the International Continence Society, thus “the complaint 
of any involuntary leakage of urine”.24 As a result, the lay-out was adapted to clarify 
the instructions on how to indicate the chosen answer. Several minor problems were 
identified which did not indicate a need to adapt the content. The Dutch versions of 
UDI-6 and IIQ-SF were then finalized (See ‘Vragenlijsten’).
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study population and study design
Inclusion criteria included males and females aged 18 years or older, symptoms of 
UI for at least three months, and fluent and literate in the Dutch language. Exclu-
sion criteria were symptomatic urinary tract infections, neurologic diseases (except 
diabetic neuropathy), active malignant tumours, dementia, and mental retardation. 
At the initial physician office visit, the treating physician explained the study to all 
consecutive patients potentially eligible for inclusion. The physician logged the name 
and gender of patients who were interested in participation, and gave an informa-
tion package including two sets of questionnaires. These patients were phoned by 
the principal investigator for further explanation, and were instructed to complete the 
first set of questionnaires (baseline) at home, and to return it by postal mail directly 
after completion, together with a signed informed consent form. The second set of 
questionnaires were completed one week after baseline, and returned by postal 
mail. Six months after baseline, patients received through postal mail a third set of 
questionnaires to be completed at home and returned by postal mail. Age and educa-
tion were documented through the questionnaire. Educational level was classified as 
“low” (primary school), “intermediate” (high school) or “high” (college or university 
degree). The test-retest period of one week between the repeated administrations 
was long enough to prevent recall, though short enough to ensure that clinical change 
had not occurred. During this period no treatment was initiated or changed. Given 
the observational nature of the study, the treating physician was free to perform any 
investigation (e.g. urodynamic studies) and prescribe any treatment after completion 
of the second round of questionnaires, for individual patient care. 
The third questionnaire included the health transition item of the RAND 36-Item Health 
Survey (RAND-36-HTI)25, in which patients were asked to score the change in their general 
health compared to one year ago. The response options were: (1) ‘much better’; (2) ‘a little 
better’; (3) ‘same’; (4) ‘a little worse’; (5) ‘much worse’. This RAND-36-HTI was used as the 
anchor (external criterion)26 for the evaluation of responsiveness and interpretability.
urodynamic studies
Because of the observational nature of this study, multichannel urodynamic testing 
was only carried out if indicated according to the standard evaluation protocol of our 
clinic as recommended by the Fourth International Consultation of Incontinence Rec-
ommendations.27 Urodynamic testing was performed according to the International 
Continence Society standards.28 Using urodynamic studies, patients were categorized 
into groups: no urodynamic abnormality detected, stress urinary incontinence 
(SUI), detrusor overactivity (DO), and detrusor underactivity. When mixed SUI/DO 
incontinence was detected the type of treatment patient received during follow-up 




Baseline data from a reference group were collected using a random subsample of 
an ISO-certified (ISO 26362) Dutch panel29. This subsample was stratified by gender, 
age, educational level and residential area, and therefore representative for the Dutch 
population above the age of 18. No medical data was available for this internet panel. 
A total of 450 panel participants were invited in order to meet our targeted sample size 
of 250 participants.
statistical methods
Statistical analysis was conducted using IBM® SPSS-software 20.0. Statistical signifi-
cance was defined as p-value <.05. The mean and standard deviation (SD) are reported 
for continuous data. For discrete data, the count and percentage are reported.
As described by the original developer6, if one or two items were missing in the 
measures, they were replaced by the average of the respondent’s observed values 
(unconditional mean imputation30). The UDI-6 or IIQ-7 scores were not calculated if 
more than two items were missing.6
To assess the differences between patient and reference group, the Student’s T-test 
was used for continuous data, and the Chi-squared test for categorical variables. Gen-
eral linear models were used to compare measure scores, controlling for variables that 
differed significantly between the patient and reference group in univariate analysis. 
The Welch’s F statistic was used as a single global test to compare means between 
groups, since homogeneity was not assumed. In case of significant differences be-
tween means, pairwise comparisons using Games-Howell analysis was performed.
For receiver operating characteristics (ROC) analysis the anchor RAND-36-HTI was 
dichotomized: patients who reported that they were “a little better” and “much better” 
were classified as “improved”, while “same”, “a little worse”, and “much worse” were 
classified as “not improved”.
We tested the measurement properties of the measures31:
- The internal consistency, i.e. the extent to which the items are measuring the same 
underlying construct, was tested by calculating Cronbach’s alpha using baseline 
scores. A Cronbach’s alpha between 0.70 and 0.95 was considered to reflect good 
internal consistency.31
- The reproducibility, i.e. the degree to which repeated measurements in the 
test-retest period provide similar answers, concerns reliability and agreement. 
The reliability, i.e. the extent to which patients can be distinguished from each 
other despite measurement errors, was calculated with the Intraclass Correla-
tion Coefficient (ICC) according to McGraw and Wong for agreement32, and was 
considered acceptable when the ICC was ≥0.70.31 Agreement, i.e. the extent to 
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which the scores on repeated measures are close to each other, was quantified 
using the limits of agreement (LOA) as described by Bland and Altman.33 The LOA 
were calculated as the absolute mean change in scores (meanchange) of repeated 
measurements during the test-retest period ±1.96*SD (SDchange). The LOA estimates 
where 95% of individual differences fall, that is the absolute measurement error. 
Agreement is considered good if the LOA are smaller than the minimal important 
change (MIC; see interpretability).31
- The construct validity, i.e. the extent to which the scores relate to other measures, 
was verified by urodynamic diagnosis for discriminative validation. We formulated 
specific hypotheses and expected at least 75% of the results to be in accordance 
with these hypotheses31:  
 1.  We expect patients without an abnormality detected on urodynamic stud-
ies, to have significantly better IIQ-SF scores than patients with a urodynamic 
diagnosis;
 2.  We expect patients with DO to score significantly worse in the irritative do-
main of the UDI-6, than patients with other urodynamic diagnoses;
 3.  We expect patients with SUI to score significantly worse in the stress domain 
of the UDI-6, than patients with other urodynamic diagnoses;
 4.  We expect patients with dysfunctional voiding or underactive detrusor, to 
score significantly worse in the obstructive domain of the UDI-6, than pa-
tients with other urodynamic diagnoses.
- To assess responsiveness, i.e. the ability of a measure to detect clinically important 
changes over time, in treated patients we firstly evaluated the linear relationship of 
the meanchange in measure scores between baseline and 6 month follow-up with the 
RAND-36-HTI score, using the Pearson correlation coefficient. In addition, the area 
under the ROC curve (AUC) for the UDI-6 and IIQ-SF measures was determined. 
The AUC indicates the probability that a measure correctly classified patients as im-
proved, using the RAND-36-HTI as an anchor. The AUC was considered adequate 
if ≥0.70. 15 
- To assess interpretability, i.e. the degree to which one can assign qualitative mean-
ing to quantitative scores, the anchor based ROC method was used to assess the 
MIC.15 The MIC was defined as the optimal ROC cut-off point, i.e. the value for 
which the sum of the proportions of misclassifications ([1-sensitivity]+[1-specificity]) 
is smallest.15 
- Floor and ceiling effects occur when high proportions of respondents report 
scores at the lower or upper end of the scale, indicating limited content valid-
ity, and thus may lead to a reduced reliability and limited responsiveness.15 Floor 
or ceiling effects are considered to be present if more than 15% of respondents 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Of 240 male and female consecutive patients, 218 were found to be eligible for inclu-
sion (Figure 2.1). Of the 218 patients, 174 (80%) consented to participate. After three 
rounds of questionnaires data were available for 160 out of 174 patients (92%) to test at 
least one measurement property (i.e. patients completed the questionnaires at base-
line and at least at one additional time-point) of at least one questionnaire (i.e. patients 
completed the UDI-6 and/or IIQ-7). Regarding the reference group, the measures 
were sent out to 450 panel participants of which 279 (62%) responded.
The study population had a mean age of 62±12 years, and 59% were female (Table 
2.1). At baseline, patients reported significantly more symptoms of UI (UDI-6, p<.001) 
and more impact of these symptoms on daily life (IIQ-7 original, IIQ-7 adjusted and 
IIQ-8 all p<.001) than the reference group. After adjusting for age and educational 
level, these differences remained significant (p <.001).
internal consistency
In the patient group, Cronbach’s alpha was 0.49 for the UDI-6 total score and the 
domains ranged between 0.46–0.65, indicating moderate internal consistency (Table 
2.2). In the reference group, Cronbach’s alpha was 0.66 for the UDI-6 total score, and 









Age (years) 62 ± 12 49 ± 16 <.001
Gender .08
Males 65 (41%) 138 (50%)
Females 95 (59%) 141 (51%)
Educational level* <.001
Low 59 (37%) 21 (8%)
Intermediate 73 (46%) 172 (62%)
High 28 (18%) 86 (31%)
Scores at baseline (0-100)**
UDI-6 46.4 ± 16.8 12.2 ± 12.7 <.001 <.001
IIQ-7 original 38.4 ± 24.6 4.0 ± 10.9 <.001 <.001
IIQ-7 adjusted 39.4 ± 25.4 4.2 ± 11.2 <.001 <.001
IIQ-8 37.3 ± 24.2 12.2 ± 12.7 <.001 <.001
Data in mean ± standard deviation or number (%).
*missing n=2
**higher scores indicate more symptom distress (UDI-6) or more impact on daily life (IIQ-SF)
***p-value: corrected for age and educational level with general linear model (GLM)
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the domains ranged between 0.44–0.58, also indicating moderate internal consis-
tency. Internal consistency remained moderate after stratification by gender (not in 
table). 
The Cronbach’s alpha of the IIQ-7 original, IIQ-7 adjusted, and IIQ-8 were respec-
tively 0.87, 0.86, and 0.87 in the patient group, indicating good internal consistency. In 
the reference group, these were 0.91, 0.91, and 0.92 respectively, also indicating good 
internal consistency.
reproducibility (reliability and agreement)
The retest assessments were completed on average 10±25 days after baseline as-
sessment. The ICCagreement was 0.84 for the UDI-6, and the domains ranged between 
0.83–0.85, indicating good reliability (Table 2.2). The ICCagreement of the IIQ-7 original, 
IIQ-7 adjusted, and IIQ-8 were 0.76, 0.77, and 0.75 respectively, also indicating good 
reliability.
The meanchange and the LOA in the test-retest period are also presented in Table 2.2. 
The LOA are smaller than the MIC (see also results Interpretability), indicating good 
agreement.
Construct validity
In 124 patients urodynamic data were available and classified according to urodynamic 
diagnosis. Sixteen of 124 patients were diagnosed with mixed incontinence and were 
classified into either SUI (n=11) and DO (n=4), while one was treated for mixed incon-
tinence and therefore not included in this analysis. Table 2.3 presents the measure 
scores in 123 patients stratified into urodynamic diagnosis.













UDI-6 0.49 (n=149) 0.66 0.84 (n=152) 6.3 ± 7.0 -7.42 to 20.0
Irritative 0.65 (n=155) 0.53 0.83 (n=152) 8.9 ± 13.1 -16.8 to 34.6
Stress 0.46 (n=152) 0.58 0.83 (n=152) 8.4 ± 11.5 -14.1 to 30.9
Obstructive/discomfort 0.54 (n=154) 0.44 0.85 (n=152) 7.3 ± 11.8 -15.8 to 30.4
IIQ-7 original 0.87 (n=147) 0.91 0.76 (n=153) 9.9 ± 14.1 -17.7 to 37.5
IIQ-7 adjusted 0.86 (n=132) 0.91 0.77 (n=150) 10.2 ± 14.1 -17.4 to 37.8
IIQ-8 0.87 (n=131) 0.92 0.75 (n=149) 10.0 ± 14.1 -17.6 to 37.6
All scale scores are transformed to a 0 – 100 point scale. 
Higher scores indicate more symptom distress (UDI-6) or more impact on daily life (IIQ-SF).
* Limits of agreement described by Bland and Altman33 = meanchange ± 1.96*SDchange
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The distribution of the mean scores of the UDI-6 irritative domain, UDI-6 stress 
domain, IIQ-7 original, IIQ-7 adjusted and IIQ-8, differed significantly between the 
urodynamic groups. Pairwise comparisons of predefined hypotheses on outcome 
resulted in 75% (3 out of 4) confirmed hypotheses indicating acceptable construct 
validity. Our confirmed hypotheses were: 
- The mean score of the irritative domain of the UDI-6 was significantly higher in 
the DO group than in patients with SUI (p=.02), dysfunctional voiding (p=.04), or 
without urodynamic abnormality (p=.02). 
- The mean score of the stress domain of the UDI-6 was significantly higher in the 
SUI group than in patients with DO (p=.02) or underactive detrusor (p<.05). 
- The mean scores of the IIQ-7 original, IIQ-7 adjusted and IIQ-8 were significantly 
lower in the group of patients without urodynamic abnormality than in patients 
with SUI (p<.01) or DO (p<.01)
responsiveness
The treatment work-up was individually determined for each patient by the treating 
physician after completion of the second round of questionnaires. Thus, 97 patients 
were treated and completed the third round of questionnaires on average 5.7±1.3 
months after baseline assessment. Treatment consisted of surgery (n=71, 73%), conser-
vative therapy (n=16, 17%), or pharmaceutics (n=10, 10%).





























































































UDI-6 (total score) 39.5 ± 12.5 48.1 ± 13.1 48.2 ± 18.9 37.6 ± 17.9 43.5 ± 12.0 .22
Irritative 37.0 ± 23.2* 68.6 ± 23.1 51.6 ± 26.0* 37.0 ± 23.2* 55.5 ± 27.8 .003
Stress 50.0 ± 23.5* 50.9 ± 24.2* 66.9 ± 22.8 50.9 ± 24.2 45.8 ± 21.4* .006
Obstructive/discomfort 31.5 ± 24.2 23.7 ± 22.8 25.0 ± 25.8 31.5 ± 24.2 29.1 ± 33.4 .90
IIQ-7 original 14.8 ± 15.3 41.0 ± 22.4** 38.8 ± 25.0** 24.9 ± 19.3 33.7 ± 17.0 .004
IIQ-7 adjusted 15.3 ± 15.2 41.7 ± 21.9** 39.2 ± 25.8** 25.5 ± 18.9 35.3 ± 16.3 .003
IIQ-8 13.9 ± 13.3 39.9 ± 22.2** 37.5 ± 24.5** 23.0 ± 17.9 33.0 ± 16.0 .001
Measure scores according to urodynamic diagnosis at baseline in mean ± SD 
All scores are transformed to a 0 – 100 point scale
Higher scores indicate more symptom distress (UDI-6) or more impact on daily life (IIQ-SF)
#Welch’s F was used for comparing means
Data in bold were used for pair wise comparisons of hypotheses using post hoc Games-Howell with 
mean difference significant at level *p<.05; **p<.01
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Table 2.4 shows the meanchange between baseline and six month follow-up of each 
measure classified by the responses of the RAND-36-HTI. Since two patients (2%) 
reported their health was “much worse”, and 10 patients (11%) reported it was “a little 
worse” compared to one year ago, we combined those categories. The relationships 
between the meanchange  of measure scores and the RAND-36-HTI as anchor were sig-
nificantly linear (Table 2.4). The AUC for the UDI-6 was 0.81 (p<.001) indicating good 
responsiveness. The AUC for the IIQ-7 original was 0.65 (p=.02); for the IIQ-7 adjusted 
0.70 (p=.004); and for the IIQ-8 0.66 (p=.02), indicating acceptable responsiveness.
interpretability
The MIC was -16.7 for the UDI-6 with a sensitivity of 0.76 and specificity of 0.78. The 
MIC was -19.0 for the IIQ-7 original, -26.2 for the IIQ-7 adjusted, and -28.8 for the 
IIQ-8, with sensitivity ranging from 0.38–0.43 and specificity ranging from 0.84–0.90 
(Table 2.4).
All MIC fell outside the LOA (Table 2.2), indicating acceptable measurement errors 
which are smaller than the values for MIC.15













Health transition item (RAND-36)*: 
A little worse / much worse 12 (12%) 5.8 ± 19.7 -2.8  ± 34.2 0.3 ± 30.5 -1.8 ± 31.8
Same 40 (41%) -7.8 ± 17.5 -1.8 ± 22.2 -1.7 ± 21.3 -1.1 ± 21.8
A little better 13 (13%) -19.3 ± 15.3 -18.3 ± 20.6 -20.1 ± 21.6 -18.9 ± 21.0
Much better 17 (18%) -27.6  ± 14.8 -16.8 ± 28.6 -21.2 ± 28.1 -18.2 ± 27.0
Missing 15 (16%)










Area under the ROC curve 0.81 0.65 0.70 0.66
p-value <.001 .02 .004 .02
Minimal important change -16.7 -19.0 -26.2 -28.8
Sensitivity; specificity 0.76; 0.78 0.43; 0.84 0.41; 0.88 0.38; 0.90
Data presented in number (%) or meanchange ± SDchange between baseline and six month follow-up
Negative scores indicate improvement of urinary incontinence symptoms (UDI-6) and impact on daily 
life (IIQ-SF) 
* “Compared to one year ago, how would you rate your health in general now?”
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Floor and ceiling effects
We observed no floor or ceiling effects in the baseline data of our patient group. The 
lowest score was reported by at most 5% of respondents (IIQ-SF), and the highest score 
by at most 0.6% or respondents (IIQ-7 adjusted). 
As expected in the reference group, no ceiling effects were observed, though floor 
effects were present in the UDI-6 (n=76; 27%); IIQ-7 original (n=212; 76%); IIQ-7 ad-
justed (n=211; 76%); and IIQ-8 (n=211; 76%).
DisCussion
The objective of this study was to validate the UDI-6 and IIQ-7 in Dutch to provide a 
useful evaluation tool for the use in both men and women suffering from UI. In our 
population, the UDI-6 and IIQ-SF had good discriminant ability. The reproducibility 
(reliability and agreement) and construct validity of these measures were good, and 
both measures proved to be responsive and interpretable. By using the values of the 
MIC we determined, a decrease of ≥16.7 points in the UDI-6 score and a decrease of 
≥19.0 points in the IIQ-7 original, ≥26.2 in the IIQ-7 adjusted, and ≥28.8 in the IIQ-8, 
can be considered as “clinically relevant” in patients undergoing any treatment for UI.
The internal consistency of the IIQ-SF in the patient group was good with Cronbach’s 
alphas of 0.91 and 0.92. However, analysis of the UDI-6 showed moderate internal 
consistency of the total score and the domains, in both patient and reference group. 
Other validation studies found comparable Cronbach’s alphas for the UDI-6.20,21 
A possible explanation is the use of unconditional mean imputation30 for measure 
scores, which is the scoring procedure as described by the developer.6 This procedure 
allows imputing a score of one UDI-6 domain into another UDI-6 domain, e.g. missing 
items of the irritative domain may be imputed by scores of the stress domain. As a 
consequence, domain scores might be ‘contaminated’. Another possible explanation 
of a moderate internal consistency of the UDI-6 was suggested by Franzén et al.20 
The UDI-6 contains items assessing symptoms of disease called “causal indicators”. 
These are called “causal indicators” since the occurrence of these symptoms can 
cause deterioration on HRQOL, but the impact of these symptoms on HRQOL may 
vary from patient to patient. Furthermore, the patient’s perception of the severity of 
their symptoms may be influenced by other factors and concomitant symptoms.34 The 
IIQ-SF contains items measuring effects of UI on HRQOL, which reflect the level of 
HRQOL, and are regarded as “effect indicators”.34 Scales based on causal indicators 
are more heterogeneous than scales based on effect indicators. For example, a patient 
with family problems may perceive UI as having a greater effect upon their HRQOL 
than usual. Since psychometric analysis is based on the assumption that all items are 
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effect indicators reflecting the same latent HRQOL construct, the properties of causal 
items (UDI-6) affect reliability measures such as Cronbach’s alpha leading to a lower 
internal consistency.34
We recognize several limitations to this study. First, we recruited patient data from a 
tertiary urology and gynaecology centre. In this setting we expect more patients with 
severe symptoms of UI, and therefore the extent to which the results of this study can 
be generalized to other settings may be limited. Second, we did not validate the mea-
sures separately for men and women. A comparison between the two genders is desir-
able since health-seeking behaviour and bother from lower urinary tract symptoms 
(LUTS)35 and UI36,37 differs significantly between men and women. Twenty-five present 
of women were bothered by the presence of LUTS compared to 18% men, with equal 
prevalence of treatment seeking of 28% and 24% respectively, however in the absence 
of evaluation of the effect of incontinence.35 In this hospital-based survey, men were 
more likely than women to seek treatment as age and severity of LUTS increased.35 
When urinary incontinence was taken into account in a community based survey, 
45% of women versus 22% of men suffering from incontinence had sought medical 
care for their problem.36 However in a different community based study, men with 
incontinence reported a higher rate of healthcare seeking of 56% compared to 46% 
of women.37 Even though we did not intend to compare sexes and their urological 
functioning as mirrored by the questionnaires, we can highly recommend this for 
future research. This study was not designed for this purpose as we would have taken 
gender distribution into account in our sampling procedure.
The strength of this study is the study design, which enabled us to address almost 
all quality criteria for measurement properties of Terwee et al.31 An exception was the 
criterion validity, which requires the availability of a gold standard. Since there are no 
gold standards of symptoms and bother of UI, we were not able to test this property. 
Our study design also allowed us to test the UDI-6 and IIQ-SF in male patients. As 
suggested in an earlier study23, we revised the gender-specific items of the IIQ-7. 
Hence, we studied the original IIQ-7 along with two variants: the IIQ-7 “adjusted” and 
the IIQ-8. The psychometric properties of these variants of IIQ-SF were equally good. 
Therefore we would like to recommend using the “original” IIQ-7 in women as well as 





In conclusion, the UDI-6 and IIQ-7 in Dutch are reliable, valid and responsive instru-
ments, and therefore suitable for assessing symptom distress and HRQOL of UI in both 
men and women, as well as evaluating outcome of treatment.
Acknowledgments
Thanks to John S. Uebersax for giving permission to validate and his advice how to validate these mea-
sures in male patients; to Pim J. van Leeuwen for his contribution to the design of this study; to Christa A. 
Lips and Ben Wasscher for their translations of the questionnaires; to Caroline B. Terwee for her meth-
odology advice; to Gerard J.J.M. Borsboom for his statistical assistance; and especially to all the patients 
who gave their time and effort to participate.
This study was funded by the Stichting Urologisch Wetenschappelijk Onderzoek (SUWO, Rotterdam, 
the Netherlands) to make reference data collection possible.
SUWO was not involved in the design, conduct, interpretation, or analysis of the study or review or ap-
proval of the manuscript. 
53
Validation of the Dutch UDI-6 and IIQ-7
2
reFerenCes
 1. Milsom I. Epidemiology of Urinary and Faecal Incontinence and Pelvic Organ Prolapse. In: 
Abrams P, Cardozo L, Khoury S, Wein A, eds. 4th International Consultation on Incontinence. 
4th ed. Paris: Health Publication Ltd; 2009.
 2. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and qual-
ity of life. Med Care 1989;27:S217-32.
 3. Korfage IJ, Hak T, de Koning HJ, Essink-Bot ML. Patients’ perceptions of the side-effects of 
prostate cancer treatment--a qualitative interview study. Soc Sci Med 2006;63:911-9.
 4. Shumaker SA, Wyman JF, Uebersax JS, McClish D, Fantl JA. Health-related quality of life mea-
sures for women with urinary incontinence: the Incontinence Impact Questionnaire and the 
Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group. Qual 
Life Res 1994;3:291-306.
 5. Wyman JF, Harkins SW, Choi SC, Taylor JR, Fantl JA. Psychosocial impact of urinary incontinence 
in women. Obstet Gynecol 1987;70:378-81.
 6. Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA. Short forms to assess life quality 
and symptom distress for urinary incontinence in women: the Incontinence Impact Question-
naire and the Urogenital Distress Inventory. Continence Program for Women Research Group. 
Neurourol Urodyn 1995;14:131-9.
 7. Staskin D, Kelleher C. Incontinence, Patient-Reported Outcome Assessment. In: Abrams 
P, Cardozo L, Khoury S, Wein A, eds. 4th International Consultation on Incontinence. 
Paris2009:363-412.
 8. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life 
measures: literature review and proposed guidelines. J Clin Epidemiol 1993;46:1417-32.
 9. van der Vaart CH, de Leeuw JR, Roovers JP, Heintz AP. Measuring health-related quality of life in 
women with urogenital dysfunction: the urogenital distress inventory and incontinence impact 
questionnaire revisited. Neurourol Urodyn 2003;22:97-104.
 10. van der Vaart CH, de Leeuw JR, Roovers JP, Heintz AP. [The influence of urinary incontinence 
on quality of life of community-dwelling, 45-70 year old Dutch women] De invloed van urine-
incontinentie op de kwaliteit van leven bij thuiswonende Nederlandse vrouwen van 45-70 jaar. 
Ned Tijdschr Geneeskd 2000;144:894-7.
 11. Labrie J, van der Graaf Y, Buskens E, Tiersma SE, van der Vaart HC. Protocol for Physiotherapy 
Or TVT Randomised Efficacy Trial (PORTRET): a multicentre randomised controlled trial to as-
sess the cost-effectiveness of the tension free vaginal tape versus pelvic floor muscle training 
in women with symptomatic moderate to severe stress urinary incontinence. BMC Womens 
Health 2009;9:24.
 12. van Leijsen SA, Kluivers KB, Mol BW, et al. Protocol for the value of urodynamics prior to stress 
incontinence surgery (VUSIS) study: a multicenter randomized controlled trial to assess the cost 
effectiveness of urodynamics in women with symptoms of stress urinary incontinence in whom 
surgical treatment is considered. BMC Womens Health 2009;9:22.
 13. Vervest HA, Bisseling TM, Heintz AP, Schraffordt Koops SE. The prevalence of voiding difficulty 
after TVT, its impact on quality of life, and related risk factors. Int Urogynecol J Pelvic Floor 
Dysfunct 2007;18:173-82.
 14. van Leijsen SA, Kluivers KB, Mol BW, et al. Can preoperative urodynamic investigation be omit-




 15. de Vet HCW, Terwee CB, Mokkink LB, Knol DL. Measurement in Medicine. 1st ed. Cambridge: 
Cambridge University Press; 2011.
 16. Altaweel W, Seyam R, Mokhtar A, Kumar P, Hanash K. Arabic validation of the short form of 
Urogenital Distress Inventory (UDI-6) questionnaire. Neurourol Urodyn 2009;28:330-4.
 17. Cam C, Sakalli M, Ay P, Cam M, Karateke A. Validation of the short forms of the incontinence 
impact questionnaire (IIQ-7) and the urogenital distress inventory (UDI-6) in a Turkish popula-
tion. Neurourol Urodyn 2007;26:129-33.
 18. Chan SS, Choy KW, Lee BP, et al. Chinese validation of Urogenital Distress Inventory and Incon-
tinence Impact Questionnaire short form. Int Urogynecol J 2010;21:807-12.
 19. El-Azab AS, Mascha EJ. Arabic validation of the Urogenital Distress Inventory and Adapted In-
continence Impact Questionnaires--short forms. Neurourology and urodynamics 2009;28:33-
9.
 20. Franzen K, Johansson JE, Karlsson J, Nilsson K. Validation of the Swedish version of the inconti-
nence impact questionnaire and the urogenital distress inventory. Acta Obstet Gynecol Scand 
2013; 92 (5):555-61.
 21. Ruiz de Vinaspre Hernandez R, Tomas Aznar C, Rubio Aranda E. [Validation of the Spanish 
version of the short forms of the Urogenital Distress Inventory (UDI-6) and the Incontinence 
Impact Questionnaire (IIQ-7) in pregnant women] Validacion de la version espanola de las for-
mas cortas del Urogenital Distress Inventory (UDI-6) y del Incontinence Impact Questionnaire 
(IIQ-7) en mujeres embarazadas. Gac Sanit 2011;25:379-84.
 22. Zhu L, Yu SJ, Lang JH, et al. [Validation of incontinence impact questionnaire short form in 
Chinese population]. Zhonghua Fu Chan Ke Za Zhi 2011;46:505-9.
 23. Moore KN, Jensen L. Testing of the Incontinence Impact Questionnaire (IIQ-7) with men after 
radical prostatectomy. J Wound Ostomy Continence Nurs 2000;27:304-12.
 24. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract 
function: report from the Standardisation Sub-committee of the International Continence 
Society. Neurourol Urodyn 2002;21:167-78.
 25. Zee vdK, Sanderman R. Het meten van de algemene gezondheidstoestand met de RAND-36. 
Een handleiding. Groningen.
 26. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related 
quality of life. J Clin Epidemiol 2003;56:395-407.
 27. Abrams P, Andersson KE, Birder L, et al. Fourth International Consultation on Incontinence Rec-
ommendations of the International Scientific Committee: Evaluation and treatment of urinary 
incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 2010;29:213-
40.
 28. Schafer W, Abrams P, Liao L, et al. Good urodynamic practices: uroflowmetry, filling cystometry, 
and pressure-flow studies. Neurourol Urodyn 2002;21:261-74.
 29. Flycatcher Academic Support Centre. 2012, at http://www.flycatcher.eu/nld/academic-
support/.)
 30. Little RJA, Rubin DB. Statistical analysis with missing data. 2nd [rev] ed: Hoboken, N.J. : Wiley-
Interscience; 2002.
 31. Terwee CB, Bot SD, de Boer MR, et al. Quality criteria were proposed for measurement proper-
ties of health status questionnaires. J Clin Epidemiol 2007;60:34-42.
 32. McGraw K, Wong S. Forming inferences about some intraclass correlation coefficients. Psycho-
logical Methods 1996;1:30-46.
55
Validation of the Dutch UDI-6 and IIQ-7
2
 33. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of 
clinical measurement. Lancet 1986;1:307-10.
 34. Fayers PM, Hand DJ, Bjordal K, Groenvold M. Causal indicators in quality of life research. Qual 
Life Res 1997;6:393-406.
 35. Apostolidis A, Kirana PS, Chiu G, Link C, Tsiouprou M, Hatzichristou D. Gender and age 
differences in the perception of bother and health care seeking for lower urinary tract symp-
toms: results from the hospitalised and outpatients’ profile and expectations study. Eur Urol 
2009;56:937-47.
 36. Harris SS, Link CL, Tennstedt SL, Kusek JW, McKinlay JB. Care seeking and treatment for urinary 
incontinence in a diverse population. J Urol 2007;177:680-4.
 37. Li Y, Cai X, Glance LG, Mukamel DB. Gender differences in healthcare-seeking behavior for 
urinary incontinence and the impact of socioeconomic status: a study of the Medicare man-


















Validation of the Pelvic Floor 
Distress Inventory (PFDI-
20) and Pelvic Floor Impact 
Questionnaire (PFIQ-7) in a 
Dutch population
Elaine Utomo, Bertil F.M. Blok, Anneke B. Steensma  
and Ida J. Korfage





The objective of this study was to validate the Pelvic Floor Distress Inventory (PFDI-20) 
and Pelvic Floor Impact Questionnaire (PFIQ-7) in Dutch women.
methods 
Patients with pelvic floor dysfunction completed the Dutch questionnaires at (1) inclu-
sion to evaluate internal consistency, (2) 1 week later to assess test-retest reliability, and 
(3) 6 months later to assess responsiveness and interpretability of change. To assess va-
lidity, floor and ceiling effects and construct validity were tested. A population-based 
sample (reference group) completed the questionnaires once.
results 
Data of 111 patients and 283 reference group participants were analysed. Internal 
consistency of baseline scores in patient and reference groups was moderate (Cron-
bach’s alpha 0.52–0.60) to adequate in the PFDI-20 (Cronbach’s alpha 0.71–0.84) and 
adequate in the PFIQ-7 (Cronbach’s alpha 0.88–0.94). Both measures presented ad-
equate test-retest reliability (intraclass correlation coefficient 0.79–0.91) and adequate 
responsiveness (area under the receiver-operating characteristic curve both 0.77). 
Interpretability was adequate for PFDI-20 and acceptable for PFIQ-7 with a clinically 
relevant minimally important change of −23 and −29 points, respectively. At baseline, 
the scales of the PFIQ-7 showed floor effects (44–55 %) in patients, though the PFIQ-7 
summary score did not. No ceiling effects were observed. Construct validity was ad-
equate with all predefined hypotheses confirmed regarding subgroup discrimination 
using pooled patient and reference group baseline data.
Conclusions 
For assessing distress and health-related quality of life of pelvic floor dysfunction, the 
Dutch PFDI-20 and PFIQ-7 are reliable and valid in the general Dutch population, and 
also responsive and interpretable among tertiary care seeking women.
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introDuCtion
Women with complaints of pelvic floor dysfunction may present a variety of symp-
toms relating to lower urinary tract dysfunction, pelvic organ prolapse, and anorectal 
dysfunction.1 Given the coexistence and complex interaction of these symptoms, 
comprehensive condition-specific health-related quality of life (HRQOL) question-
naires are needed to measure severity and impact of pelvic floor dysfunction in a 
standardized and reproducible manner.2
The Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ)3 
were developed and validated to measure symptom distress and impact on HRQOL, fo-
cusing on pelvic organ prolapse (POP), urinary incontinence (UI), and fecal incontinence 
(FI). Short versions of the PFDI (i.e., PFDI-20) and PFIQ (i.e., PFIQ-7) were developed to 
reduce respondent’s burden.4,5 The PFDI-20 and PFIQ-7 have been validated in different 
languages6-14 though not yet in Dutch. We therefore translated the PFDI-20 and PFIQ-7 
into Dutch. Since measures must adequately address measurement properties to be 
useful in research or in practice15, 16 we tested their reliability, validity, responsiveness, and 
interpretability in Dutch women with symptoms of pelvic floor dysfunction.
methoDs
This observational study was conducted at a tertiary urology and gynaecology centre 
as part of a larger validation study of HRQOL pelvic floor measures. The study was 
approved by the Institutional Ethics Committee (MEC-2008-376).
questionnaires
In both PFDI-20 and PFIQ-7, patients reported whether they experienced symptoms of 
pelvic floor dysfunction, and if so, the extent to which these symptoms were bother-
some to them. The PFDI-20 has three scales: Pelvic Organ Prolapse Distress Inven-
tory (POPDI-6), Colorectal-Anal Distress Inventory (CRADI-8), and Urinary Distress 
Inventory (UDI-6). Response options for rating distress associated with each symptom 
ranged from 0 (“no” as in no symptoms) to 1 (“not at all” as in symptoms are pres-
ent but not bothered at all) to 4 (“quite a bit” as in symptoms are present and quite 
a bit bothered). Per scale, the mean score of answered items is multiplied by 25 to 
obtain the scale score (range 0–100).4 Summary scores are calculated by adding up 
the scale scores (range 0–300). Higher scores indicate more symptom distress.4 The 
PFIQ-7 measures impact of bladder, bowel, and vaginal symptoms on daily physical 
activity, travel, social/relationships, and emotional health. The PFIQ-7 has three scales: 
the Urinary Impact Questionnaire (UIQ-7), the Colorectal-Anal Impact Questionnaire 
Chapter 3
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(CRAIQ-7), and the Pelvic Organ Prolapse Impact Questionnaire (POPIQ-7). Response 
options range from 0 (“not at all”) to 3 (“quite a bit”). Per scale, the mean score of 
answered items is multiplied by 33.3 to obtain the scale score (range 0–100).4 Sum-
mary scores are calculated by adding up the scale scores (range 0–300).4 Higher scores 
indicate more impact on daily activity.
Linguistic validation
The measures were translated into Dutch following standardized forward-backward 
procedures,17 i.e., three independent forward translations, backward translation by a na-
tive speaker, and tested face-to-face in ten patients with pelvic floor dysfunction. Several 
minor problems were identified without the need to adapt the content of the measures. 
The Dutch versions of PFDI-20 and PFIQ-7 were then finalized (See ‘Vragenlijsten’).
study population and study design
For the patient group, inclusion criteria were women aged 18 years or older, with at 
least one symptom of pelvic floor dysfunction (UI, POP, or FI) existing for at least 3 
months, and fluent and literate in the Dutch language. Exclusion criteria were active 
malignant tumours, dementia, and mental retardation. The definitions used for UI, 
POP, and FI were according to the standardized International Continence Society 
terminology.18, 19 Thus, UI was defined as “the complaint of any involuntary leakage 
of urine,” POP as “the symptomatic descent of one or more of the anterior vaginal 
wall, the posterior vaginal wall, and the apex of the vagina or vault after hysterectomy,” 
and FI as “any involuntary loss of fecal material”.19 At the initial office visit, the treating 
physician recruited all consecutive patients potentially eligible for inclusion.
Patients received the same questionnaires at three time points (1) baseline, (2) 1 week 
later, and (3) 6 months later, and returned them through postal mail. During the test-
retest period of 1 week, no treatment was initiated or changed. One week between 
the repeated administrations was long enough to prevent recall, though short enough 
to ensure that clinical change had not occurred. Given the observational nature of this 
study, the treating physician was unrestricted in prescribing therapy after completion 
of the test-retest for individual patient care. Age and education were documented 
through the questionnaire. Educational level was classified as “low” (primary school), 
“intermediate” (high school), or “high” (college or university degree). In the third round 
the health transition item of the RAND 36-Item Health Survey (RAND 36-HTI)20, 21 was 
included through which patients scored the change in their general health compared 
to 1 year ago. The response options range from 1 (“much better”) to 5 (“much worse”). 
The prescribed treatment between baseline and the third round of the questionnaire 
was obtained from the patient’s medical record. This was categorized into conserva-
tive, pharmaceutical, or surgical treatment.
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reference group
We collected baseline data from a representative sample of adult women in the 
Netherlands through an ISO-certified (ISO 26362) Dutch panel.22 This subsample 
was stratified by gender, age, educational level, and residential area and therefore 
representative of the Dutch population above the age of 18. No medical data were 
available for this panel, and thus the presence or absence of pelvic floor dysfunction 
was unknown.
measurement properties
The psychometric measurement properties addressing the quality domains reliability, 
validity, and responsiveness were tested, and we assessed interpretability which is an 
important characteristic of measures.15
· Internal consistency (i.e., the degree of interrelatedness among the items) was 
assessed with Cronbach’s alpha. Cronbach’s alpha was determined for the sum-
mary score as well as for the scale scores. The scales intend to measure a single 
underlying concept by using multiple items. A high Cronbach’s alpha indicates 
high correlations between the multiple items in a scale, i.e., redundancy of one or 
more items thus measuring the same concept. Values between 0.70 and 0.95 were 
considered to reflect adequate internal consistency.16, 23
· Test-retest reliability (i.e., the degree to which repeated measurements in stable 
persons provide similar answers) was assessed through the intraclass correlation 
coefficient (ICC) for agreement.24 We used the two-way mixed single measures 
model in IBM® SPSS software 20.0 to calculate this. Values ≥0.70 were considered 
to reflect adequate reliability.16
· Measurement error (i.e., the systematic and random error of a patient’s score not 
attributed to true changes) was quantified using the limits of agreement (LOA) by 
Bland and Altman.25 The LOA were calculated as the absolute mean change in 
scores (meanchange) of repeated measurements during the test-retest period ±1.96 
SD (SDchange). The absolute change in mean scores of the test-retest was presented 
without a specific direction of change.
· Content validity (i.e., the degree to which the content of a measure is an adequate 
reflection of the target construct) was subjectively assessed and verified (“face 
validity”) by examining whether the items appeared to be measuring what they are 
intended to measure. We also assessed floor and ceiling effects. These occur when 
≥15 % of scores are at the lower or upper end of the scale.16, 23
· Construct validity (i.e., the degree to which measure scores are consistent with 
hypotheses based on the assumption that the measure validly measures the target 
construct) was verified by hypotheses testing of the measures using known groups 
based on patient and reference group baseline scores.23 Since no medical back-
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ground information was available for the reference group (e.g., care-seeking or not, 
presence or absence of symptoms of pelvic floor  dysfunction), we defined the 
presence of symptoms according to the response options given in the measures. 
The PFIQ-7 scale scores were used to assess PFDI-20 construct validity, i.e., the pres-
ence of POP, FI, or UI was defined as a score above zero on the POPIQ-7, CRAIW-7, 
or UIQ-7 scale, respectively.  Specific items of the PFDI-20 scores were used to assess 
PFIQ-7 construct validity, i.e., an affirmative response to any of the items of the PFDI-
20 indicating a sensation of a “bulge” in the pelvic area was defined as presence of 
POP; an affirmative response to any of the items of the PFDI-20 indicating “stool loss” 
was defined as presence of FI; and an affirmative response to any of the items of the 
PFDI-20 indicating “urine leakage” was defined as presence of UI. We formulated the 
following hypotheses:
 1.  The subgroup with POP symptoms will report significantly higher POPDI-6 
and POPIQ-7 scale scores than the subgroup without POP symptoms.
 2.  The subgroup with symptoms of FI will report significantly higher CRADI-8 
and CRAIQ-7 scale scores than the subgroup without FI symptoms.
 3.  The subgroup with symptoms of UI will report significantly higher UDI-6 and 
UIQ-7 scale scores than the subgroup without UI symptoms. 
   Construct validity was considered adequate when at least 75 % of these hy-
potheses were confirmed.16
· The responsiveness (i.e., the ability of a measure to detect changes over time) was 
assessed in all patients who received any treatment during follow-up. We evalu-
ated the linear relationship of the meanchange in measure scores between baseline 
and 6-month follow-up with the RAND 36-HTI score using the Pearson correlation 
coefficient (r). Additionally, the area under the receiver-operating characteristic 
(ROC) curve (AUC) for the measures was determined.23 By determining the AUC, 
the measures are considered as a diagnostic test, and the RAND 36-HTI functions 
as the gold standard. The AUC indicates the probability that a measure correctly 
classifies patients as improved using the RAND 36-HTI as an anchor. The AUC was 
considered adequate if ≥0.70.23
· The interpretability (i.e., the degree to which one can assign qualitative meaning 
to a measure’s quantitative score or change in scores) was tested using the anchor-
based ROC method to assess the minimally important change (MIC).23 As in diag-
nostic studies, the optimal ROC cut-off point is chosen, i.e., the value for which 
the sum of the proportions of misclassifications [(1-sensitivity) + (1-specificity)] is 
smallest. In analogy, the MIC is defined as this optimal ROC cut-off point.23
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statistical methods
Statistical analysis was performed using IBM® SPSS software 20.0. Significance was set 
at a p-value <.05. For comparison of two independent groups we used the unpaired t 
test when numerical data were considered and the chi-square test when categorical 
data were considered. For comparison of more than two independent groups, we 
used the one-way analysis of variance (ANOVA). General linear models were used to 
compare measure scores, controlling for variables that differed significantly between 
patient and reference groups in univariate analysis.
The anchor RAND 36-HTI was dichotomized for ROC analysis: patients reporting to 
be “a little better” or “much better” were classified as “improved,” while “same,” “a little 
worse,” or “much worse” were classified as “not improved.”
resuLts
Of 187 consecutive female patients, 161 (86%) were eligible for inclusion of which 117 
(73%) consented to participate (Figure 3.1). After three rounds of questionnaires, data 
were available for 111/117 (95%) patients to test at least one measurement property 
(i.e., patients completed a questionnaire at baseline and at least at one additional time 
point) of at least one measure (i.e., patients completed the PFDI-20 and/or PFIQ-7). 
Regarding the reference group, the measures were sent out to 450 panel participants 
of which 283 (63 %) responded.
The mean age was higher (p<.001) in the patient group (59±12 years) than in the 
reference group (47±15 years, Table 3.1). When completing the PFDI-20, 96% of the 
patients reported symptoms of UI, 57% symptoms of POP, and 47% symptoms of FI. 
These prevalence rates were lower (p<.001) in the reference group. Of the patients, 
74% (n=82) had more than one symptom of pelvic floor dysfunction (i.e., UI, or POP, or 
FI), compared to 17% (n=49) in the reference group.
Patients reported more symptom distress (PFDI-20) and more impact on daily 
activity (PFIQ-7) than the reference group (both p<.001). After adjusting for age and 
educational level, these differences remained significant.
internal consistency
The PFDI-20 summary score demonstrated adequate internal consistency with 
Cronbach’s alphas of 0.74 and 0.84 in patient and reference groups, respectively 
(Table 3.2). The scales of the PFDI-20 demonstrated moderate internal consistency 
for both patient (Cronbach’s alpha 0.52–0.71) and reference groups (Cronbach’s alpha 
0.60–0.74). The PFIQ-7 summary and scale scores demonstrated adequate internal 
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Age (years) 58.6 ± 12.2 47.0 ± 15.3 <.001
Educational level <.001
Low 45 (41%) 84 (30%)
Intermediate 51 (46%) 47 (17%)
High 15 (14%) 152 (54%)
Parity 2.3 ± 1.2 NA
missing 25 (23%) NA
Urinary Incontinencea (%) 106 (96%) 128 (45%) <.001
Pelvic Organ Prolapseb (%) 63 (57%) 59 (21%) <.001
Faecal Incontinencec (%) 51 (47%) 24 (9%) <.001
missing 2 (2%) 0 (0%)
Symptoms of pelvic floor dysfunction 
per patient (n)d <.001
0 0 (0%) 109 (39%)
1 29 (26%) 125 (44%)
2 55 (50%) 34 (12%)
3 27 (24%) 15 (5%)
Scores at baseline*
PFDI-20 (0-300) 93.4 ± 41.5 27.1 ± 31.7 <.001 <.001
missing 1 (1%) 0 (0%)
POPDI-6 (0-100) 22.2 ± 16.5 5.6 ± 9.8 <.001 <.001
CRADI-8 (0-100) 26.7 ± 19.5 9.3 ± 12.4 <.001 <.001
missing 1 (1%) 0 (0%)
UDI-6 (0-100) 44.7 ± 20.7 12.3 ± 16.1 <.001 <.001
PFIQ-7 (0-300) 69.0  ± 52.5 12.7 ± 27.0 <.001 <.001
missing 14 (13%) 0 (0%)
POPIQ-7 (0-100) 14.6 ± 22.4 3.4 ± 10.0 <.001 <.001
missing 14 (13%) 0 (0%)
CRAIQ-7 (0-100) 20.9 ± 27.2 4.3 ±11.9 <.001 <.001
missing 12 (11%) 0 (0%)
UIQ-7 (0-100) 35.1 ± 26.3 5.0 ± 11.3 <.001 <.001
missing 6 (5%) 0 (0%)
Data in mean ± standard deviation or number (%). No data was missing unless otherwise indicated.
Abbreviations: GLM general linear models; NA not available
*A higher score indicates greater symptom distress or impact on health-related quality of life
**p-value: corrected for age and educational level with general linear modelling (GLM)
aDefined as affirmative response to any of the items based on “urine leakage” (i.e. items 15, 16, 17 or 18 
of the PFDI-20).
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187 patients were interested to participate in the study 
 














111 patients completed 1st round of PFDI-20 
105 patients completed 1st round of PFIQ-7 
 
 108 patients completed 2nd round of PFDI-20 
107 patients completed 2nd round of PFIQ-7 
 
 
100 patients completed 3rd round of PFDI-20 










111 patients available for analysis to measure at least 





Figure 3.1 Flowchart: inclusion process of patient group
bDefined as affirmative response to any of the items based on a sensation of “a bulge” in the pelvic area 
(i.e. items 3, 4, 6 or 14 of the PFDI-20).
c Defined as affirmative response to any of the items based on “stool loss” (i.e. items 9 or 10 of the PFDI-
20). 
dPelvic floor dysfunction include urinary incontinence, pelvic organ prolapse, and faecal incontinence
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consistency in both patient (Cronbach’s alpha 0.89–0.94) and reference groups (Cron-
bach’s alpha 0.88–0.93).
reliability
The retest assessments were completed on average 8 days after baseline measure-
ment. The ICCagreement was 0.88 for the PFDI-20 summary score and ranged from 0.86 
to 0.90 for the PFDI-20 scales (Table 3.2). The ICCagreement of the PFIQ-7 summary score 
was 0.83 and ranged from 0.79 to 0.91 for the PFIQ-7 scales. All retest assessments 
indicated adequate reliability.
measurement error
The absolute meanchange of repeated measurements during the test-retest period, the 
corresponding SDchange, and the LOA are presented in Table 3.2. Relating the LOA range 
to the range of all possible measure scores, the overall magnitude of the measurement 
error is 10% (59.2 of 600) for the PFDI-20 summary score and 13–14%(27, 27.4, and 26.6 
of 200 for the POPDI-6, CRADI-8, and UDI-6, respectively) for scale scores, 17% (101.9 
of 600) for the PFIQ-7 summary score, and 20–26% (52.2, 40, and 49.8 of 200 for the 
POPIQ-7, CRAIQ-7, and UIQ-7, respectively) for scale scores.
Floor and ceiling effects
No ceiling effects were observed in the PFDI-20 and PFIQ-7 summary and scale scores, 
either in the patient or reference group. In patients, floor effects were found in two 

















PFDI-20 (0-300) 0.74 (n=96) 0.84 0.88 (n=99) 13.3 ± 15.1 -16.3 – 42.9
POPDI-6 (0-100) 0.52 (n=103) 0.60 0.86 (n=100) 5.6 ± 6.9 -7.9 – 19.1
CRADI-8 (0-100) 0.71 (n=106) 0.71 0.90 (n=99) 5.6 ± 7.0 -8.1 – 19.3
UDI-6 (0-100) 0.60 (n=104) 0.74 0.89 (n=100) 6.8 ± 6.8 -6.5 – 20.1
PFIQ-7 (0-300) 0.89 (n=89) 0.93 0.83 (n=85) 19.2 ± 26.0 -31.8 – 70.1
POPIQ-7 (0-100) 0.92 (n=90) 0.92 0.79 (n=86) 7.3 ± 13.3 -18.8 – 33.4
CRAIQ-7 (0-100) 0.94 (n=94) 0.92 0.91 (n=86) 5.8 ± 10.2 -14.2 – 25.8
UIQ-7 (0-100) 0.90 (n=101) 0.88 0.82 (n=95) 9.9 ± 12.7 -15.0 – 34.8
*Higher scores indicate greater symptom distress or impact on health-related quality of life
** Limits of agreement described by Bland and Altman25= meanchange ± 1.96*SDchange
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scales of the PFIQ-7, i.e., POPIQ-7 and CRAIQ-7, with 55 and 44% of subjects, respec-
tively, exhibiting the most favourable low score of zero (Table 3.3). No floor effects 
were observed in the PFIQ-7 summary score. In the reference group, the PFDI-20 and 
PFIQ-7 summary and scale scores had floor effects ranging from 23 to 84%.
Construct validity
We appropriately confirmed all three predefined hypotheses (Figure 3.2): 
1. The subgroup with POP symptoms (symptoms of vaginal bulge) reported higher 
scores on the POPDI-6 (23.3±17.9) and POIQ-7 (12.8±20.6) scales than the subgroup 
without symptoms (5.7±9.3 and 3.4±10.7, respectively), (p<.0001).
2. The subgroup with FI symptoms (stool loss) reported higher scores on the CRADI-8 
(30.0±18.7) and CRAIQ-7 (30.2±28.4) scales than the subgroup without symptoms 
(7.0±9.4 and 3.6±10.7, respectively), (p<.0001).
3. The subgroup with UI symptoms (urine leakage) reported higher scores on the 
UDI-6 (39.1±21.8) and UIQ-7 (19.3±23.7) scales than the subgroup without symp-
toms (7.2±9.5 and 1.3±6.0, respectively), (p<.0001).
responsiveness
A total of 100 patients completed the PFDI-20 and 97 patients the PFIQ-7 on average 
5.7 months after baseline assessment (third round, Figure 3.1). Of 111 patients, 67 (60%) 
received treatment during follow-up as determined by the treating physician. Patients 
received conservative (n=50, 75 %), pharmaceutical (n=11, 16 %), and/or surgical 
treatment (n =44, 66 %). Table 3.4 presents the meanchange in measure summary scores 
between baseline and 6-month follow-up of the measures, stratified by the responses 
of the RAND 36-HTI. We combined the categories of patients reporting their health 
Table 3.3 Floor and ceiling effects of baseline scores
Questionnaire
Patients (n=111) Reference group (n=283)













PFDI-20 (0 – 300) 0 0 0 0 64 23 0 0
POPDI-6 (0 – 100) 14 13 0 0 177 63 0 0
CRADI-8 (0 – 100) 10 9 0 0 127 45 0 0
UDI-6 (0 – 100) 4 4 0 0 117 41 0 0
PFIQ-7 (0 – 300) 5 5 0 0 172 61 0 0
POPIQ-7 (0 – 100) 53 55 1 1 237 84 0 0
CRAIQ-7 (0 – 100) 44 44 1 1 225 80 0 0
UIQ-7 (0 – 100) 14 13 1 1 205 72 0 0
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compared to 1 year ago as “much worse” (n=4) or “a little worse” (n=9). The relation-
ships between the meanchange of the summary scores of the measures and the RAND 
36-HTI as anchor were linear (PFDI-20 r =0.49, p<.001; PFIQ-7 r =0.41, p=.002). The 
AUC for both measures was 0.77 (p<.001 for PFDI-20 and p=.001 for PFIQ-7), demon-
strating adequate responsiveness.
interpretability
Using ROC analysis, the optimum cut-off point was used to determine the MIC. Thus, 
with 73% correctly identified as improved and 75%as not improved, the MIC for the 
PFDI-20 summary score was −22.9 (Table 3.4). According to the lower limit of the LOA 
(Table 3.2), improvements in PFDI-20 summary scores of ≤16.3 cannot be attributed 
to a true improvement of the respondent, but should be attributed to a measurement 
error. The MIC of the PFDI-20 (−22.9) lies adequately outside the LOA (−16.3 to 42.9), 
meaning an improvement of ≥22.9 points on the PFDI-20 summary scale is a true 
clinically relevant change in score. Treated patients reporting “a little better” on the 
RAND 36-HTI 6 months after baseline showed mean changes of −32.3 on the PFDI-20 
summary score, which indicates a true clinically relevant improvement.
The MIC for the PFIQ-7 summary score was −28.6, with 75% correctly identified as 
improved and 77 % as not improved (Table 3.4). This MIC (−28.6) lies between the 
LOA (Table 3.2: −31.8 to 70.1) and therefore cannot be detected as a true clinically 
relevant improvement, since an improvement of ≤31.8 points should be attributed to 

























































































Figure 3.2 Construct validity. Pooled patient and reference baseline scales scores with comparisons 
between known groups. The bold lines indicates the median scale score and the box the interquartile 
range, the whiskers presenting the min.-max. The mean is indicated with a plus sign. 
69
Validation of the Dutch PFDI-20 and PFIQ-7
3
a measurement error. The change values lying between the lower LOA (−31.8) and the 
MIC (−28.6) are considered important by patients, but cannot be distinguished from 
measurement error. Treated patients reporting “a little better” on the RAND 36-HTI 6 
months after baseline showed mean changes of −31.3 for the PFIQ-7 (Table 3.4), which 
is close to the lower limit of the LOA.
DisCussion
The objective of this study was to validate the PFDI-20 and PFIQ-7 in Dutch to provide 
an adequate tool to assess symptom distress and impact of pelvic floor dysfunction on 
HRQOL. Our findings regarding the reliability, construct validity, and responsiveness 
were generally very positive.
Both summary scales and four of six scales scores showed adequate internal 
consistency. The POPDI-6 and UDI-6 showed low to moderate internal consistency 
with Cronbach’s alphas of 0.52 and 0.60 in patient groups, respectively, indicating 
Table 3.4 Responsiveness and Interpretability
Health transition item (RAND-36)*
Number (%)







Much worse / A little worse 13 (16%) -1 ± 18.4 -23.2 ± 52.6
Same 31 (39%) -13.3 ± 25.3 -1.8 ± 40.7
A little better 9 (11%) -32.3 ± 40.2 -31.3  ± 36.4
Much better 14 (18%) -47.7 ± 39.6 -73.6  ± 51.7
p-value between RAND-36 items** .001 .001






Area under the ROC curve 0.77 0.77
p-value <.001 .001
Minimal important change -22.9 -28.6
Sensitivity; specificity 0.73 ; 0.75 0.75 ; 0.77
Data presented in number (%) or meanchange ± SDchange between baseline and 6-month follow-up. Nega-
tive scores indicate an improvement in pelvic floor distress and/or impact.
Abbreviation: ROC receiver-operative characteristic
* “Compared to one year ago, how would you rate your health in general now?”
** Analysis of variance (ANOVA) was used
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low homogeneity. Similar alphas were found in the Turkish11 and Swedish10 versions. 
As expected, floor effects were present in the reference group (23–84%) and ceiling 
effects were absent (0%) in summary and scale scores of both measures. In patients, 
we observed substantial floor effects in the POPIQ-7 (55%) and CRAIQ-7 scales (44%), 
indicating a not normal score distribution towards the most favourable low score of 
zero. The PFIQ-7 summary score did not demonstrate floor effects. Potentially patients 
typically experience different types of pelvic floor dysfunction (Table 3.1), but not 
necessarily all possible symptoms, e.g., POP and FI without UI.
The MIC of the PFIQ-7 indicated that the measurement error was too wide to detect 
clinically relevant improvement. However, the LOA are group averages, and just as 
the normal distribution, the measurement error range is bell-shaped and balances 
out towards the outer limits and therefore possibly less clinically relevant at the lower 
limit. Furthermore, the MIC lies close to the lower limit of agreement, with a small dif-
ference of 3.2 points on a scale of 0–300 which represents meaningful improvement, 
but cannot be distinguished from measurement error. We therefore recommend using 
the lower limit of agreement of −31.8 as MIC for PFIQ-7. 
Our study has some limitations. First, it is desirable to have a correlation of 0.5–0.6 
between the anchor and the meanchange in scores at the 6-month follow-up23, while 
our anchor had a correlation of r =0.49 and r =0.41 for the PFDI-20 and PFIQ-7, respec-
tively. This can be because generic measures, such as our RAND 36-HTI anchor, may 
not reveal the impact of sexual, urinary, and bowel dysfunctions on patients, because 
such dysfunctions tend not to be perceived as health problems.26 Furthermore, it is 
preferable to measure the change in health prospectively. Second, since medical in-
formation about the reference group was not available, we determined the prevalence 
rates of symptoms of pelvic floor dysfunction using self-reported items of the PFDI-
20. Third, this validation study applies to measurements in groups of patients, thus 
not directly to individual patients for individual measurements. Nevertheless, these 
questionnaires may create the opportunity to discuss certain important, but possibly 
less obvious, topics (e.g., emotional health) with the patient. Fourth, our study setting 
allowed us to determine the MIC of improvement, though not of deterioration. Only 
patients after treatment were included for analysis of responsiveness and interpret-
ability. These patients were treated with the intention to improve their condition. We 
therefore did not determine the MIC of deterioration. And lastly, our study lacks the 
use of objective measures for assessment of symptoms of pelvic floor dysfunction.
The strengths of our study are the extensive assessment of measurement properties, 
covering the reliability (test-retest), validity, and—in particular—the responsiveness 
and interpretability of the measures in women after any treatment of pelvic floor 
dysfunction. An exception is the criterion validity, which requires the availability of 
a gold standard. Since there are no gold standards of symptoms and bother of pelvic 
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floor dysfunction, we were not able to test this property. We also included a reference 
population which is an important addition for the interpretation of the score distribu-
tion of the general population. The prevalence rates we found were comparable to the 
reported rates in the literature. In our study, the prevalence rates of UI and FI in the ref-
erence group were 45 and 9%, respectively, and are similar to the reported prevalence 
of UI in women in the general population (30–60%)27,28 and FI in men and women in 
the general population (0–15.2% without significant gender differences).29 The preva-
lence of POP in our reference group (21%) was higher than the reported prevalence 
of 4–15%.27 Though this may be explained by the definition used by Milsom27: the 
reported rates are based on pelvic heaviness, genital bulge, and digital pressure on the 
vagina or perineum by defecation, and we included the need for digital pressure in the 
vaginal area for urination in the definition of POP. Ultimately, we had a high response 
rate of 73% with a limited dropout rate at 6 months of only 17%. 
In conclusion, our findings provide positive evidence for the appropriateness of the 
Dutch PFDI-20 and PFIQ-7 to measure symptom distress and quality of life changes in 
women with pelvic floor dysfunction. With this study we validated the Dutch versions 
of the PFDI-20 and PFIQ-7 allowing use of these short forms for clinical or research 
purposes. 
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Fecal incontinence (FI) is known to have a major impact on quality of life. The Fecal 
Incontinence Quality of Life scale (FIQL) and Fecal Incontinence Severity Index (FISI) 
have been developed to assess this impact. The aim of this study was to validate the 
FIQL and FISI in the Dutch language. 
methods
The study population consisted of women and men experiencing FI and a reference 
group. The FIQL (four domains) and FISI questionnaires were validated by testing 
standardized measurement properties: discriminative ability, internal consistency, 
reproducibility, construct validity, and responsiveness.
resuLts
A total of 55 patients and 277 reference participants were included. Patients had 
significant lower and higher scores at the FIQL and FISI, respectively, than references 
(FIQL: 2.58±0.70 and 3.92±0.36, FISI: 38.57±10.73 and 23.17±15.01; p<.001), indicating 
worse functioning in patients and with this the discriminative abilities of the measures. 
The FIQL demonstrated adequate internal consistency on all domains (0.72–0.96), 
except for the embarrassment domain (0.55). The reproducibility was good for both 
measures. A negative correlation was found between the FIQL and FISI. Furthermore, 
the FIQL showed a positive (0.77) and the FISI a negative correlation -0.31) with the 
Mental Component Summary scale of the SF-12. Responsiveness analysis showed a 
minimal important change of 0.40 points for the FIQL.
ConCLusion
Validity and reliability were good in the Dutch FIQL, but inconclusive in the FISI. The 
Dutch FIQL can support physicians in determining the impact of FI on patient’s quality 
of life. 
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introDuCtion
The spectrum of fecal incontinence (FI) comprises the involuntary loss of gas, liquid, 
and solid stool.1 Prevalence figures differ from 1.4% to 42%, depending on the age 
and sex of the population and the definition of incontinence.2-4 The incidence of FI 
is higher in women and higher with age. FI is known to have a major impact on the 
quality of life (QoL) in patients, resulting in psychological symptoms, functional loss 
in daily life, and even social isolation.5 Furthermore, FI is associated with other pelvic 
floor disorders such as urinary incontinence and pelvic organ prolapse.6 
To assess the severity of FI and its impact on QoL, standardized and validated instru-
ments are needed, which can also be used to diagnose FI and to assess the effective-
ness of FI therapy. It is important to establish that measures adequately evaluate the 
topic of interest before they can be used in clinical practice. Standardized validation 
processes have been developed to assess this ability.7 Several validated questionnaires 
are available in English, such as the International Consultation on Incontinence Modu-
lar Questionnaire-Bowel symptoms (ICIQ-BS),8 Manchester Bowel Questionnaire, 9 
Fecal Incontinence Quality of Life scale (FIQL)10 and the Fecal Incontinence Severity 
Index (FISI).11 
We have chosen to use the FIQL and the FISI because of the grade B recommenda-
tion by the International Continence Society, prevalent use in clinical research about 
pelvic floor disorders, and personal preference. The FIQL was also validated in various 
other languages.12–17 The FIQL is a condition-specific quality of life measure to assess 
FI.10 The FISI is a scoring system to assess the severity of symptoms of FI.11 To enable 
the use of proper measures in Dutch clinical practice, versions of the FISI and FIQL 
have yet to be translated and validated. The aim of this study is to provide validated 
versions of the Dutch FISI and FIQL following a standardized procedure to evaluate 
the measurement properties.18
methoDs
This study is part of a large health-related QoL study among patients visiting a tertiary 
pelvic floor center.19–21 Approval was obtained by the local medical research ethics 
committee (MEC-2008-376) and guidelines following good clinical practice were 
followed.
Linguistic Validation
A standardized guideline was used for the translation of the FIQL and the FISI mea-
sures.22 Three native Dutch each independently translated the English FIQL and FISI to 
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Dutch. After discussion and revision of differences, a native English speaker performed 
a backward translation. In a pilot study, 10 patients participated in a face-to-face vali-
dation and changes were made according to their feedback. The final versions of the 
FISI and FIQL were then used for this study (See “Vragenlijsten”).
study Population
Patient group
Women and men were eligible for inclusion when they experienced symptoms of 
FI for at least 3 months, spoke fluently Dutch, and were over 18 years old. Patients 
with current malignancy, dementia, mental retardation, and/or another neurologi-
cal disease were excluded. Eligible patients were informed about this study by their 
physician during a regular outpatient visit. If interested in participation, they received 
an information package containing the consent form and the first two questionnaires. 
After written informed consent was given, these questionnaires were to be filled out 
during the inclusion visit, and 1 week after inclusion. The second set of questionnaires 
was sent out through postal mail and completed 6 months after inclusion. Treatment 
was not initiated during the first week of study participation. An extra question taken 
from the RAND 36-Item Health Survey, the RAND 36- Health Transition Item (RAND 
36-HTI), was added to the last questionnaires.23 This question compares the general 
health of patients to 1 year ago. 
Reference group 
An ISO-certified (ISO 26362) panel was used as a reference group. Stratification for 
age, educational level, and residence was performed to create a representative group 
of the Dutch general population. Beforehand, the presence of FI was unknown.
questionnaire
The questionnaire consisted of three measures: 
· The FIQL is a condition-specific measure that evaluates QoL in patients who ex-
perience FI. The measure consists of 29 questions, subdivided into four subscales: 
Lifestyle, Coping/Behaviour, Depression/Self-perception, and Embarrassment. 
With a few exceptions, responses are graded on a 4-point Likert-scale ranging 
from 1 ‘‘strongly agree’’ to 4 ‘‘strongly’’ disagree. The additional response option 
‘‘not applicable’’ is graded with a score of 4, in concordance with Dr. Rockwood, 
developer of the FIQL.10 Question 1, general health, is graded from 1 ‘‘excellent’’ 
to 5 ‘‘poor’’ and is reversely scored. Question 4, FI specific depression, is graded 
from 1 ‘‘extremely so’’ to 6 ‘‘not at all.’’ The scale scores are calculated by adding 
the numerical values of all responses in that specific scale and then dividing by its 
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number of items. Scale scores are only calculated if at least half of the items have 
been answered. Higher scores indicate a better QoL.10
· The FISI is a severity rating score for FI. This score evaluates the frequency of four 
types of FI: gas, mucus, and liquid and solid stool. Frequency options range from 
‘‘two or more times a day’’ to ‘‘never.’’ Surgeon and patient specific ratings are avail-
able. In this study, the scores were based on patient specific ratings. Higher scores 
indicate more severe FI.11
· The Short Form Health Survey (SF-12) is a general health QoL questionnaire. Based 
on the responses two summary measures can be calculated, the physical compo-
nent summary (PCS-12) and the mental component summary (MCS-12).24 The SF-12 
was distributed to the patient group only.
measurement Properties




This indicates the extent to which the items in a (sub) scale assess the same construct. 
A Cronbach’s alpha of >0.70 was considered to show adequate and >0.50 to show 
moderate internal consistency.18
Reproducibility
This indicates the degree to which scores in a stable patient remain similar on repeated 
measurements. The intraclass correlation coefficient (ICC) was calculated to evaluate 
test-retest reliability, that is, the extent to which patients can be differentiated from 
each other, despite measurement error. A value of at least 0.70 was required for ad-
equate test-retest reliability.25 Agreement concerns the similarity between scores on 
repeated measures. The measurement error (systematic and random error of a score 
not due to true changes) was quantified as limits of agreement (LOA). The LOA repre-
sent the range of a specific percentage of the differences between two sets of scores 
and are calculated as the mean change in score ±1.96 * standard deviation (SD) of the 
changes.26 The impact of the measurement error has been calculated by relating the 
range of the LOA to the range of the total score of the measure.
Validity
Content validity
This is the extent to which the measure addresses the concepts of interest in the target 
population. Face validity is the degree to which the measures indeed presents an ad-
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equate reflection of the construct to be measured, in this case clinical symptoms and 
quality of life dependent on FI.18 Floor or ceiling effects are present if more than 15% 
of the responders reported the highest or the lowest score.18 Floor and ceiling effects 
were determined for total and scale scores.
Criterion validity
This is the correlation between the measure of interest and a gold standard. No perfect 
gold standard exists for the FIQL or FISI. The SF-12 was chosen as a substitute, because 
it is a commonly used generic health-related QoL measures and consists of a physical 
and a mental component scale, which could correspond to the FISI and FIQL, respec-
tively. The correlation between the FIQL and FISI was determined as well. Pearson’s r 
was used to calculate the correlations between the different measures.18
Construct validity
This is the extent to which predefined hypotheses about the scores of the FIQL and 
FISI measures in relation to other measurements could be confirmed. If at least 75% 
of these hypothesis were correct, construct validity was considered adequate.18 We 
formulated the following hypotheses:
a. FISI and FIQL scores will be negatively correlated.
b. FISI scores will be higher in patients than in the reference group.
c. FIQL scores will be lower in patients than in the reference group.
d. In patients FIQL scores will be positively correlated with MCS-12 scores.
Responsiveness
This is the ability of a measure to detect clinical important change over time. This was 
only calculated for patients who received treatment. The area under the receiver op-
erating characteristic (ROC) curve (AUC) shows the ability of a measure to distinguish 
patients who have improved from those who have not. The RAND 36-HTI was used as 
an external criterion to determine the AUC for the FIQL and FISI scores. An AUC of at 
least 0.50 was considered adequate.18
Interpretability
This is the degree to which a qualitative meaning can be assigned to the quantitative 
scores of the measure. To indicate a true clinical relevant improvement we used the 
minimal important change (MIC), defined as the optimal ROC cut-off point; the value 
for which the sum of proportions for misclassifications ([1-sensitivity]+[1-specificity]) 
was smallest.7 The LOA should be smaller than the MIC.18
81
Validation of the Dutch FIQL and FISI
4
statistical methods
To determine an adequate sample size quality criteria were followed, which stated 
that at least 50 patients were required.18 We reported continuous data as mean and SD 
and the categorical data as numbers and percentages. Differences between patient 
and reference group were evaluated using the Student’s t-test and Chi-square test 
for continuous and categorical variables, respectively. One-way analysis of variance 
(ANOVA) was used for the evaluation of more than two independent groups. Treat-
ment options were divided into three subgroups; conservative, pharmaceutical, and 
surgical. A two-sided p-value of <.05 was considered significant. Statistical analysis was 
performed using SPSS version 21.0 (IBM Crop., Armonk, NY).
resuLts
Out of the 91 patients interested in study participation, 55 (60%) completed the first 
questionnaire (Figure 4.1). Table 4.1 displays the characteristics of patient and refer-
ence group (n=277) and shows a higher percentage of women in the patient group 
than in the reference group. The total score and four subscale scores of the FIQL are 
significantly lower in the patient group, indicating a worse quality of life due to FI. The 




For the FIQL the Cronbach’s alpha ranged from 0.55 to 0.96 on the total score and 
on the four separate domains in the patient group. It was below 0.70 for the  embar-
rassment domain only, indicating moderate internal consistency for that domain and 
adequate internal consistency for the total score and the three other domains. For 
the reference group the Cronbach’s alpha for the FIQL were adequate as well (Table 
4.2). The FISI had a low Cronbach’s alpha of 0.22 in patients, while it had a moderate 
Cronbach’s alpha of 0.66 in the reference group (Table 4.2).
Reproducibility
The test retest period had a mean duration of 7.5 days. Table 4.2 demonstrates the 
excellent reliability for the total (ICC 0.95) and domain scores (ICC 0.80–0.95) of the 
FIQL. A good reliability was shown for the FISI (ICC 0.72) as well. The impact of the 
measurement error is expected to be 25% when relating the range of the LOA (-0.51 to 
0.47) to the range of the total FIQL score (0–4). For the FISI the impact of  the measure-





Face validity was considered adequate for the FIQL and FISI by the researchers and 10 
patients during the pilot study. For the total score of the FIQL, a ceiling effect was ob-
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Eligible for study participation 
(n = 74) 
Completed first 
questionnaire 
(n = 55) 
Not eligible: 
• Already started treatment 
(n = 12) 
• No symptoms of fecal 
incontinence (n = 3) 
• Dementia (n = 1) 
• Recent malignancy (n = 1) 
Completed second 
questionnaire 
(n = 45) 
Non-responders 10/55 
Declined participation  
(n = 12) 
Non-responders 




(n = 41) 
Non-responders 4/55 
Available for analysis 






Consent to study participation 
(n = 57) 
Incomplete questionnaire 
(n=2) 
Figure 4.1 Flowchart: inclusion process of patient group
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For the FISI, a floor effect was observed in the reference group (16%), again reflecting 
the low prevalence of FI.
Criterion validity
In the patient group no correlation was found between FIQL (or any of its domain 
scores) and FISI, while in the reference group significant negative correlations were 
found (Table 4.3). Correlations of the FIQL and the FISI with the PCS-12 were insig-
nificant (Table 4.3). Significant positive correlations were found for all four domains 
and total score of the FIQL with the MCS-12, and a significant negative correlation was 
found for the FISI and MCS-12. 






Gender, number of women (%) 52 (95) 141 (51) < .001
Age (years), mean±SD 59.3 ± 12.45 48.7 ± 16.2 < .001
Educational level, number(%)
Lower 20 (36) 59 (21) .01
Middle 25 (45) 133 (48)
Higher 10 (18) 85 (31)
Scores, mean ± SD
FISIa 38.57 ± 10.73 23.17 ± 15.01 <.001
FIQLb 2.58 ± 0.70 3.92 ± 0.36 <.001
Lifestyle 2.82 ± 0.93 3.92 ± 0.33 <.001
Coping/behaviour 2.07 ± 0.73 3.85 ± 0.43 <.001
Depression/self-perception 3.20 ± 0.98 4.04 ± 0.41 <.001
Embarrassment 2.23 ± 0.80 3.86 ± 0.43 <.001
Scores at 6 month follow-up, mean±SD (n=45)
FISIa 35.91 ± 14.41 .16d
FIQLb 2.72 ± 0.66 .01d
Lifestyle 2.97 ± 0.76 .02d
Coping/behaviour 2.24 ± 0.77 .01d
Depression/self-perception 3.33 ± 0.79 .17d
Embarrassment 2.37 ± 0.89 .06d
Scores SF-12, mean±SD (n = 23)
PCS-12c 41.50 ± 11.66
MCS-12c 46.26 ± 13.39
a Higher FISI scores indicate more severe FI.
b Higher FIQL scores indicate a better FI quality of life.
c Scores higher than 50 indicates better quality of life, scores lower than 50 indicates poorer quality of life.
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Construct validity
Three of four predefined hypotheses were confirmed, indicating good construct validity. 
a. An insignificant correlation was found between FIQL and FISI scores, and the hy-
pothesis could therefore not be confirmed.
b. FISI scores of patients were higher than those of the reference group.
c. FIQL scores of patients were lower scores than those of the reference group.
d. The MCS-12 was positively correlated with the FIQL on all domains.
Responsiveness
At 6 month follow-up 45 patients completed the FIQL and FISI, of whom 32 patients 
had received treatment. Treatment was conservative in 17 patients, pharmaceutical in 
nine patients and surgical in six patients. The change in scores is shown in Table 4.1. The 
AUC for the FIQL in this group was 0.69, with a p-value of .08 (Table 4.4). For the FISI 
an AUC of 0.45 was found, with a p-value of .62. 
Interpretability
Table 4.4 displays a MIC for the FIQL of 0.40 with 63% correctly identified as improved 
and 75% as not improved. The MIC is just within the range of the LOA, indicating that a 
change of 0.40 points could possibly be attributed to measurement error. For the FISI 
a MIC of 11.50 with 100% correctly identified as improved and 16% as not improved is 
found. This MIC is within the LOA range, indicating that with a change of 11.50 points a 
true improvement cannot be de distinguished from a measurement error. 
Table 4.4 The FIQL and FISI scores in patients who have received treatment and their corresponding 







RAND-36 health transition item
Much worse / a little worse 5 (16) 0.23 ± 0.88 2.80 ± 9.42
Same 15 (48) 0.28 ± 0.34 -8.21 ± 15.85
A little better 5 (16) 0.40 ± 0.39 1.60 ± 6.43
Much better 6 (19) 0.74 ± 0.45 -11.67 ± 15.27
Area under the ROC curve 0.69 0.45
p-value .08 .62
Minimal important change 0.40 11.50
Sensitivity; specificity 0.63 ; 0.75 1.00 ; 0.16
The RAND-36 functions as an anchor.
Data presented are in number (%) or meanchange ±SDchange between baseline and follow-up at 6 months.
aResponsiveness has only been reported for the 31 patients who received treatment. 
bPositive scores indicate an improvement in quality of life.




With this study, we have addressed the need for validated measures in the Dutch 
language for the assessment of the impact and severity of FI. We found an adequate 
reliability and validity for the FIQL, for the FISI these remain inconclusive. The results 
differed significantly between patient and reference groups for both measures, indicat-
ing worse quality of life and more severe symptoms of FI in the patient group, thereby 
demonstrating their discriminative power.
The Cronbach’s alpha ranged between 0.55 and 0.95 for the total score and the 
four separate domains, which is similar to other validation studies.12,13,15,17 The internal 
consistency was, therefore, adequate for all but one domain. The Cronbach’s alpha for 
the embarrassment scale of 0.55 was below the minimum of 0.70 that is considered 
adequate. Such a low Cronbach’s alpha has previously also been reported in other 
validation studies.12,15,17 This embarrassment scale consists of (only) three questions. It 
addresses two unrelated aspects of shame, which may have led to a diverse pattern of 
answers and thus a relatively low Cronbach’s alpha. In our opinion, the lower internal 
consistency for this scale is not problematic. 
The low internal consistency we found for the FISI could (partially) be explained by 
the fact that the FISI is a scoring system for symptoms of FI. The construct measured by 
the FISI is observable and it is therefore clear that each item of the FISI contributes to 
the construct of FI. Guidelines state that low internal consistency does not have to be 
problematic if the construct to be measured is evident.7
For both measures the high ICC indicates an excellent reproducibility. The ICC 
for the FIQL total score and its four different domain scales range from 0.80 to 0.95, 
similar to previous validation studies.12–14,17 The embarrassment scale showed a good 
reproducibility (ICC 0.80), even though it showed a sub adequate internal consistency 
(Cronbach’s alpha 0.55). This strengthens the earlier assumption that the low internal 
consistency is acceptable. Future research could focus on this embarrassment scale 
by assessing the impact of redistribution of the scale items, deletion of the scale or 
patient interviews.
Similar to other validation studies, a scoring system was used to assess the correlation 
between clinical symptoms and the FIQL questionnaire. The FISI measure was chosen 
for this study, other studies have used both the FISI and Wexner scores.13,15,17 Nega-
tive correlations between the FIQL and FISI were seen in both patient and reference 
groups, however, these were only significant in the reference group. The insignificant 
correlation in the patient group might be explained by the small sample size. This is the 
only  predefined hypothesis that was not confirmed for the construct validity.
We found a good correlation for the FIQL and the FISI with the MCS-12. This was 
expected, given that the four domains of the FIQL mainly address the experience of 
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FI and not so much the (physical) symptoms. In other validation studies, which used 
the SF-36 to determine criterion validity,13,15 positive correlations were found between 
the FIQL and some of the physical domain scores of the SF-36, however, we could not 
repeat this since we used the PCS-12. Therefore, an adequate comparison with the 
other validation studies cannot be made. 
Responsiveness analysis of the FIQL showed a borderline significant AUC of 0.69 
(p=.08), indicating a good correlation of the FIQL with clinical change determined with 
the RAND 36-HTI. The small number of patients available for this analysis might have 
contributed to the borderline significant p-value for the FIQL, and also have caused 
the AUC of 0.45 for the FISI. In addition, the weak correlation between the FISI and 
the RAND 36-HTI could be caused by the more divergent FISI scores. However, we 
could not elucidate the cause of this weak correlation. The difference between the 
constructs to be measured, that is, the experience versus the actual severity of the FI 
symptoms, could explain the difference found during the responsiveness and inter-
pretability analysis with the RAND 36-HTI for the FIQL and FISI. 
The strengths of this study are the use of standardized measurement properties 
to evaluate the quality of the Dutch versions of the FIQL and FISI and the use of a 
reference group to assess the ability of both measures to detect clinically relevant dif-
ferences. Limitations of this study include the small number of patients who received 
treatment during the 6 months follow-up. This complicated the adequate evaluation 
of responsiveness and interpretability for the FISI.
ConCLusion
The Dutch version of the FIQL showed good reliability and validity for use in patients 
with FI. The measurement properties of the FISI were found to be inconclusive. It is 
recommended to confirm the responsiveness of the FIQL and measurement proper-
ties of the FISI in a bigger cohort in future research. 
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To establish the reliability and validity of the Dutch version of the Pelvic Organ Pro-
lapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) in women with pelvic 
floor dysfunction.
methods 
The PISQ-12 was translated into Dutch following a standardized translation process. A 
group of 124 women involved in a heterosexual relationship that have had symptoms 
of urinary incontinence, fecal incontinence and/or pelvic organ prolapse for at least 
3 months were eligible for inclusion. A reference group was used for assessment of 
discriminative ability. Data were analysed for internal consistency, reproducibility, 
construct validity, responsiveness, and interpretability. An alteration was made to item 
12 and was corrected for during the analysis.
results 
The patient group comprised 70 of the 124 eligible women, and the reference group 
comprised 208 women from a panel representative of the Dutch female population. 
The Dutch PISQ-12 showed an adequate internal consistency with a Cronbach’s alpha 
of 0.57 – 0.69, increasing with correction for item 12 to 0.69 – 0.75, for the reference 
and patient group, respectively. Scores in the patient group were lower (32.6±6.9) than 
in the reference group (36.3±4.8; p=.0001), indicating a lower sexual function in the 
patient group and good discriminative ability. Reproducibility was excellent with an 
Intraclass correlation coefficient for agreement of 0.93 (0.88 – 0.96). A positive cor-
relation was found with the Short Form-12 Health Survey (SF-12) measure representing 
good criterion validity. Due to the small number of patients who had received treat-
ment at the 6-month follow-up, no significant responsiveness could be established. 
Conclusion
This study showed that the Dutch version of the PISQ-12 has good validity and reliabil-
ity. The PISQ-12 will enable Dutch physicians to evaluate sexual dysfunction in women 
with pelvic floor disorders.
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introDuCtion
Women who suffer from pelvic floor disorders (PFD) generally experience a reduced 
quality of life.1 PFD includes urinary incontinence (UI), pelvic organ prolapse (POP) 
and/or fecal incontinence (FI). The prevalence of PFD in adult women has been es-
timated to be 23.7% and increases with age up to 49.7% in women aged 80 years or 
older.2 Several studies have shown that women suffering from UI and POP experience 
a deterioration in sexual function,3-5 and FI has also been associated with poorer sexual 
function.6 Given the number of women suffering from PFD, it is important to evaluate 
their sexual function. Questionnaires can be used to assess the necessity for treatment 
of sexual dysfunction, and to determine treatment effectiveness. 
The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) is 
a validated condition-specific quality of life questionnaire.7 The International Conti-
nence Society recommends this questionnaire (with grade A) to assess sexual function 
with urinary symptoms.8 In recent years the PISQ-12 has been validated in different 
languages: Arabic, Chinese, French, Persian, Portuguese, Swedish, and Turkish.9-15 
The increased awareness of sexual dysfunction in association with PFD strengthens 
the need for a validated Dutch measurement tool for sexual function.16 A recent study 
has used a Dutch translation of the PISQ-12 to evaluate sexual function in the Dutch 
population.17 However, this version was not validated and the results can therefore 
not be considered internationally compatible. The aim of this study is to develop a 
validated Dutch version of the PISQ-12 measure.
methoDs
This observational study was performed at a tertiary pelvic floor centre. It is part of a 
larger health-related quality of life study, which was approved by the medical research 
ethics committee (MEC-2008-376).18,19 
study populations
Patient group
Women were eligible for inclusion if they spoke Dutch fluently, were aged over 18 
years, and in a heterosexual relationship. Also, they needed to have been experienc-
ing symptoms of UI, POP stage 2 or higher and/or FI for at least 3 months. Exclusion 
criteria consisted of dementia, mental retardation, active malignant tumours, and no 
sexual activity during the past 6 months. During a regular outpatient visit all poten-
tially eligible patients were informed about the study, and invited to participate by 
their treating physician. A patient information package containing the consent form 
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and the first two sets of measures were handed out. Patients were asked to fill in the 
questionnaires at three predetermined time-points (during the inclusion visit, and at 1 
week and 6 months after inclusion), and to return the questionnaires by post directly 
after completion. The patients’ educational levels were determined and classified as 
“lower” (primary school), “middle” (high school), and “higher” (college or university). 
The final questionnaire contained an extra question taken from the RAND 36-Item 
Health Survey (RAND 36-HTI). Patients were asked to compare their current general 
health status to their status 1 year ago.20 No treatment was initiated during the first 
week following inclusion. Physicians and patients were unrestricted in the choice of 
treatment given the observational character of this study. For treatment evaluation we 
distinguished conservative, pharmaceutical and surgical treatments.
Reference group
The reference group in this study was taken from an ISO-certified (ISO 26362) panel of 
Dutch women 18 years of age or older. This group was stratified for age, educational 
level and residence to act as a representative group of the Dutch female population. 
Beforehand, the presence of pelvic floor symptoms in this group was unknown.
questionnaire
The questionnaire consisted of two measures: 
· The PISQ-12 is a short-form of the PISQ-31 measure.21 It is a condition-specific mea-
sure that evaluates sexual function in heterosexual women who suffer from UI and/
or POP. The PISQ-12 measures three domains: behavioural-emotive (items 1 – 4), 
physical (items 5 – 9) and partner-related (items 10 – 12). It is a self-administered 
questionnaire, and responses are graded on a five-point Likert scale ranging from 0 
(always) to 4 (never). Items 1 – 4 are reversely scored and a total of 48 is the maximum 
score22; higher scores indicate better sexual function. Up to two missing responses 
are accepted. The total score sum with missing values is calculated by multiplying 
the number of items by the mean of the responses to the items reported by that 
person. The PISQ-12 is reported as a single sexual function score. It does not report 
the separate domains.7
· The Short Form-12 Health Survey (SF-12) consists of two summary measures, 
physical component scores (PCS-12) and mental component scores (MCS-12).23 It 
is the short-form of the SF-36 measure and is frequently used as a gold standard 
for health-related quality of life questionnaires.10,14 The SF-12 was distributed to the 
patient group only. 
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Linguistic validation 
The translation process of the PISQ-12 was performed according to a standardized 
guideline.24 First the English PISQ-12 was forward-translated by three independent 
native Dutch speakers. Differences were discussed and consensus was reached on the 
final version, which was then backward-translated by a native English speaker. A face-
to-face test with ten patients was performed, and small textural changes were made 
accordingly without the need to adapt the content, resulting in the final Dutch version 
(See “Vragenlijsten”).
measurement properties
The questionnaire was validated according to the following measurement properties:
Content validity
Content validity is the extent to which the questionnaire measures the concepts of 
interest in the target population. The correspondence between the questionnaire 
items and clinical symptoms was subjectively assessed by the researchers. Face validity 
was determined by the researchers and a selected group of patients during linguistic 
validation.25
Internal consistency
Internal consistency is the correlation between different items in a questionnaire for 
the total and subscale scores, i.e. do the questions measure the same construct? A 
Cronbach’s alpha was calculated for the total score and three subscale scores sepa-
rately. Internal consistency is considered good if the Cronbach’s alpha was between 
0.70 and 0.95.25 For study-related reasons we also calculated the Cronbach’s alpha of 
the PISQ-12 minus item 12 for total score and the partner-related subscale score. 
Reproducibility
Reproducibility is the degree to which scores on a questionnaire are similar in a 
stable person on repeated measurements. This can be reported through reliability and 
agreement.25
Reliability 
Reliability considers the degree to which patients can be differentiated from each 
other, despite measurement error. The Intraclass correlation coefficient (ICC) for 





Agreement concerns the similarity in scores when measured on separate occasions, 
i.e. the measurement error. The limits of agreement (LOA) were reported and equal 
the mean change in scores of repeated measurements±1.96*standard deviation (SD) 
of the changes.27
Criterion Validity
Criterion validity is the degree to which questionnaire scores correlate with a gold 
standard. For the PISQ-12 no perfect gold standard exists. Therefore, criterion valid-
ity was determined using the SF-12, a quality of life measure resulting in physical and 
mental summary scores, which was also used in the Chinese validation.10 Spearman’s 
correlation was determined with values ranging from −1 to +1. A stronger negative or 
positive correlation is found when values are close to the extremes.25 
Construct Validity
Construct validity is the extent to which hypotheses about the scores of a questionnaire 
in relation to other measures are valid. If at least 75% of the predefined hypotheses are 
correct, construct validity is considered adequate.25
The predetermined hypotheses were:
1. Women with lower scores on the PCS-12 have lower scores on the PISQ-12.
2. Women in the patient group will have lower PISQ-12 scores than women in the 
reference group. 
3. PISQ-12 scores will increase after women have received treatment.
Responsiveness
Responsiveness is the extent to which a questionnaire is able to detect clinically 
important changes over time. This was calculated for all patients who had received 
treatment. The RAND 36-HTI was used as an external criterion in the determination of 
the area under the receiver operating characteristic (ROC) curve (AUC) for the PISQ-12 
measurements. The AUC shows the ability of a questionnaire to distinguish patients 
who have improved. An AUC of at least 0.50 is considered adequate.25
Interpretability
Interpretability is the degree to which a qualitative meaning can be assigned to the 
quantitative questionnaire scores. The minimal important change (MIC) is the minimal 
change required to indicate a true clinically relevant improvement. The LOA should be 
smaller than the MIC.25 The anchor-based ROC approach was used to determine the 
MIC. The MIC is the optimal ROC cut-off point and is defined as the value for which the 
sum of the proportions for misclassifications ((1 − sensitivity)+(1− specificity)) is smallest.28
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Floor and ceiling effects
Floor and ceiling effects occur when more than 15% of the women have received the 
lowest or highest possible score.25 Floor and ceiling effects were assessed at the total 
and subscale levels.
statistical methods
To determine the sample size the quality criteria proposed by Terwee et al.25 were 
followed. These state that a sample size of at least 50 patients is considered adequate 
to validate the questionnaire in Dutch. For continuous data we report the mean and 
standard deviation (SD). For categorical data we report counts and percentages. To 
evaluate the differences between the patient and reference group Student’s t test and 
the chi-squared test were used for continuous and categorical variables, respectively. 
One-way analysis of variance (ANOVA) was used for the evaluation of more than two 
independent groups. A two-sided p-value of <.05 was considered significant. The 
anchor RAND 36-HTI was dichotomized to “improved” and “not improved”; “a little 
better” and “much better” were classified as “improved”, while “same”, “a little worse” 
and “much worse” were classified as “not improved”. Statistical analysis of the data was 
done using SPSS version 21.0 (IBM Corp., Armonk, NY)
resuLts
Of the 124 consecutive patients who were interested in participation in the study, 
100 were found to be eligible and 70 of these patients consented to participate after 
receiving further information. During analysis, data from 70 patients were available, 
and consisted of at least one completed measure at one time-point (Figure 5.1). The 
reference group consisted of 208 women who had responded of 450 Dutch women 
contacted. Table 5.1 displays the nature of PFD in the patient group. The women in the 
reference group were younger than the women in the patient group (45.1±14.2 years 
and 53.6±12.3 years, respectively; p<.001). There was also a significant difference in 
educational level, with an average higher level of education in the reference group 
(p=.004). During the layout process of the PISQ-12 the answers to item 12 were incor-
rectly altered from “much less intense to much more intense” to “always to never”. This 
unfortunate alteration resulted in suboptimal answer options. Therefore, we calculated 
the total score without item 12 as well. The reference group showed a significantly 
overall higher scores on the PISQ-12 measure than the patient group, indicating better 
sexual function in this group. After correcting for the altered item 12, the difference 
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Figure 5.1 Flowchart: inclusion process of patient group
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Internal consistency
Table 5.2 shows that the PISQ-12 total score had an adequate internal consistency in 
the patient group, with a Cronbach’s alpha of 0.69. In the reference group the internal 
consistency showed a moderate Cronbach’s alpha of 0.57. The domain scales differed 
between the patient and reference groups from 0.37 – 0.85 and 0.13 – 0.72,  respec-
tively. In addition, we calculated the Cronbach’s alpha without item 12. The PISQ-12 







Age (years), mean ± SD 53.6 ± 12.3 45.1 ± 14.2 <.001d
Education, n (%) .004e
Lower 21 (31) 60 (29)
Middle 38 (57) 86 (41)
Higher 8 (12) 62 (30)








PISQ-12 scores, mean ± SDb
Baseline 32.7 ± 7.0 36.3 ± 4.7 .001d
Baseline, minus item 12 30.7 ± 7.1 34.8 ± 5.1 .01d
6 months (n=56)     33.5 ± 6.5 
6 months, minus item 12 31.4 ± 7.0
SF-12 scores, mean ± SDc
Baseline (n=56)
PCS-12 41.7 ± 12.0
MCS-12 48.1 ± 10.5
6 months (n=46)
PCS-12 44.6 ± 10.9
MCS-12 45.4 ± 12.0
aUnless stated otherwise
bHigher scores indicate better sexual function






showed an adequate internal consistency of 0.75 and 0.69 for the patient and refer-
ence groups, respectively. For the partner-related scale internal consistency improved 
from 0.37 to 0.55 for the patient group, and from 0.13 to 0.49 for the reference group. 
Reproducibility
A total of 62 patients completed the questionnaires at baseline and the retest after a 
week (Table 5.2). The average test–retest period was 6.8±2.6 days. For the PISQ-12 ICC 
for agreement was 0.93 (range 0.88 – 0.96). This indicates adequate reliability. The 
ICC for agreement remained adequate after correction for item 12: 0.94 (range 0.90 – 
0.96). Relating the LOA range (10.6) to the total PISQ-12 score range (48) resulted in an 
expected measurement error of 22 %.
Criterion validity
The PISQ-12 scores showed positive correlations with the two summary scores of the 
SF-12 (PCS-12 and MCS-12; Figure 5.2). For the PISQ-12 and PCS-12 adequate agree-
ment was found at baseline and the 6-month follow-up (Spearman’s rho 0.41 and 0.34, 
respectively). The PISQ-12 and MCS-12 showed only adequate agreement at baseline 
(Spearman’s rho 0.32).
Construct validity
Two of our three predefined hypotheses were confirmed:
Table 5.2 Internal consistency and reproducibility
The Cronbach’s alpha reflects the internal consistency for the total and subscale scores. 








































PISQ-12 total 0.69 0.57 32.6 ± 7.1 33.0 ±7.1 0.93(0.88-0.96) -0.32 ± 2.71 -5.63 to 4.99
Minus item 12 0.75 0.69 30.7 ± 7.3 31.0 ± 7.3 0.94(0.90-0.96) -0.32 ± 2.52 -5.26 to 4.62
Behavioral emotive 0.85 0.72 9.58 ± 3.86 9.68 ± 3.69 0.90(0.84-0.94) -0.05 ± 1.45 -2.89 to 2.79
Physical 0.71 0.62 14.48 ± 4.53 14.71 ± 4.38 0.94(0.90-0.96) -0.23 ± 1.54 -3.25 to 2.79
Partner-related 0.37 0.13 8.58 ± 2.27 8.63 ± 2.31 0.80(0.69-0.87) -0.05 ± 1.67 -3.32 to 3.22
Minus item 12 0.55 0.49 6.66 ± 1.80 6.71 ± 2.00 0.85(0.77-0.91) -0.05 ± 1.03 -2.07 to 1.97
a Calculated as: meanchange ± 1.96 * SDchange
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1. A significant correlation was found between the PCS-12 score and the PISQ-12 
score (Figure 5.2).
2. Women in the patient group did indeed have lower PISQ-12 scores than women in 
the reference group (Table 5.1).
3. Women who received treatment did not show a significant improvement in PISQ-
12 score compared to before treatment (Table 5.3).
Responsiveness
At the 6-month follow-up, 56 patients completed the third round of questionnaires 
as shown in Table 5.1. Of these patients, 27 had received treatment for either UI, POP 
or FI. This treatment consisted of surgical treatment in 15 patients (56 %), conservative 
treatment in 9 patients (33 %) and pharmaceutical treatment in 3 patients (11 %). Of 
these 27 patients, 24 answered the RAND 36-HTI question. The AUC for the PISQ-12 in 
this group was 0.69 (p=.14, not significant; Table 5.3).
Figure 5.2 Correlations between PISQ-12 and SF-12 scores to establish the criterion validity.
a)  PISQ-12 vs. PCS-12 at baseline (n=56; Spearman’s rho 0.41; p=.005)
b)  PISQ-12 vs. PCS-12 at 6 months (n=46; Spearman’s rho 0.34; p=.02)
c)  PISQ-12 vs. MCS-12 at baseline (n=56; Spearman’s rho 0.32; p=.03)




The MIC was −0.50 with a sensitivity of 0.89 and a specificity of 0.60 (Table 5.3). This 
corresponds with 89 % correctly identified as improved and 60 % as not improved. 
The MIC was inside the range of the LOA, indicating that the change in score of −0.50 
in treated patients who have reported an improvement on the RAND 36-HTI was not 
clinically relevant. 
Floor and ceiling effects
The distribution of floor and ceiling effects for the patient and reference groups is 
shown in Table 5.4. No floor and ceiling effects were reported in the patient group 
or the reference group for the PISQ-12 total score. Furthermore, no floor and ceiling 
effects were reported in the patient group on the scale level. In the reference group, 
only a ceiling effect on the physical scale was reported.
Table 5.3 PISQ-12 scores in patients who received treatment and their corresponding RAND-36 re-
sponse reflect responsiveness and interpretability of the PISQ-12. 




RAND-36 health transition item
Much worse / a little worse 5 (21) 2.60 ± 8.38
Same 10 (42) -0.10 ± 5.97
A little better 5 (21) 2.20 ± 3.27
Much better 4 (17) 5.00 ± 4.97
Area under the ROC curve 0.69
p-value .14
Minimal important change -0.50
Sensitivity; specificity 0.89 ; 0.60
Data presented are in number (%) or mean change ±SD change between baseline and follow-up at 6 
months
aResponsiveness reported only for the 24 patients who received treatment
bPositive scores indicate an improvement in sexual function
Table 5.4 The floor and ceiling effects at baseline for the patient and reference groups
Patient group (n = 70) Reference group (n = 208)
Floor Ceiling Floor Ceiling
PISQ-12 Total score 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Behavioral emotive 3 (4%) 0 (0%) 1 (0.5%) 2 (1%)
Physical 0 (0%) 10 (14%) 0 (0%) 53 (25%)
Partner-related 0 (0%) 7 (10%) 0 (0%) 13 (6%)
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DisCussion
In response to the growing need for a validated measure for sexual dysfunction in 
women with PFD, the aim of this study was to provide a validated Dutch version of the 
PISQ-12 measure. In women with PFD significantly lower PISQ-12 scores were observed 
than in the reference group representing the Dutch female population. This indicates 
poorer sexual function in the patient group, as expected, confirming the discriminative 
ability of the PISQ-12 measure. It also stresses the need to consider treatment options 
for sexual dysfunction in addition to treatment options for PFD alone.
The study showed that the Dutch version of the PISQ-12 has moderate internal 
consistency. Cronbach’s alpha was 0.69 in the patient group and 0.57 in the reference 
group. Other studies validating the PISQ-12 in different languages have shown higher 
Cronbach’s alpha values, ranging from 0.71 to 0.79.10, 13,-15 The lower value found in this 
study originated from the partner-related item scale, probably due to the alteration 
of item 12. A Cronbach’s alpha for the partner-related scale of 0.37 was found in the 
patient group, in contrast to 0.13 in the reference group when no adjustment for item 
12 was performed. With correction for item 12, Cronbach’s alpha scores for both the 
total score and the partner-related score increased to values comparable to those 
found for the earlier translated PISQ-12 versions. The internal consistency of the 
PISQ-12 then showed an adequate value of 0.75 for the patient group and 0.69 for the 
reference group. The big discrepancy found between the patient and reference group 
at the scale level was also resolved with the correction. This suggests that the incorrect 
answer options for item 12 caused the lower values before correction. Overall, the 
PISQ-12 showed an adequate consistency for the remaining 11 items.
The internal consistency of the partner-related scale was lower than that of the total 
score and both the behavioural-emotive scale and the physical scale, even after cor-
rection for item 12. This was also found in previous translations of the PISQ-12.10, 15 It 
should be noted that the partner-related scale evaluates the physical sexual function 
related to the partner. However, even though sexual function is related to the partner, 
a poorer physical sexual function in the partner will not automatically result in a similar 
sexual dysfunction in the woman. A lower partner-related scale score does not need 
to be correlated with the behavioural-emotive and physical scale scores. 
The reproducibility for the Dutch PISQ-12 in terms of the test–retest scores was 
excellent. The ICC for agreement was 0.93, comparable to that of the Swedish PISQ-
1214, confirming the reproducibility of this measure. With correction for item 12 the 
reliability remained stable, as expected, since patients received the same version of 
the measure at both time-points. The good ICC value enables the use of the PISQ-12 
as a measure for distinguishing the severity of sexual dysfunction between patients.
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The criterion validity of a questionnaire is preferably determined by the degree of its 
correlation the gold standard. Since no gold standard is available to determine sexual 
dysfunction in women with PFD we chose to use the SF-1223 to assess the criterion va-
lidity of the PISQ-12. The SF-12 is a commonly used generic measure for health-related 
quality of life and was also used in the Chinese validation study of the PISQ-12.10 We 
found a positive correlation between sexual dysfunction as assessed with the PISQ-12 
and both summary scores of the SF-12 at baseline. However, at the 6-month follow-up 
the PISQ-12 showed a significant correlation with the PCS-12, but not with the MCS-12. 
This weakened correlation at follow-up could potentially be explained by the fact that 
the group of patients was smaller at 6 months. It is also possible that the SF-12 was not 
the right choice to assess the criterion validity because the SF-12 is a generic measure: 
changes in quality of life unrelated to sexual dysfunction might have  influenced the 
SF-12 score without influencing the PISQ-12 score (criterion contamination). We are 
thus unable to conclude that the PISQ-12 has a good criterion validity using the SF-12. 
Therefore, we recommend the use of a larger patient group to determine the criterion 
validity of the PISQ-12. 
The responsiveness and interpretability reported were not adequate. Of the 35 
patients who did receive treatment during the 6-month follow-up, only 24 completed 
the third questionnaire including RAND 36-HTI. This small number of patients could 
explain why the AUC and MIC were not significant. Furthermore, the study was con-
ducted at a tertiary centre, where women might present with more severe symptoms 
of PFD. Treatment options might therefore be more limited, which could explain 
the only slight overall improvement of PISQ-12 scores after treatment. This probably 
also contributed to the inability to confirm hypothesis 3 for the construct validity. In 
addition, the anchor used for responsiveness evaluation, the RAND 36-HTI, solely 
addresses one aspect of general health, while sexual function is multifactorial. It might 
therefore not provide an adequate comparison for this specific evaluation. 
No floor or ceiling effects were found for the total score of the PISQ-12 for the patient 
group or the reference group. The complexity of symptoms of PFD could have con-
tributed to the lack of floor and ceiling effects in the patient group. In the reference 
group ceiling effects were found only on the physical subscale. This has previously also 
been demonstrated in patients.29 After treatment the physical subscale showed ceiling 
effects, while the other subscales did not. 
The strength of this study was the use of the quality criteria for the evaluation of the 
measurement properties tested, as proposed by Terwee et al.25 Also, the use of a refer-
ence group enabled clarification of differences in sexual function between patients 
with PFD and a reference population. There are some limitations to this study. First, 
item 12 was altered during the layout process. In our opinion, errors can (and will) al-
ways occur. If an error does occur, we think it best to acknowledge it and try to correct 
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for it in the analysis. Second, the small number of patients during our 6-month follow-
up made it difficult to properly assess the responsiveness of the Dutch PISQ-12. Third, 
the PISQ-12 can only be used in sexually active women. Consequently, an assessment 
of sexual dysfunction in sexually inactive women cannot be performed. The PISQ-IR 
is a new questionnaire that does take sexual function and activity or inactivity into ac-
count 30. Therefore, the PISQ-IR can be used in all patients presenting with symptoms 
of PFD. However, currently no validated Dutch version is available. The actual use 
of the Dutch PISQ-12 might affect treatment in sexually active women. It would be 
worthwhile to evaluate the impact of the use of the Dutch PISQ-12 in clinical practice.
In conclusion, this Dutch version of PISQ-12 was tested following well-established 
guidelines on measurement properties. It was demonstrated to have adequate validity 
and reproducibility, especially after correction for item 12 on the partner-related scale. 
The use of this measure in clinical practice will enable Dutch physicians to assess the 
impact of sexual dysfunction on women with PFD who are sexually active. It is recom-
mended that responsiveness be determined in a larger group of patients.
Acknowledgments





 1. Norton PA, MacDonald LD, Sedgwick PM, Stanton SL. Distress and delay associated with 
urinary incontinence, frequency, and urgency in women. BMJ 1988;297:1187-9.
 2. Nygaard I, Barber MD, Burgio KL, et al. Prevalence of symptomatic pelvic floor disorders in US 
women. JAMA 2008;300:1311-6.
 3. Handa VL, Cundiff G, Chang HH, Helzlsouer KJ. Female sexual function and pelvic floor disor-
ders. Obstet Gynecol 2008;111:1045-52.
 4. Rogers GR, Villarreal A, Kammerer-Doak D, Qualls C. Sexual function in women with and with-
out urinary incontinence and/or pelvic organ prolapse. Int Urogynecol J Pelvic Floor Dysfunct 
2001;12:361-5.
 5. Barber MD, Visco AG, Wyman JF, Fantl JA, Bump RC, Continence Program for Women Research 
G. Sexual function in women with urinary incontinence and pelvic organ prolapse. Obstet 
Gynecol 2002;99:281-9.
 6. Cichowski SB, Komesu YM, Dunivan GC, Rogers RG. The association between fecal inconti-
nence and sexual activity and function in women attending a tertiary referral center. Int Urogy-
necol J 2013;24:1489-94.
 7. Rogers RG, Coates KW, Kammerer-Doak D, Khalsa S, Qualls C. A short form of the Pelvic Organ 
Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). Int Urogynecol J Pelvic Floor 
Dysfunct 2003;14:164-8; discussion 8.
 8. Abrams P, Cardozo L, Khoury S, Wein A. Incontinence, 4th edition.: Health Publications Ltd.; 
2009.
 9. Shaaban MM, Abdelwahab HA, Ahmed MR, Shalaby E. Assessment of female sexual function 
among women with pelvic organ prolapse or urinary incontinence via an Arabic validated 
short-form sexual questionnaire. Int J Gynaecol Obstet 2014;124:24-6.
 10. Zhu L, Yu S, Xu T, Yang X, Lu Y, Lang J. Validation of the Chinese version of the Pelvic Organ Pro-
lapse/Urinary Incontinence Sexual Questionnaire short form (PISQ-12). Int J Gynaecol Obstet 
2012;116:117-9.
 11. Fatton B, Letouzey V, Lagrange E, Mares P, Jacquetin B, de Tayrac R. [Validation of a French 
version of the short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Question-
naire (PISQ-12)] Validation linguistique en francais de la version courte du questionnaire sur la 
sexualite (PISQ-12) chez les patientes presentant un prolapsus genital et/ou une incontinence 
urinaire. J Gynecol Obstet Biol Reprod (Paris) 2009;38:662-7.
 12. Zohre M, Minoo P, Ali M. Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire 
(PISQ-12): psychometric validation of the Iranian version. Int Urogynecol J 2014.
 13. Santana GW, Aoki T, Auge AP. The Portuguese validation of the short form of the Pelvic Organ 
Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). Int Urogynecol J 2012;23:117-
21.
 14. Teleman P, Stenzelius K, Iorizzo L, Jakobsson U. Validation of the Swedish short forms of the 
Pelvic Floor Impact Questionnaire (PFIQ-7), Pelvic Floor Distress Inventory (PFDI-20) and Pelvic 
Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). Acta Obstet Gynecol 
Scand 2011;90:483-7.
 15. Bilgic Celik D, Beji NK, Yalcin O. Turkish adaptation of the short form of the Pelvic Organ 
Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12): a validation and reli-
ability study. Neurourol Urodyn 2013;32:1068-73.
107
Validation of the Dutch PISQ-12
5
 16. Rogers RG. Sexual function in women with pelvic floor disorders. Can Urol Assoc J 2013;7:S199-
201.
 17. Panman CM, Wiegersma M, Talsma MN, et al. Sexual function in older women with pelvic floor 
symptoms: a cross-sectional study in general practice. Br J Gen Pract 2014;64:e144-50.
 18. Utomo E, Korfage IJ, Wildhagen MF, Steensma AB, Bangma CH, Blok BF. Validation of the Uro-
genital Distress Inventory (UDI-6) and Incontinence Impact Questionnaire (IIQ-7) in a Dutch 
population. Neurourol Urodyn 2015;34:24-31.
 19. Utomo E, Blok BF, Steensma AB, Korfage IJ. Validation of the Pelvic Floor Distress Inventory 
(PFDI-20) and Pelvic Floor Impact Questionnaire (PFIQ-7) in a Dutch population. Int Urogyne-
col J 2014;25:531-44.
 20. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ 
1993;2:217-27.
 21. Rogers RG, Kammerer-Doak D, Villarreal A, Coates K, Qualls C. A new instrument to measure 
sexual function in women with urinary incontinence or pelvic organ prolapse. Am J Obstet 
Gynecol 2001;184:552-8.
 22. Rogers RG, Coates KW, Kammerer-Doak D, Khalsa S, Qualls C. A short form of the pelvic organ 
Prolapse/Urinary incontinence sexual questionnaire (PISQ-12) (vol 14, pg 164, 2003). Interna-
tional Urogynecology Journal 2004;15:219-.
 23. Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales 
and preliminary tests of reliability and validity. Med Care 1996;34:220-33.
 24. Guillemin F, Bombardier C, Beaton D. Cross-cultural adaptation of health-related quality of life 
measures: literature review and proposed guidelines. J Clin Epidemiol 1993;46:1417-32.
 25. Terwee CB, Bot SD, de Boer MR, et al. Quality criteria were proposed for measurement proper-
ties of health status questionnaires. J Clin Epidemiol 2007;60:34-42.
 26. McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. 
Psychol Methods 1996;1:30-46.
 27. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of 
clinical measurement. Lancet 1986;1:307-10.
 28. de Vet HC, et al. Measurement in medicine. Cambridge: Cambridge University Press; 2011.
 29. Roy S, Mohandas A, Coyne K, et al. Assessment of the psychometric properties of the Short-
Form Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) following surgical place-
ment of Prolift+M: a transvaginal partially absorbable mesh system for the treatment of pelvic 
organ prolapse. J Sex Med 2012;9:1190-9.
 30. Rogers RG, Rockwood TH, Constantine ML, et al. A new measure of sexual function in women 
with pelvic floor disorders (PFD): the Pelvic Organ Prolapse/Incontinence Sexual Question-


















The measurement properties 
of the five-item International 
Index of Erectile Function  
(IIEF-5): a Dutch validation 
study
Elaine Utomo, Bertil F.M. Blok, Hester Pastoor,  





Erectile dysfunction, affecting men worldwide, is associated with worse mental health. 
The severity of erectile dysfunction as well as the effect of its treatment can be assessed 
using valid self-reported outcome measures. A widely used measure is the Interna-
tional Index of Erectile Function short form (IIEF-5) which is not yet validated in Dutch. 
The objective of this study was to translate the IIEF-5 into Dutch and to investigate 
its reliability and validity to provide a useful evaluation tool. The IIEF-5 was translated 
into Dutch following standardized forward-backward procedures. To conduct this 
observational study, men with symptoms of erectile dysfunction completed the Dutch 
IIEF-5 at inclusion, one week later, and six months after inclusion. A population-based 
sample (reference group) completed the IIEF-5 once. The quality domains reliability 
and validity were addressed by testing the measurement properties internal consis-
tency, reliability, measurement error, and content validity. Data of 82 patients and 253 
reference group participants were analysed. Internal consistency was adequate with 
Cronbach’s alpha of 0.94 in both patient and reference group. In patients, the test-
retest reliability was adequate with an Intraclass correlation coefficient for agreement 
of 0.88. A floor effect was present in the patient group (42%), though not in the refer-
ence group (3%). There was no ceiling effect in patients (0%), while this was present 
in the reference group (17%). Analysis of responsiveness was not possible due to the 
limited number of patients receiving treatment. The Dutch IIEF-5 is a reliable and valid 
measure to determine severity of symptoms of erectile dysfunction. This evaluation 
tool is valuable for clinical use and interpreting results across international clinical 
studies. The context of a patient’s sexual life is however indispensable and should be 
taken in mind.
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introDuCtion
The estimated overall prevalence rate of erectile dysfunction (ED) ranges from 10% to 
20% worldwide, considering variations in definitions, methodology, and study popu-
lation.1 A population-based study in the Netherlands - the Krimpen study - determined 
a crude incidence of 14.1 cases per 1,000 person years for clinically relevant ED.2 We 
defined ED as a man’s consistent or recurrent inability to attain and/or maintain penile 
erection sufficient for sexual activity.3 Erectile dysfunction, as well as satisfaction with 
sex life, were found to be related with worse mental health in men of all ages.4,5 As help 
seeking behaviour of Dutch men with ED slightly increased in the past 20 years6, valid 
self-reported measures are important to evaluate symptoms associated with ED as well 
as to evaluate treatment effect. The International Index of Erectile Function (IIEF) is 
such a measure.7,8 The widely used IIEF was “Grade A” recommended in erectile func-
tion assessment by the International Consultation of Sexual Medicine in 2010.9 The 
demand for a brief, easily administered measure resulted in an abridged five-item 
version of the 15-item IIEF: the IIEF-5, also known as the Sexual Health Inventory for 
Men (SHIM).10,11 It was developed for screening and diagnostic severity assessment in 
clinical practice and in clinical trials. Although the IIEF-5 has been validated in other 
languages,12-15 a Dutch version is still lacking. We therefore translated the IIEF-5 into 
Dutch. For translated measures to be useful in research or clinical practice, they must 
adequately address measurement properties, including reliability, validity, responsive-
ness, and interpretability.16,17
This study was designed to translate the IIEF-5 into Dutch and to investigate its reli-
ability and validity to provide a useful evaluation tool for men reporting symptoms of 
ED. 
methoDs
We conducted this observational study at a tertiary urology centre as part of a larger 
validation study of health-related quality of life (HRQOL) pelvic floor measures.18,19 
The study was approved by the Institutional Ethics Committee (MEC-2008-376) and 
pre-registered at The Netherlands National Trial Register (NTR2355).
study population and study design
Patient inclusion criteria were men aged 18 years or older with self-reported ED, and 
fluent and literate in the Dutch language. As described by the original developer, men 
were also supposed to be in a stable relationship with a female partner and to have the 
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possibility to engage in sexual activity and intercourse.20 Exclusion criteria were active 
malignant tumours, dementia, and mental retardation.
At the initial visit, the treating practitioner explained the study to each consecutive 
patient potentially eligible for inclusion. The practitioner provided an information 
package including two sets of questionnaires to patients who were interested in 
participation. As this study was part of a larger validation study of HRQOL pelvic floor 
measures, the practitioner specified on the cover of the sets of questionnaires for 
which measure or measures the patient was eligible. The patients were then phoned 
by the investigator for further explanation, and were asked to complete the informed 
consent form and the first questionnaire immediately (baseline) and the second 
questionnaire one week later (T1). Six months after baseline patients received a third 
questionnaire to be completed at home through postal mail (T2). After each comple-
tion patients returned the questionnaires through postal mail using a return envelope. 
No treatment was initiated or changed during the test-retest period of one week. This 
one week period was long enough to prevent recall, though short enough to ensure 
that clinical change had not occurred. Information from the patient’s medical record 
was retrieved about the cause of ED and the applied treatment, if any. Treatment was 
categorized into “conservative”, “pharmaceutical”, or “surgical”. Date of birth and edu-
cation were documented through the questionnaire. Educational level was classified 
as “low” (primary school), “intermediate” (high school), or “high” (college or university 
degree). The third questionnaire included a question about the change in patient’s 
general health compared to one year ago. This health transition item of the RAND 
36-Item Health Survey21-23 contained the following response options: “much better”, “a 
little better”, “same”, “a little worse”, and “much worse”. Patients who did not return the 
questionnaire were sent a reminder including a reply form where they could indicate if 
they required a replacement questionnaire, or if they refrained from further participa-
tion with the option to motivate. If questions were skipped or questionnaires were left 
empty without providing any reasons, a copy of the uncompleted questionnaire was 
sent immediately to the patient with the request to fully complete the questionnaire. 
Also, patients were then asked to motivate if they intentionally skipped a question or 
questions.
reference data
Data from a representative sample of men aged 18 years or older in the Netherlands 
were collected through an ISO-certified Dutch online panel (ISO 26362).24 This sample 
was stratified by age, educational level and residential area, and therefore representa-
tive for the Dutch male population above the age of 18. The presence or absence of 
ED in the participants was unknown beforehand. No inclusion or exclusion criteria 
were applied.
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questionnaire
The IIEF-5 consists of five items originating from the IIEF. Four of its five items were taken 
from the six-item erectile function domain of the IIEF which is a validated measure as a 
diagnostic evaluation tool.25 The fifth item of the IIEF-5 concerns intercourse satisfaction.
Response options are based on rating scales from 0 to 5 or 1 to 5. The responses 
are summed resulting in a total IIEF-5 score ranging from 1 to 25, with lower values 
representing poorer sexual function. Erectile dysfunction can be classified into five 
severity grades: absence of ED (IIEF-5 score 22-25), mild (17-21), mild to moderate (12-
16), moderate (8-11), and severe (1-7).10,11
Linguistic validation
The IIEF-5 was translated into Dutch following standardized forward-backward proce-
dures: three independent forward translations and a backward translation by a native 
speaker.26 The Dutch version of the IIEF-5 was tested in 10 patients with ED, where po-
tential problems were explored and discussed guided by a checklist. Erectile dysfunc-
tion was defined according to the International Consultation on Sexual Dysfunctions.9 
This pilot testing led to the following adjustments: the word “penetration” (question 
3) appeared too formal. We therefore used “entered” and put the word “penetration” 
between brackets. The words “sexual stimulation” (question 2) and “intercourse” 
(questions 3 to 5) were exemplified with footnotes.  Some other minor textual changes 
were added without changing the content. The Dutch version of the IIEF-5 was then 
finalized and subsequently used in this validation study (See “Vragenlijsten”).
measurement properties
To address the quality domains reliability and validity, we tested the measurement 
properties internal consistency, reliability, measurement error, and content validity of 
the Dutch IIEF-5.16
- The internal consistency is the degree of interrelatedness among the items in the 
measure. A reliable measure assesses a single underlying concept by using multiple 
items. This was calculated with the Cronbach’s alpha. A high Cronbach’s alpha 
indicates high correlations between the multiple items. Values between 0.70 and 
0.95 were considered to reflect adequate internal consistency.17,27
- The reliability is the proportion of the total variance because of “true” differences 
among patients. To assess the degree to which repeated measurements in stable 
patients provide similar answers we performed a test-retest. An Intraclass correla-
tion coefficient (ICC) for agreement24 of  ≥ 0.70 was considered to reflect adequate 
reliability.17,27
- The measurement error is the systematic and random error of a patient’s score 
not attributed to true changes. This was quantified using the limits of agreement 
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by Bland and Altman.28 The absolute mean change in scores of repeated measure-
ments during the test-retest period (meanchange)±1.96*standard deviation of these 
changes (SDchange) were the limits of agreement.
- The content validity is the degree to which the content of a measure adequately 
reflects the target construct. This was subjectively assessed and verified by ex-
amining whether the items appeared to be measuring what they are intended to 
measure (“face validity”). The floor and ceiling effects were also assessed. This may 
occur when 15% or more of the respondents score at the lower (floor) or upper 
(ceiling) end of the scale, thus could indicate a limited content validity.17,27
statistical methods
Statistical significance was defined as p-value <.05. For comparison of patient and ref-
erence group the unpaired t test was used for numerical variables, and the chi-square 
test for categorical variables. General linear models were used to compare measure 
scores, controlling for demographics that differed significantly between patient and 
reference group in univariate analysis. Statistical analysis was performed using IBM® 
SPSS software 21.0, SPSS Inc., Chicago, IL, USA.
resuLts
A total of 108 consecutive patients were initially interested and eligible, of which 82 
(76%) consented to participate (Flowchart, Figure 6.1). The measure was sent out to 
480 panel participants of which 253 (53%) responded. In the patient group, the mean 
age (64.4 ± 11.5 years) was higher (p<.001) than in the reference group (50.6 ± 15.7 years, 
Table 6.1). Also, educational levels differed significantly between patient and reference 
group. Information from the patient’s medical record indicated that symptoms of ED 
were mostly due to an organic cause (81%). The patient group had a significant (p<.001) 
lower score of IIEF-5 (mean 5.5 ± 6.1, Table 6.2), indicating worse sexual health than 
the reference group (mean 18.8±7.2). The IIEF-5 score was used to classify the severity 
of ED: the majority of the patients (71%) versus 13% of the participants of the refer-
ence group were classified as “severe” ED. Most participants of the reference group 
had no ED (53%). These differences remained significant after adjusting for age and 
educational level.
Before reminders were sent, the missing item rate was highest in the questionnaire 
after one week follow-up (Table 6.3): 15% of patients left at least one item empty (three 
questionnaires were left completely empty). The final missing rates and the missing 
rates at other time-points were 6 to 7%. Missing items were balanced in numbers 
across the different items of the IIEF-5. 
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internal consistency, reliability and measurement error
The IIEF-5 score demonstrated adequate internal consistency with a high Cronbach’s 
alpha of 0.94 in both patient and reference group (Table 6.4). On average, the retest 
assessments were completed nine days after baseline measurement. The ICCagreement 
Interested to know about
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Figure 6.1 Study fl owchart
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of the IIEF-5 score was 0.88 (Table 6.4) and indicates adequate reliability. Table 6.4 
also presents the absolute meanchange of repeated measurements during the test-retest 
period, the corresponding SDchange, and the limits of agreement. Relating the range 
of the limits of agreement (10.1) to the range of the possible test-retest scores on the 
IIEF-5, that is -25 to +25 (50), the magnitude of the measurement error is 20%. 







Age (years) 64.4 ± 11.5 50.6 ± 15.7 <.001
Educational level <.001
Low 23 (29%) 24 (10%)
Intermediate 36 (45%) 166 (66%)
High 21 (26%) 63 (25%)





Data are mean ± standard deviation or number (%). 
Abbreviations: GLM general linear models; NA not available
ap-value: corrected for age and educational level with general linear modeling 









Score IIEF-5a at baseline ± SD (range 1 – 25) 5.5 ± 6.1 18.8 ± 7.2 <.001 <.001
Missing  5 (6%) 0 (0%)
Score IIEF-5 after 1 week ± SD (range 1 – 25) 5.5 ± 5.6 NA
Missing 6 (7%) NA
Score IIEF-5 after 6 months ± SD (range 1 – 25) 4.6 ± 5.4 NA
Missing 4 (6%) NA
Classification of severity of ED at baselinec, number (%) <.001
Severe (score 1-7) 55 (71%) 32 (13%)
Moderate (score 8-11) 8 (10%) 15 (6%)
Mild to moderate (score 12-16) 7  (9%) 20 (8%)
Mild (score 17-21) 7 (9%) 52 (21%)
No ED (22-25) 0 134 (53%)
aTotal score of IIEF-5 was only calculated if there were no missings, higher scores indicates better sexual 
health
bP-value: corrected for age and educational level with general linear model (GLM)
cClassification according to total score IIEF-520, 11
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Content validity
In patients, no ceiling effect (0%) was observed in the IIEF-5 score, while floor effect 
was present in 42%, exhibiting a non-normal score distribution towards the less favour-
able low score of one (Table 6.5). In the reference group, the contrary was seen: the 
floor effects were acceptably low (3%) while a ceiling effect (17%) was present. 
Follow-up
A total of 70 patients completed the IIEF-5 on average 5.9 months after baseline as-
sessment (T2, Figure 6.1 Flowchart). Of these patients, 10 received treatment during 
follow-up and 60 men were untreated because they received urinary incontinence 
therapy (n=49), refused surgical treatment (n=7), or they cancelled surgery due to 
unknown reasons (n=4). The change in IIEF-5 score in treated patients after six months 
was 2.2 ± 3.9 compared to -0.6 ± 2.8 in untreated patients (p=.007). The change seen 
is in accordance with the hypothesis that IIEF-5 scores of treated patients will increase, 
Table 6.3 Number of times missing per item
Item of IIEF-5
Baselinea 1 week follow-upb 6 months follow-upc
(n) (n)  (n)
1 3 6 4
2 3 7 1
3 2 3 2
4 2 4 2
5 1 6 2
% (number) of patient who 
skipped an item after reminder 
6% (5/82) 7% (6/82)d 6% (4/70)e
aOne questionnaire was left completely empty: unknown reason
bThree questionnaires were left completely empty: unknown reason, all were completed after sending 
reminder
cOne questionnaire was left completely empty: not sexually active because ED after radical prostatec-
tomy
dAt one week follow-up, six patients initially skipped an item before reminder was sent
eAt six months follow-up, one patient initially skipped an item before reminder was sent













n = 77 n = 253 n = 73
IIEF-total score (1-25) 0.94 0.94 0.88 1.4 ± 2.6 -3.7 – 6.4
aHigher scores indicate better sexual health
bLimits of agreement described by Bland and Altman28 = meanchange ± 1.96*SDchange 
Chapter 6
118
and therefore suggestive of sensitivity. Analysis of responsiveness and interpretability 
was not possible because of the limited number of treated patients.
DisCussion
The objective of this study was to validate the Dutch version of the IIEF-5 and thereby 
to provide a useful measure for use in men with symptoms of ED. Generally, our find-
ings regarding the internal consistency, reliability, and measurement error were very 
positive. Cronbach’s alphas of 0.94 in both patient and reference group are consid-
ered high. We found an ICCagreement of 0.88 (test–retest) for the five items of the Dutch 
translation of the IIEF-5, which demonstrates adequate reliability. Furthermore, the 
meanchange after one week was ± 1.4 IIEF-5 score points, demonstrating adequate agree-
ment. Finally, comparing patient and reference group mean scores, the IIEF-5 had 
adequate discriminative ability (p<.001). Results obtained in our study were similar to 
previously reported findings in other studies. Shamloul et al. reported adequate inter-
nal consistency with high Cronbach’s alpha of 0.91 and adequate test-retest reliability 
with a high ICCagreement of 0.92.14
Ceiling effects were high in the reference group and floor effects were low, while in 
patients ceiling effects were absent but substantial floor effects were observed. This 
means that 42% of patients, who were all in a stable relationship, actually did not at-
tempted sexual intercourse. Cappelleri et al. stated that the IIEF-5 score range of 1 to 
7 - representing severe ED - indicates sexual functioning that is so poor that men do 
not bother to attempt sexual activity and intercourse.20 We agree with Cappelleri et 
al. that the IIEF-5 should not be used blindly and should be placed in context. More 
important, it is intended to complement clinical judgment and diagnostic assessment, 
and the practitioner should explore patient’s desire and opportunity for sexual activity 
to ensure that low IIEF-5 scores are truly indicative of severe ED.29 In other words, the 
sexual response cycle of the patient consisting of sexual desire and erection (excite-
ment phase); sensation of orgasm and contentment of ejaculation (orgasmic phase); 
and detumescence including satisfaction (resolution phase); should be examined.30 






Floor Ceiling Floor Ceiling
n % n % n % n %
IIEF-5 total score (1-25) 32 42 0 0 7 3 42 17
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Furthermore, sexual activity consists of more than intercourse alone and therefore 
assessment should also include solo sexual activity like masturbation. Regarding the 
importance of clinical judgment, we were not able to propose any inclusion criteria for 
the reference group. This group could have been comprised of respondents who are 
able to have and maintain an erection, but do not have a partner; do not have sexual 
contact with their partner; or do have sexual contact but no sexual intercourse. Such 
men will have a score of 21 or lower, indicating ED according to the IIEF-5 classification, 
while they actually do not have an erection problem. Such an IIEF-5 classification will 
thus give the wrong impression. 
Concerning our evaluation of the measurement properties; unfortunately we were 
not able to assess convergent and discriminant validity. To assess convergent validity 
we need to assess its positive correlation with measures of similar constructs. To our 
knowledge there are no other Dutch validated measures available with similar con-
struct as the IIEF-5, and therefore we were not able to assess convergent validity. For 
discriminative validity we needed to be able to assess the ability of the measure to dif-
ferentiate between expected differences between subgroups of patients. We actually 
found a significant difference in IIEF-5 score between our patient and reference group. 
However, as discussed earlier, the IIEF-5 classification in the reference group may be 
not correctly classified as the context of the presence or absence of sexual activity 
is unknown. Another limitation of our study was that analysing responsiveness and 
interpretability appeared to be impossible since only 10 patients received treatment 
during follow-up. During six months of follow-up, the number of men who actually 
started treatment for ED was limited. Using the IIEF-5 as a measure of responsiveness 
of ED treatment is debatable. Treatment of ED, with, for example a phosphodiesterase 
type 5 inhibitor, entails that patients are encouraged to at least attempt sexual activ-
ity and/or intercourse. If a patient who presents with ED did not engage in sexual 
activity and/or intercourse before ED treatment, his IIEF-5 score will improve with at 
least four points after the initiation of treatment since the attempt in itself will result in 
better IIEF-5 scores. This may suggest that treatment worked while the treatment did 
not necessarily result in better erectile function. Finally, the absence of a comorbidity 
index to assess and score any potential comorbid condition, as outcomes of a chronic 
condition represents another limitation; indeed, ED may be affected by coexisting 
comorbid chronic conditions.
In conclusion, our findings support positive evidence for the appropriateness of 
the Dutch IIEF-5 to evaluate severity of ED symptoms allowing to be used in clinical 
decision making as a diagnostic aid. This cultural and linguistic adjustment provides 
opportunity to compare self-reported ED status in international research and analysis 
of treatment. It seems however necessary to use this measure complementary to the 
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context of a patient’s sexual life. The suitability of the IIEF-5 as a measure of responsive-
ness remains open to discussion.
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The most common type of functional bladder outlet obstruction in patients with neu-
rogenic bladder is detrusor-sphincter dyssynergia (DSD). The lack of co-ordination 
between the bladder and the external urethral sphincter muscle (EUS) in DSD can 
result in poor bladder emptying and high bladder pressures, which may eventually 
lead to progressive renal damage.
objectives  
To assess the effectiveness of different surgical therapies for the treatment of functional 
bladder outlet obstruction (i.e. DSD) in adults with neurogenic bladder dysfunction.
search methods  
We searched the Cochrane Incontinence Group Specialised Register, which contains 
trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), 
MEDLINE, MEDLINE In-Process, and hand searching of journals and conference pro-
ceedings (searched 20 February 2014), and the reference lists of relevant articles.
selection criteria  
Randomised controlled trials (RCTs) or quasi-RCTs comparing a surgical treatment 
of DSD in adults suffering from neurogenic bladder dysfunction, with no treatment, 
placebo, non-surgical treatment, or other surgical treatment, alone or in combination.
Data collection and analysis  
Two review authors independently assessed trial quality and extracted data.
main results  
We included five trials (total of 199 participants, average age of 40 years). The neuro-
logical diseases causing DSD were traumatic spinal cord injury (SCI), multiple sclerosis 
(MS), or congenital malformations.
One trial compared placement of sphincteric stent prosthesis with sphincterotomy. 
For urodynamic measurements, results for postvoid residual urine volume (PVR) and 
cystometric bladder capacity were inconclusive and consistent with benefit of either 
sphincteric stent prosthesis or sphincterotomy at three, six, 12, and 24 months. Results 
for maximum detrusor pressure (Pdet.max) were also inconclusive at three, six, and 12 
months; however, after two years, the Pdet.max after sphincterotomy was lower than after 
stent placement (mean difference (MD) -30 cmH2O, 95% confidence interval (CI) 8.99 
to 51.01).
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Four trials considered botulinum A toxin (BTX-A) injection in the EUS, either alone or 
in combination with other treatments. The comparators included oral baclofen, oral 
alpha blocker, lidocaine, and placebo. The BTX-A trials all differed in protocols, and 
therefore we did not undertake meta-analysis. A single 100 units transperineal BTX-A 
injection (Botox®) in patients with MS resulted in higher voided urine volumes (MD 69 
mL, 95% CI 11.87 to 126.13), lower pre-micturition detrusor pressure (MD -10 cmH2O, 
95% CI -17.62 to -2.38), and lower Pdet.max (MD -14 cmH2O, 95% CI -25.32 to -2.68) after 
30 days, compared to placebo injection. Results for PVR using catheterisation, basal 
detrusor pressure, maximal bladder capacity, maximum urinary flow, bladder compli-
ance at functional bladder capacity, maximal urethral pressure, and closure urethral 
pressure at 30 days were inconclusive and consistent with benefit of either BTX-A 
injection or placebo injections. In participants with SCI, treatment with 200 units of 
Chinese manufactured BTX-A injected at eight different sites resulted in better blad-
der compliance (MD 7.5 mL/cmH2O, 95% CI -10.74 to -4.26) than participants who 
received the same injections with the addition of oral baclofen. Results for maximum 
uroflow rate, maximal cystometric capacity, and volume per voiding were inconclu-
sive and consistent with benefit of either BTX-A injection or BTX-A injection with the 
addition of oral baclofen. However, the poor quality of reporting in this trial caused us 
to question the relevance of bladder compliance as an adequate outcome measure.
In participants with DSD due to traumatic SCI, MS, or congenital malformation, 
the results for PVRs after one day were inconclusive and consistent with benefit of 
either a single 100 units transperineal BTX-A (Botox®) injection or lidocaine injection. 
However, after seven and 30 days of BTX-A injection, PVRs were lower (MD -163 and 
-158 mL, 95% CI -308.65 to -17.35 and 95% CI -277.57 to -39.03, respectively) compared 
to participants who received lidocaine injections. Results at one month for Pdet.max on 
voiding, EUS activity in electromyography, and maximal urethral pressure were incon-
clusive and consistent with benefit of either BTX-A or lidocaine injections.
Finally, one small trial consisting of five men with SCI compared weekly BTX-A injec-
tions with normal saline as placebo. The placebo had no effect on DSD in the two 
participants allocated to the placebo treatment. Their urodynamic parameters were 
unchanged from baseline values until subsequent injections with BTX-A once a week 
for three weeks. These subsequent injections resulted in similar responses to those of 
the three participants who were allocated to the BTX-A treatment. Unfortunately, the 
report presented no data on placebo treatment.
Only the trial that compared sphincterotomy with stent placement reported out-
come measures renal function and urologic complications related to DSD. Results 
for renal function at 12 and 24 months, and urologic complications related to DSD at 
three, six, 12, and 24 months were inconclusive and consistent with benefit of either 
sphincteric stent prosthesis or sphincterotomy.
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Adverse effects reported were haematuria due to the cystoscopic injection and 
muscle weakness, of which the latter may be related to the BTX-A dose used.
All trials had some methodological shortcomings, so insufficient information was 
available to permit judgment of risk of bias. At least half of the trials had an unclear 
risk of selection bias and reporting bias. One trial had a high risk of attrition bias, and 
another trial had a high risk of reporting bias.
Authors’ conclusions  
Results from small studies with a high risk of bias have identified evidence of limited 
quality that intraurethral BTX-A injections improve some urodynamic measures af-
ter 30 days in the treatment of functional bladder outlet obstruction in adults with 
neurogenic bladder dysfunction. The necessity of reinjection of BTX-A is a significant 
drawback; a sphincterotomy might therefore be a more effective treatment option for 
lowering bladder pressure in the long-term.
However, because of the limited availability of eligible trials, this review was un-
able to provide robust evidence in favour of any of the surgical treatment options. 
More RCTs are needed, measuring improvement on quality of life and on other types 
of surgical treatment options for DSD since these are lacking. Future RCTs assessing 
the effectiveness of BTX-A injections also need to address the uncertainty about the 
optimal dose and mode of injection for this specific type of urological condition.
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bACkGrounD
Description of the condition  
The central nervous system controls urination. Normal urination requires a synergic 
action between the detrusor muscle (smooth muscle) and the external urethral 
sphincter (striated muscle). To expel urine from the bladder, the external urethral 
sphincter relaxes, which is followed by a detrusor contraction. The pontine micturition 
centre controls this synergy between the detrusor muscle and the external urethral 
sphincter.1 Disruption of the pathways between the pontine micturition centre and the 
caudal part of the spinal cord often results in detrusor-sphincter dyssynergia (DSD). 
In this condition, a detrusor contraction occurs concurrently with an inappropriate 
contraction of the urethral striated muscle, the periurethral striated muscle, or both, 
thus, blocking the bladder outlet.2
The most common form of bladder outlet obstruction (BOO) in people with neuro-
genic bladder is DSD. Detrusor-sphincter dyssynergia typically occurs in people with 
traumatic supra-sacral spinal lesions (spinal cord injury). Other common causes of 
DSD are multiple sclerosis (MS), acute transverse myelitis, and myelomeningocele.3-7 
Detrusor-sphincter dyssynergia can result in poor bladder emptying and high bladder 
pressures, which in turn can cause recurrent urinary tract infections, high intravesical 
pressures, vesico-ureteral reflux, and hydronephrosis. If untreated, progressive renal 
damage may occur.8
Several authors have attempted to classify DSD. For instance, Blaivas et al.9 defined 
three types of DSD depending on electromyography (EMG) findings. Type three was 
the predominant type, characterised by a sustained sphincter contraction that coin-
cided with the detrusor contraction. Another classification was proposed by Yalla et 
al.10 who described three DSD types based on clinical and urodynamic observations. 
There is a significant overlap between these two classification schemes, and their 
clinical relevance has been questioned. A simpler way of describing the results of EMG 
trials is to describe the frequency of external urethral sphincter contraction during 
detrusor contraction as either intermittent or continuous.8
The symptoms associated with DSD represent a functional disability that may result 
in considerable impairment of a person’s quality of life (QoL). Neurogenic bladder 
problems were associated with lower QoL scores in people with traumatic spinal 
cord injury.11 Therefore, QoL is a very important consideration in the management 
of people with neurogenic bladder dysfunction. Moreover, a relationship between 
bladder management methods and QoL in people with spinal cord injury was found: 




Management of DSD is aimed at reducing intravesical pressure and promoting 
bladder emptying. First-line conservative treatment includes an optimised com-
bination of antimuscarinic agents (anticholinergic drugs) and clean intermittent 
self-catheterisation. The effect on the bladder pressure should be strictly monitored 
urodynamically after initiation of antimuscarinic treatment.13 However, more invasive 
treatment is necessary in people in whom bladder pressure is pathologically elevated 
with antimuscarinics, who cannot tolerate antimuscarinic agents, or who are unable to 
perform clean intermittent self-catheterisation (e.g. people with quadriplegia).
The optimal surgical management of BOO secondary to DSD remains unknown and 
is the focus of this review. Other causes of BOO, such as benign prostatic enlargement 
and urethral stricture, are out with the scope of the review.14-16 Furthermore, we have 
not addressed the treatment of high bladder pressure in patients with only detrusor 
overactivity and not DSD. Upper urinary tract diversion is usually reserved as a last 
resort17 and was not considered as a part of this review, but we did include suprapubic 
catheterisation.
Description of the intervention  
1. Sphincterotomy
External sphincterotomy is a transurethral treatment of the sphincteric hypertonicity, 
which is present in DSD by disrupting, either partially or totally, the continuity of the 
external urethral sphincter. It is performed either with the use of electrocautery18 or a 
contact laser.19,20 The goal is to reduce the intravesical voiding pressure and to lower 
detrusor leak-point pressure. Sphincterotomy should prevent urologic complications, 
such as urosepsis and deterioration of renal function; reduce vesico-ureteral reflux; 
and eliminate the need for chronic indwelling catheterisation. A degree of continence 
may be maintained if bladder neck function can be preserved. Sphincterotomy can 
provide an extended period of satisfactory bladder emptying.21 However, on-going 
revision may be required and a number of complications have been described, prin-
cipally postoperative haemorrhage, erectile dysfunction (complete or partial loss of 
tumescence), urine extravasation, urethral stricture, and fistula formation.21,22
2. Implantable urethral stents
Urethral stents mechanically keep open the external urethral sphincter and thereby 
lower the detrusor leak-point pressure. The stents are either permanent or temporary.
The permanent UroLume® prosthesis (also known as Wallstent in Europe, AMS 
Medinvent SA, Lausanne, Switzerland) was initially developed as a self-expanding 
prosthesis used to maintain the patency of stenotic arteries after balloon angioplasty. 
Milroy et al.23 first described the use of this stent in the treatment of recurrent urethral 
strictures. The stent is made of a stainless steel super alloy, which is corrosion-resistant 
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and non-magnetic. This alloy is woven into a braided, pliable, self-expanding cylindri-
cal mesh. After insertion, the mesh exerts a strong, continuous, outward force against 
the wall of the urethra (lumen) and maintains a patent diameter of up to 42 F. The 
mesh becomes epithelialized by urothelium and is considered to be permanent. Shaw 
et al.24 were the first to use this urethral stent as a successful alternative to external 
sphincterotomy in the treatment of DSD. Since then, studies have confirmed its long-
term clinical benefit and safety, by showing improvements in maximum detrusor 
pressure and postvoid residual urine volume, alongside unchanged bladder capacity 
and reduced hydronephrosis.25,26
Soni et al.27 first described the use of the Memokath® temporary stent (Engineers & 
Doctors A/S, Hornbaek, Denmark) to treat DSD. The stent is composed of a nickel-
titanium alloy with ‘shape memory’. The stent will return to a preformed shape after 
deformation when heated to 45 ºC or above. When cooled (10 ºC or below), the stent 
becomes soft and easy to remove. Because of its closed, tight, spiral structure, urothe-
lial ingrowth is prevented, and this allows the stent to be easily removed if required. It 
has shown short-term success in patients with DSD in terms of decreasing the detrusor 
pressure and postvoid residual urine volume.28
3. Urethral balloon dilatation
Balloon dilatation of the external urethral sphincter was first introduced as a treatment 
for benign prostatic hyperplasia. Chancellor et al.29 reported on their technique and 
early experience with balloon dilatation of the external urethral sphincter in seven 
spinal cord-injured men with DSD. Balloon dilatation of the external urethral sphincter 
uses placement of the Optilume Prostate Dilator® (American Medical Systems Inc, 
Minnesota, USA) under fluoroscopic guidance. The balloon is inflated to a diameter of 
90 F under a pressure of three to four atmospheres for 10 minutes. Balloon dilatation 
was effective in significantly reducing postvoid residual urine volume.30 Balloon dilata-
tion and UroLume® stenting both proved to be as effective as external sphincterotomy 
in the treatment of DSD.31 In contrast, McFarlane et al.32 reported a lower success rate 
than both sphincterotomy and sphincter stenting and did not recommend balloon 
dilatation for the treatment of DSD.
4. Intraurethral botulinum A toxin (BTX-A) injection
Botulinum A toxin (BTX-A) is a protein neurotoxin produced by a bacterium of the 
Clostridium genus. It is an inhibitor of acetylcholine release at the neuromuscular 
junction. BTX-A is injected directly into the target muscle, and the clinical effect is to 
induce relaxation of the injected striated muscle. The clinical effects begin within two 
to three days and are reversible as terminal nerve resprouting occurs within three to six 
months. BTX-A has previously been used successfully in the management of muscular 
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disorders, including strabismus, focal dystonia, skeletal muscle spasms, and spasticity. 
Application of BTX-A in the lower urinary tract has produced promising results in treat-
ing lower urinary tract dysfunction.33 Its use for the treatment of DSD was first reported 
by Dykstra & Sidi34 BTX-A was injected once a week for three weeks into the external 
urethral sphincter of 11 spinal cord-injured men with DSD.
Currently, two preparations of BTX-A are commercially available: onabotulinum-
toxinA or Botox® (Allergan Inc., Irvine, California, USA) and abobotulinumtoxinA or 
Dysport® (Ipsen Ltd, Slough, UK). BTX-A treatment has the advantage of being mini-
mally invasive, can be injected on an outpatient basis, and has a good safety profile. 
However, it provides only temporary relief of symptoms, because the BTX-A-treated 
nerve terminals do not degenerate and axonal resprouting and formation of new neu-
romuscular junctions occurs.35 As a result of this regeneration, repeat BTX-A sphincter 
injections are necessary. The duration of effect of a single treatment is two to three 
months, whereas repeat treatments appear to have cumulative efficacy lasting nine to 
13 months.36
5. Intrathecal baclofen
Baclofen is a well-recognised option for the treatment of skeletal muscle spasticity.37 It 
acts by activating gamma-aminobutyric acid-B receptors, by normalising and decreas-
ing interneuron and motor neuron activity in the spinal cord. Although baclofen has 
been used for over two decades as an oral preparation, its difficulty in passing through 
the blood-brain barrier limited its usefulness for the treatment of DSD. Intrathecal ba-
clofen delivery systems were developed to circumvent this problem: Patients receive 
a continuous intradural administration of baclofen via an implanted pump. Thus, it 
can be delivered directly into the spinal fluid to allow higher concentrations in the 
spinal cord. The rationale behind this modality is to minimise the systemic baclofen 
side-effects from higher oral doses (weakness, dizziness, drowsiness, rash, and hal-
lucinations), while enhancing its therapeutic benefit. After intrathecal application of 
baclofen, urethral pressure shows urethral relaxation during isovolumetric bladder 
contractions in spinal cord-injured rats.38 It has been proposed that baclofen activates 
inhibitory interneurons that, in turn, inhibit directly external urethral sphincter mo-
toneurons in the nucleus of Onuf.39 Steers et al.40 showed a 40% decrease of DSD in 
people with severe spasticity due to spinal cord pathology after intrathecal baclofen.
6. Pudendal nerve block
The pudendal nerve contains the motor axons to the external urethral sphincter as 
well as other nerve fibres innervating the external anal sphincter and other pelvic floor 
muscles. By blocking the pudendal nerve, action potential propagation in the nerve 
is blocked and thus reduces or blocks unwanted external urethral sphincter activity.
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Pudendal nerve block using phenol solution has been widely used as a neurolytic 
agent for the relief of spasticity. Pudendal neurolysis can be done in a relatively non-
invasive way and can be easily performed on an outpatient basis. Treatment of DSD 
with this technique was first described in 1979.41 Other clinical studies showed that 
pudendal nerve block performed by phenol solution was safe, easy to perform, and 
effective as a treatment for DSD in selected people with spinal cord injury.42,43 How-
ever, a number of authors have reported that the duration of the effect of the nerve 
block was unpredictable.
A relatively recent approach involves the use of high-frequency stimulation to block 
the pudendal nerve. Several animal studies have demonstrated high-frequency stimu-
lation as a potential method for suppressing DSD and improving effective voiding.44-47
7. Suprapubic catheterisation
In a small subset of people with DSD, insertion of an indwelling transurethral or su-
prapubic catheter is necessary. Insertion of a suprapubic catheter is a simple form of 
urinary diversion, which involves inserting a catheter directly into the bladder through 
the abdominal wall. The handling and long-term risks of a suprapubic catheter are 
often the subject of debate.48
Compared to clean intermittent self-catheterisation, the use of an indwelling cath-
eter (either suprapubic or transurethral) significantly increases the risk of bladder and 
renal stones, complicated urinary tract infections, urethral fistulas, renal failure, stric-
tures, and erosions.48,49 A controversial issue is the association of long-term use of an 
indwelling catheter and squamous cell carcinoma of the bladder.50 There are several 
advantages of a suprapubic catheter compared to a transurethral catheter: reduced 
risk of urethral trauma, destruction, or both; less risk of prostatitis or epididymitis; 
and less urethral pain. However, it requires a minimal ‘surgical’ intervention to insert 
the suprapubic catheter, with potential to injure structures adjacent to the bladder, 
especially the bowel. The preferred insertion technique appears to be quite variable, 
and there is no evidence of any one best way to insert the suprapubic catheter.51
An epidemiological follow-up study found that suprapubic catheters were more 
frequently used at follow up compared to an initially placed transurethral catheter.52 
This could be due to a shift from the indwelling transurethral catheter towards the 
suprapubic catheter because of complications related to these, but it is also more 
convenient as it permits sexual function.53
Why it is important to do this review  
The wide variety of surgical treatments available for curing or improving BOO in adults 
with neurogenic bladder dysfunction indicates a lack of consensus for what is optimal 
treatment. Provided that sufficient numbers of trials of adequate quality have been 
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conducted, the most reliable evidence is likely to come from the consideration of 
randomised controlled trials, and this will be the basis for this review. The aim is to 
help identify optimal practice and to highlight where there is need for further research.
Other relevant Cochrane reviews that may be of interest to the reader include the 
following:
· Intermittent catheterisation for long-term bladder management;54
· Which anticholinergic drug for overactive bladder symptoms in adults;55
· Catheter policies for management of long term voiding problems in adults with 
neurogenic bladder disorders;56
· Urinary diversion and bladder reconstruction/replacement using intestinal seg-
ments for intractable incontinence or following cystectomy;17 and
· Washout policies in long-term indwelling urinary catheterisation in adults.57
objeCtiVes
To assess the effectiveness of different surgical therapies for the treatment of functional 
bladder outlet obstruction (i.e. DSD) in adults with neurogenic bladder dysfunction.
We considered the following comparisons:
1. Sphincterotomy
 o Sphincterotomy versus no intervention or placebo
 o Sphincterotomy versus non-surgical therapy
 o Sphincterotomy versus other surgical therapy
2. Implantable urethral stents
 o Implantable urethral stents versus no intervention or placebo
 o Implantable urethral stents versus non-surgical therapy
 o Implantable urethral stents versus other surgical therapy
3. Urethral balloon dilatation
 o Urethral balloon dilatation versus no intervention or placebo
 o Urethral balloon dilatation versus non-surgical therapy
 o Urethral balloon dilatation versus other surgical therapy
4. Intraurethral botulinum A toxin (BTX-A) injection
 o Intraurethral BTX-A injection versus no intervention or placebo
 o Intraurethral BTX-A injection versus non-surgical therapy
 o Intraurethral BTX-A injection versus other surgical therapy
5. Intrathecal baclofen
 o Intrathecal baclofen versus no intervention or placebo
 o Intrathecal baclofen versus non-surgical therapy
 o Intrathecal baclofen versus other surgical therapy
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6. Pudendal nerve block
 o Pudendal nerve block versus no intervention or placebo
 o Pudendal nerve block versus non-surgical therapy
 o Pudendal nerve block versus other surgical therapy
7. Suprapubic catheterisation
 o Suprapubic catheterisation versus no intervention or placebo
 o Suprapubic catheterisation versus non-surgical therapy
 o Suprapubic catheterisation versus other surgical therapy
methoDs  
Criteria for considering studies for this review  
Types of studies  
Randomised controlled trials (RCT) or quasi-randomised controlled clinical trials in 
which at least one arm is a surgical method of managing functional BOO in adults 
suffering from neurogenic bladder dysfunction, including cross-over trials.
Types of participants  
All adult men and women with functional BOO due to neurogenic bladder dysfunc-
tion, diagnosed either by symptom and history-taking or urodynamic studies. We ac-
cepted the trialists’ definition of an adult and their diagnosis and classification of DSD.
Types of interventions  
At least one arm of the trial included a surgical treatment for functional BOO due to 
neurogenic bladder dysfunction:
· sphincterotomy;
· implantable urethral stents;
· urethral balloon dilatation;
· intraurethral BTX-A injection;
· intrathecal baclofen;
· pudendal nerve block; or
· suprapubic catheterisation.
These interventions were compared with no treatment or placebo; non-surgical treat-
ment; or with each other, alone, or in combination.
The review did not address the following:
· urinary retention as a result of failure of the detrusor muscle to contract (areflexia);
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· non-functional causes of BOO (e.g. benign prostatic enlargement and urethral 
stricture);
· treatment of high bladder pressure in people who do not also have DSD, such as 
using intravesical botulinum A toxin (BTX-A) with clean intermittent self-catheteri-
sation and bladder augmentation; and
· urinary diversion, which is usually reserved as a last resort and was not considered 
as a part of this review.
Types of outcome measures  
Primary outcomes  
1. Clinicians’ observations
· Urodynamic measurements/studies (e.g. detrusor leak-point pressure, bladder 
pressure, postvoid residual urine volume, bladder capacity)
· Renal function
· Adverse effects: number of urologic complications related to DSD (e.g. urinary 
tract infections)
Secondary outcomes  
1. Quantification of symptoms
· Frequency of incontinent episodes from self-report or voiding diary
· Frequency of urinary retention rates
· Clean intermittent self-catheterisation rates
· Use of rescue antibiotics
2. Quality of life
· Acceptability of procedure or satisfaction with outcome (e.g. Patient Global Im-
pression of Improvement (PGI-I)58)
· Condition-specific health measures (e.g. Qualiveen59)
· Other condition-specific quality of life questionnaires related to urinary incon-
tinence or voiding symptoms (e.g. Bristol Female Lower Urinary Tract Symptoms 
(BFLUTS) Questionnaire, Incontinence Impact Questionnaire (IIQ), King's Health 
Questionnaire (KHQ), Overactive Bladder Questionnaire (OAB-q), International 
Consultation on Incontinence Modular Questionnaire (ICIQ modules)) or sexual 
matters (e.g. International index of Erectile Function Questionnaire (IIEF), Pelvic Or-
gan Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ), ICIQ modules)
· Generic quality of life or health status measures (e.g. Short-Form 3660, EuroQol61)
· Psychological outcome measures (e.g. Hospital Anxiety Depression Scale (HADS)62)
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3. Measures of associated symptoms (objective or subjective)
· Bladder symptoms (including symptomatic and occult incontinence)
· Sexual symptoms
4. Surgical outcome measures
· Operating time
· Blood loss
· Need for transfusion
· Additional surgery or other treatment for DSD
· Length of inpatient hospital stay
· Use of antibiotic prophylaxis
5. Adverse effects
· Infection related to the procedure
· Number with perioperative surgical complications (e.g. infection, haemorrhage, 
etc.)
· Number of urethral strictures due to the procedure with the need of further treat-
ment
· Number with other complications inherent to the procedure
6. Socioeconomic measures
For example, catheter days, inpatient days, days to return to activities of daily living.
· Use of resources
· Cost of interventions or resources
· Resource implications of effects of treatment
· Formal economic evaluations
7. Other outcomes
· Non-prespecified outcomes judged important when performing the review
search methods for identification of studies  
We did not impose any language or other restrictions on the searches, and we identi-
fied the trials from the sources listed below.
Electronic searches  
Relevant trials were identified from the Cochrane Incontinence Group Specialised 
Register (date of last search: 20 February 2014). The Register contains trials identified 
from the Cochrane Central Register of Controlled Trials (CENTRAL) (1999 onwards), 
MEDLINE (1966 onwards), MEDLINE In-Process (2001 onwards), and hand searching 
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of journals and conference proceedings. The methods used to derive this, including 
the search strategy, are described under the Group’s module in The Cochrane Library63. 
The terms used to search the Incontinence Group Specialised Register are given be-
low:
(({DESIGN.CCT*} OR {DESIGN.RCT*}) AND {TOPIC.URINE.NEUROGENIC*} AND 
{INTVENT.SURG*})
All searches were of the keyword field of Reference Manager (Reference Manager 
Professional Ed. version 2012, New York; Thomson Reuters).
Searching other resources  
We searched the reference lists of all relevant reviews and trial reports to identify 
further relevant trials.
Data collection and analysis  
We processed included trial data as described in the Cochrane Handbook for Systematic 
Reviews of Interventions.64 We resolved any differences of opinion related to trial inclu-
sion, methodological quality, or data extraction by discussion with a third party. We 
described comparability of trial groups in terms of potential confounding variables, 
such as use of antimuscarinics, age, and gender.
When appropriate, we undertook meta-analysis. For categorical outcomes, we re-
lated the numbers reporting an outcome to the numbers at risk in each group to derive 
a relative risk (RR). For continuous variables, we used means and standard deviations 
to derive a mean difference (MD). We used a fixed-effect model for calculation of 95% 
confidence intervals (95% CI). We had planned to investigate differences between tri-
als if significant heterogeneity was found or appeared obvious from visual inspection 
of the results.
Where reports included insufficient data for use in the review or where we required 
further information or clarification on any matters, we made attempts to contact the 
trial authors.
Selection of studies  
Two review authors independently screened the trials identified by the literature 
search for eligibility by title and abstract, excluding obviously irrelevant reports. For 
the trials considered eligible, we obtained full-text papers. If there was any uncertainty 
about the eligibility of the trials based on title and abstract, the same two reviewers 
reviewed the full paper, resolving any disagreements by discussion and consulting the 
third review author when disagreement arose. We have listed trials formally consid-
141
Cochrane review of surgical management of neurogenic BOO
7
ered for the review but excluded in Table 7.1 ‘Characteristics of excluded studies’ with 
reasons given for their exclusion.
We used Early Review Organizing Software (EROS 2013, Buenos Aires, Argentina) to 
perform the selection of the trials. EROS is a web-based program for the initial phases 
of a systematic review. It facilitates independent revision of references and immediate 
resolution of discrepancies.
Data extraction and management  
Two reviewers independently undertook assessment of methodological quality and data 
extraction using data extraction forms, based on the Incontinence Group’s assessment 
criteria, which include quality of random allocation and concealment, description of 
dropouts and withdrawals, analysis by intention-to-treat, and ‘blinding’ during treatment 
and at outcome assessment. Extracted data and quality assessment were cross-checked 
and any disagreements discussed and, if necessary, resolved by a third reviewer.
resuLts
Description of studies
The characteristics of included studies are described in Table “Characteristics 
of included studies” which is available online http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD004927.pub4/full at The Cochrane Library.65
The characteristics of excluded studies are described in Table 7.1.
Results of the search  
The search strategy (first run in October 2011) identified 43 records. An updated search 
run in December 2012 retrieved five additional records, and another updated search 
run in February 2014 retrieved four additional records. This resulted in a total of 52 
records (Figure 7.1). After examination of the titles and abstracts of these references, 
we removed one duplicate and excluded 33; thus, we accessed 18 trials for eligibility. 
We obtained full-text copies of these trials, which we subjected to further assessment.
Included studies  
The further assessment of the 18 full-text reports identified five trials evaluating surgical 
management of functional BOO in adults with neurogenic bladder dysfunction.66-70 
One trial was published in Chinese67 and translated by a native Chinese urologist-
in-training with Dutch as a second language. We have provided further details in the 
‘Characteristics of included studies’ which is available online.65 
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Table 7.1 Characteristics of excluded studies
Study Reasons for exclusion
Chancellor MB, Rivas DA, Abdill CK, et al31.
Arch Phys Med Rehabil. 1994 Mar;75(3):297-305
Not a RCT. Quote: “Each patient selected his own 
form of treatment”
Dunn MD, Portis AJ, Kahn SA Yan Y, et al.81
J Endourol. 2000 Mar;14(2):195-202.
Not urethral stents, but ureteral pigtail stents. Not 
on functional BOO in adults with neurogenic 
bladder dysfunction
Herschorn S, Gajewski J, Ethans K, et al.72
Neurourology and Urodynamics 2009;28(7):608–9
Not intraurethral BTX-A injection but intradetrusor 
injection for the treatment of neurogenic urinary 
incontinence
Herschorn S, Gajewski J, Ethans K, et al.71
Neurourology and Urodynamics 2009;28(2):138–9.
Not intraurethral BTX-A injection but intradetrusor 
injection for the treatment of neurogenic urinary 
incontinence
Loubser PG, Narayan RK, Sandin KJ, et al.77
Paraplegia 1991;29(1):48–64.
7 participants underwent urodynamics in this 
trial, 1 participant continued to have detrusor 
hyperreflexia with DSD, but this 1 participant 
cannot be randomised
Mehta S, Hill D, Foley N, et al78
Arch Phys Med Rehabil. 2012 Apr;93(4):597-603.
Non-randomised: review paper for the treatment 
of incomplete voiding after SCI. The authors 
reviewed 2 studies on DSD,68,69 which we already 
included
Meythaler JM, Guin-Renfroe S, Brunner RC, et al80
Stroke 2001;32(9):2099–109.
Treatment of spasticity of extremities with 
intrathecal baclofen; no evaluation of lower 
urinary tract function
Naumann M, So Y, Argoff CE, et al.79
Neurology 2008;70(19):1707–14.
Non-randomised; review paper on BTX-A for the 
treatment of autonomic disorders and pain. They 
reviewed 3 studies on DSD,68-70 which we already 
included
Schurch B, de Seze M, Denys P, et al.74
Neurourology and Urodynamics. 2004; Vol. 23, issue 
5/6:609–10.
Not intraurethral BTX-A injections but 
intradetrusor injections for the treatment of 
neurogenic urinary incontinence
Schurch B, de Sèze M, Denys P, et al.73
Neurourology and Urodynamics 2005;24(5/6):545–6.
Not intraurethral BTX-A injections but 
intradetrusor injections for the treatment of 
neurogenic urinary incontinence
Schurch B, Denys P, Kozma CM, et al.75
European  Urology 2007;52(3):850–8.
Not intraurethral BTX-A injections but 
intradetrusor injections for the treatment of 
neurogenic urinary incontinence
Steers WD, Meythaler JM, Haworth C, et al.40
Journal of Urology 1992;148(6):1849–55.
Not a RCT
Thavaseelan JT, Burns-Cox N, Jordan K, et al.76
BJU International 2005;95 (Suppl 1):4–5.
RCT. However, no intra-urethral BTX-A injections 
but intra-detrusor injections for the treatment of 
neurogenic urinary incontinence
The characteristics of included studies are described in Table “Characteristics of included studies” 
which is available online at http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004927.pub4/
full at The Cochrane Library.65 
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The surgical treatments studied in the included trials were as follows:
· sphincterotomy66 ;
· placement of sphincteric stent prosthesis66 ;
· BTX-A injection into the external urethral sphincter67-70 ; and
· lidocaine injection in the external urethral sphincter.68
Two trials included placebo as a comparator,69,70 and two added oral medication to 
the surgical intervention.67,70
52 records identified 
through database 
searching 
(date of last search 20 
February 2014)
No additional records 
identified through 
other sources
1 duplicated record removed
51 records screened 33 records excluded
18 full-text articles assessed for 
eligibility
13 full-text articles excluded 
(Table 7.1)
5 studies included in 
qualitative synthesis
0 studies included in 
quantitative synthesis 
(meta-analysis)




All included trials were RCTs with two arms, of which two trials66,70 were parallel-arm 
trials of two interventions. In Cui et al.67 all included participants received the same 
surgical intervention, and on the second day, only a randomised subgroup received a 
pharmaceutical treatment. In de Sèze et al.68participants who reported a negative result 
at the end of the trial received treatment from the other arm, and in Dykstra & Sidi69 the 
participants who were allocated to the placebo arm received the actual intervention 
after completion of the study.
Setting
Care was provided in a hospital setting in four trials: in a urology department in China,67 
at the physical medicine unit of two different centres in France,68 in a university clinic 
on an outpatient basis in the United States,69 and in an outpatient setting of five univer-
sity hospitals and one rehabilitation clinic in France.70 One trial provided care at three 
spinal cord injury centres in the United States.66
Participants
The trials enrolled a total of 199 participants. The number of participants in individual 
trials ranged from five to 86.
· One trial only enrolled participants with DSD due to MS.70 
· Three trials66,67,69 only enrolled participants with DSD due to traumatic spinal cord 
injury.
· One trial68 included participants with different reasons for cord lesion (traumatic, 
MS, and congenital malformation).
Duration of neurological disease
The average duration of onset of underlying neurological disease was 10 years66-70 and 
ranged from 2.567 to 16 years.70 The presence of DSD was urodynamically confirmed in 
all trials,66-70 of which two added needle-electrode EMG to diagnose DSD,68,69 and de 
Sèze et al.68 added also voiding cystourethrography to confirm DSD.
Age and gender
The average age of the study participants overall was 40 years, ranging from 3269 to 
5070 years. Two trials66,69 enrolled only men. In one trial67, we found a discrepancy be-
tween the reported gender in the abstract and in the main text: The abstract reported 
31 men and seven women, while the main text reported 28 men and seven women. 
The remaining trials included either more men (92%)68 or more women (67%).70
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Other concurrent treatment
Two trials68,70 made statements about the use of other treatments or medication during 
the trial. Participants from de Sèze et al.68 discontinued use of forms of treatment that 
interfered with bladder function during the trial, except in two participants for whom 
oral antispastic medication (baclofen) was maintained at a constant dose throughout 
the study. Participants from Gallien et al.70 were excluded if they took any treatment 
that could have altered neuromuscular transmission.
Interventions
There were no trials evaluating urethral balloon dilatation, intrathecal baclofen, 
pudendal nerve block, or suprapubic catheterisation. The trials tested the following 
surgical interventions.
Sphincterotomy
· External urethral sphincterotomy versus implantable urethral stent placement66 
Intraurethral botulinum A toxin (BTX-A) injection
· BTX-A injection into the external urethral sphincter with and without oral baclofen67
· BTX-A injection versus lidocaine injection into the external urethral sphincter68 
· BTX-A injection versus placebo (saline) injection into the external urethral sphinc-
ter69
· BTX-A injection versus placebo (saline) injection into the external urethral sphinc-
ter with all participants also having oral alpha blockers70
Intraurethral botulinum A toxin (BTX-A) injection protocols
The variety in single and repeat injections and mode of BTX-A injection differed be-
tween trials:
· De Sèze et al.68 and Gallien et al.70 administered BTX-A injections one time with a 
single injection transperineally;
· Cui et al.67 also administered BTX-A injections one time, but with a cystoscope 
transurethrally at eight different sites into the external urethral sphincter; and
· Dykstra & Sidi69 administered BTX-A injections once a week for three weeks, using 
a cystoscope transurethrally to inject at three to four different sites into the external 
urethral sphincter.
Cui et al.67 used BTX-A produced in China (Lanzhou Biotechnology). The other three 
trials used onabotulinumtoxinA.68-70 
Also, the dose in units (U) of BTX-A differed between trials:
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Table 7.2 Adverse effects
Included 
studies
Reported adverse events Details of reported adverse events Consequences for participants Trial author’s conclusions
Chancellor 
et al.66
1.  device removal (stent)
2.  additional insertion procedures (stent)
3.  requirement of repeat sphincterotomy due 
to restenosis of the sphincter
4.  bladder neck obstruction
5.  no alterations in erectile function or 
ejaculation in both groups
1.  Stent explantation in 6 of 31 participants 
(19%) due to the following:
-  stent migration detected at 3-month 
follow up (n =3);
-  incorrect placement of stent at insertion (n 
= 1);
-  participant’s own request because he did 
not like using the condom catheter to 
collect urine (n = 1); and
-  pain and symptoms of dysreflexia during 
reflex voiding (n = 1)
2.  Additional insertion procedures of stent 
(i.e. more than 1 insertion procedure) in 7 
participants (23%):
- 2 procedures (n = 6); and
- 3 procedures (n = 1)
3.  Repeat sphincterotomy in 2 of 26 
participants (8%) 6 months postoperatively
4.  Of all participants, 9% required 
urethrotomy because of a urethral stricture 
(Analysis 1.14*), and 21% were treated for 
bladder neck obstruction (Analysis 1.12*)
1.  stents were removed without difficulty (despite 
epithelialisation) or longterm complications; 
prosthesis migration was easily diagnosed in all 
cases
2.  consequences not mentioned
3.  consequences not mentioned
4.  consequences not mentioned
No author’s conclusions concerning adverse effects
Cui et al.67 1.  haematuria
2.  muscle weakness and central nervous 
system symptoms in BTX-A with oral 
baclofen group
Toxic and adverse events were recorded 
between 2 to 9 months postoperatively 
1.  all participants in both groups had varying 
degrees of haematuria
2.  after 1 week of oral baclofen,
3  participants reported muscle weakness 
and central nervous system symptoms like 
dizziness, malaise, and weakness
1.  haematuria resolved without additional 
treatment after 2 to 3 days in all but 1, who 
received haemostatic agents and required 
hospitalisation for observation
2.  discontinued the use of baclofen after 1 week but 
continued follow up
BTX-A with baclofen is relatively safe with few 
complications, which are easily accepted by the 
participants; however, the long-term toxicity is 
unknown
De Sèze et 
al.68
1.  faecal incontinence after lidocaine injection
2.  transitory exacerbation of urinary 
incontinence for 2 weeks after BTX-A
3.  no complications involving haemorrhaging 
or infection
4.  no systemic side-effects (e.g. nausea, 
vomiting, dry mouth, dysphagia, weakness 
in the respiratory muscles, or paresis of the 
extremities) in both groups
Adverse effects were evaluated at the end of 
the study (30 days)
1.  consequences not mentioned
2.  consequences not mentioned
BTX-A is safe because of the very scarce side-effects 
reported by the participants
Dykstra and 
Sidi69
1.  mild, generalised upper extremity weakness
2.  mild haematuria after cystoscopic injections
3.  no urinary tract infections due to 
cystoscopic injections
4.  no adverse effects, such as nausea, 
vomiting, dry mouth, diplopia, blurred 
vision, photophobia, dysphonia, dysarthria, 
dysphagia, or subjective weakness of the 
respiratory muscles
1.  mild generalised upper extremity 
weakness in 3 participants, of which in 1 
participant - 3 weeks after the last injection 
single-fiber electromyography studies 
revealed increased fiber density and a 
small increase in jitter at slow-firing rates (3 
Hz) in the left deltoid 
2.  haematuria resolved within 24 hours
1.  caused difficulty with transfers and some 
activities of daily living; these gradually subsided 
over a 2- to 3-week period, after which the 
strength returned to normal
2.  consequences not mentioned
The transient weakness suffered by 3 participants 
was probably caused by receiving a too-large toxin 
dose in a 3-week period. An initial dose of 140 units 
of toxin was injected, followed by 2 doses of 240 
units each week. To prevent weakness from the 
initial 3 injections, the trial authors now wait 2 weeks 
between injections
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Table 7.2 Adverse effects
Included 
studies
Reported adverse events Details of reported adverse events Consequences for participants Trial author’s conclusions
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et al.66
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ejaculation in both groups
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(19%) due to the following:
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= 1);
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not like using the condom catheter to 
collect urine (n = 1); and
-  pain and symptoms of dysreflexia during 
reflex voiding (n = 1)
2.  Additional insertion procedures of stent 
(i.e. more than 1 insertion procedure) in 7 
participants (23%):
- 2 procedures (n = 6); and
- 3 procedures (n = 1)
3.  Repeat sphincterotomy in 2 of 26 
participants (8%) 6 months postoperatively
4.  Of all participants, 9% required 
urethrotomy because of a urethral stricture 
(Analysis 1.14*), and 21% were treated for 
bladder neck obstruction (Analysis 1.12*)
1.  stents were removed without difficulty (despite 
epithelialisation) or longterm complications; 
prosthesis migration was easily diagnosed in all 
cases
2.  consequences not mentioned
3.  consequences not mentioned
4.  consequences not mentioned
No author’s conclusions concerning adverse effects
Cui et al.67 1.  haematuria
2.  muscle weakness and central nervous 
system symptoms in BTX-A with oral 
baclofen group
Toxic and adverse events were recorded 
between 2 to 9 months postoperatively 
1.  all participants in both groups had varying 
degrees of haematuria
2.  after 1 week of oral baclofen,
3  participants reported muscle weakness 
and central nervous system symptoms like 
dizziness, malaise, and weakness
1.  haematuria resolved without additional 
treatment after 2 to 3 days in all but 1, who 
received haemostatic agents and required 
hospitalisation for observation
2.  discontinued the use of baclofen after 1 week but 
continued follow up
BTX-A with baclofen is relatively safe with few 
complications, which are easily accepted by the 
participants; however, the long-term toxicity is 
unknown
De Sèze et 
al.68
1.  faecal incontinence after lidocaine injection
2.  transitory exacerbation of urinary 
incontinence for 2 weeks after BTX-A
3.  no complications involving haemorrhaging 
or infection
4.  no systemic side-effects (e.g. nausea, 
vomiting, dry mouth, dysphagia, weakness 
in the respiratory muscles, or paresis of the 
extremities) in both groups
Adverse effects were evaluated at the end of 
the study (30 days)
1.  consequences not mentioned
2.  consequences not mentioned
BTX-A is safe because of the very scarce side-effects 
reported by the participants
Dykstra and 
Sidi69
1.  mild, generalised upper extremity weakness
2.  mild haematuria after cystoscopic injections
3.  no urinary tract infections due to 
cystoscopic injections
4.  no adverse effects, such as nausea, 
vomiting, dry mouth, diplopia, blurred 
vision, photophobia, dysphonia, dysarthria, 
dysphagia, or subjective weakness of the 
respiratory muscles
1.  mild generalised upper extremity 
weakness in 3 participants, of which in 1 
participant - 3 weeks after the last injection 
single-fiber electromyography studies 
revealed increased fiber density and a 
small increase in jitter at slow-firing rates (3 
Hz) in the left deltoid 
2.  haematuria resolved within 24 hours
1.  caused difficulty with transfers and some 
activities of daily living; these gradually subsided 
over a 2- to 3-week period, after which the 
strength returned to normal
2.  consequences not mentioned
The transient weakness suffered by 3 participants 
was probably caused by receiving a too-large toxin 
dose in a 3-week period. An initial dose of 140 units 
of toxin was injected, followed by 2 doses of 240 
units each week. To prevent weakness from the 




· 100 U68,70 ;
· 200 U67 ; and
· 140 U initially, and subsequent injections of 240 U.69
Outcomes
Primary outcomes
All trials reported urodynamics measurements, including the postvoid residual urine 
volume - either measured urodynamically or using catheterisation. Other reported 
urodynamic outcomes were as follows: detrusor pressure, bladder capacity, bladder 
compliance, uroflow rate, voided volume, urethral pressure profile, and EMG of exter-
nal urethral sphincter activity.
The urodynamic outcomes were all measured at different time points. Three tri-
als67,68,70 measured primary outcomes one month after injection and one trial,69 a week 
after each injection. Chancellor et al.66 considered primary outcomes at three, six, 12, 
and 24 months postoperatively.
Table 7.2 Adverse effects (continued)
Included 
studies




1.  multiple sclerosis attack
2.  pyelonephritis
3.  lumbar radicular pain
4.  femoral fracture
5.  uterine leiomyoma
6.  drug-induced confusion
7.  dyspnoea
Non-serious adverse events:
8.  urinary tract infections
9.  multiple sclerosis attack
10.  urinary leakages
11.  faecal incontinence
12 serious adverse events in 11 different 
participants during follow-up:
1.  2 and 4 participants in the placebo and 
BTX-A group, respectively
2.  1 participant in placebo group
3.  1 participant in placebo group
4.  1 participant in placebo group
5.  1 participant in BTX-A group
6.  1 participant in BTX-A group
7.  1 participant in BTX-A group
64 non-serious adverse events were reported 
in 45 participants during follow- up:
8.  urinary tract infections in 38 participants 
(placebo n = 12; 29%, and BTX-A n = 16; 
36%; RR 1.24, 95% CI 0.67 to 2. 29, Analysis 
2.11.1)
9.  multiple sclerosis attack in 9 participants 
(placebo n = 3; 7%, and BTX-A n = 6; 13%; 
RR 1.86, 95% CI 0.50 to 6.95, Analysis 2.8*) 
10.  urinary leakages in 4 participants (placebo 
n =2; 5%, and BTX-A n = 2; 4%; RR 0.93, 
95% CI 0.14 to 6.30, Analysis 2.11.2*)
11.  1 participant in BTXA group (placebo n = 
0, and BTX-A n = 1; RR 2.80, 95%CI 0.12 to 
66.70, Analysis 2.11.3* )
All 11 participants with a serious adverse event were 
declared in the context of hospitalisation
No serious adverse event could be attributable to 
BTX-A
*) The details of the statistical data analyses are available online at The Cochrane Library.65 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004927.pub4/full
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Only one trial66 reported renal function, in terms of hydronephrosis and vesico-
ureteric reflux, and urologic complications related to DSD (e.g. urinary tract infection).
Secondary outcomes
Chancellor et al.66 quantified DSD symptoms by reporting the catheterisation rates. 
Four trials reported quality of life,66-68,70 using different instruments to measure satis-
faction rate67,68 and condition-specific quality of life.66,67,70 However, no trial reported 
if the instruments (questionnaires) were validated measures. Only Chancellor et al.66 
described associated symptoms, such as alterations in erectile function or ejaculation. 
Four trials reported associated symptoms of the underlying neurologic disease, such 
as autonomic dysreflexia symptoms66,68,69 or MS attacks.70 All trials reported surgical 
outcomes, consisting of blood loss, infection related to the procedure, hospital-stay 
length, occurrence of urethral strictures, complications, toxic effects, adverse events, 
tolerance, and side-effects.66-70 Further details on adverse effects can be found in Table 
7.2.
Table 7.2 Adverse effects (continued)
Included 
studies
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64 non-serious adverse events were reported 
in 45 participants during follow- up:
8.  urinary tract infections in 38 participants 
(placebo n = 12; 29%, and BTX-A n = 16; 
36%; RR 1.24, 95% CI 0.67 to 2. 29, Analysis 
2.11.1)
9.  multiple sclerosis attack in 9 participants 
(placebo n = 3; 7%, and BTX-A n = 6; 13%; 
RR 1.86, 95% CI 0.50 to 6.95, Analysis 2.8*) 
10.  urinary leakages in 4 participants (placebo 
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95% CI 0.14 to 6.30, Analysis 2.11.2*)
11.  1 participant in BTXA group (placebo n = 
0, and BTX-A n = 1; RR 2.80, 95%CI 0.12 to 
66.70, Analysis 2.11.3* )
All 11 participants with a serious adverse event were 
declared in the context of hospitalisation
No serious adverse event could be attributable to 
BTX-A




No trial reported socioeconomic measures, and therefore we did not describe these 
measures in the results. Other important outcomes reported were the need for re-
intervention68 and participant-reported days of effect.68,69 
Excluded studies  
We excluded 13 trials after further assessment of the 18 full-text reports.
· Six trials compared surgical interventions on detrusor overactivity but not func-
tional BOO.71-76 
· Five trials were not randomised.31,40,77-79
· Meythaler et al.80 determined the effect of intervention on spasticity of extremities, 
but not on the urological tract.
· Dunn et al.81 compared stents for the upper urinary tract (ureteric stents) instead of 
the lower urinary tract (urethral stents).
We provide further details in the ‘Characteristics of excluded studies’ tables (Table 7.1).
risk of bias in included studies  
We present specific characteristics, details of assessment, methodological quality, and 
risk of bias of the included trials in the ‘Characteristics of included studies’ tables avail-
able online65 and in Figure 7.2 and Figure 7.3.
Figure 7.2 Risk of bias graph
review authors’ judgements about each ‘Risk of bias’ item presented as percentages across all included 
studies
Allocation (selection bias)  
Random sequence generation (selection bias)
The method used for random sequence generation was unclear in three of five tri-
als66-68: All three trials simply stated the trial was randomised, but provided no further 
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details about the sequence generation process. We judged two trials to be at low risk: 
both Dykstra & Sidi69 and Gallien et al.70 used a computer random number generator.
Allocation concealment (selection bias)
We judged three of five trials68-70 as having an adequate method of concealment of al-
location prior to assignment since they used central allocation. The remaining two66,67 
did not provide details about allocation concealment; hence, we judged them as 
‘unclear’ risk of bias.
Blinding (performance bias and detection bias)  
We judged the performance bias due to knowledge of the allocated interventions by 
participants and personnel during the study and the detection bias during outcome 
assessment as ‘low’ risk of bias in four of five trials: Three trials68-70 stated that they were 
‘double-blind’ and provided a clear description of the blinding of the participants and 
personnel and outcome assessment, whereas due to specific surgical approaches, 
blinding in Chancellor et al.66 was not possible. However, the review authors judged 
that the outcomes of Chancellor et al.66 were not likely to be influenced by lack of 
blinding.
Figure 7.3 Risk of bias summary
review authors’ judgements about each ‘Risk of 
bias’ item for each included study
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One trial67 did not provide details about blinding of participants and personnel, nor 
about blinding of outcome assessment, so we therefore judged as ‘unclear’ risk of 
performance and detection bias.
Incomplete outcome data (attrition bias)  
Two trials68,69 did not contain missing data; therefore, we judged them to be at low risk 
of attrition bias. Two trials66,70 did not provide a satisfactory explanation for the missing 
of data, and therefore there was insufficient information available to permit judgement 
of ‘low’ or ‘high’ risk of attrition bias. We judged one trial to be at high risk of bias 
because there was dropout due to adverse events only in the experimental group.67 
Only one trial70 reported that they had performed an intention-to-treat analysis. How-
ever, they did not report how they handled missing values. The other trials66-69 did not 
report how they handled data from participants who deviated from the protocol, but 
we assumed that they were analysed in the groups to which they were randomised.
Selective reporting (reporting bias)  
It was unclear if there was selective reporting of the outcomes in three trials, because 
the protocols were not available.66-68 However, it has to be noted that the trials re-
ported the outcomes of all study parameters mentioned in the Methods section. Even 
though no trial protocol was available for Dykstra & Sidi,69 the review authors judged 
the risk of selective reporting as ‘low’ since correspondence with a trial author assured 
that all of the trial’s prespecified outcomes were reported in the prespecified way. We 
judged one trial70 as high risk for reporting bias since the report provided no result for 
an outcome of interest mentioned in the methods section.
effects of interventions  
The details of the following statistical data analyses are available online at The Cochrane 
Library.65 http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004927.pub4/full
Comparison 01: implantable urethral stent versus sphincterotomy
One small trial addressed this comparison.66 All participants had traumatic spinal cord 
injury with urodynamically verified DSD. Chancellor et al.66 compared implantation of 
the UroLume® sphincteric stent prosthesis with conventional external sphincterotomy.
Primary outcome measures
Urodynamic measurements
Postvoid residual urine volume (Analysis 1.1) and cystometric bladder capacity (Analy-
sis 1.2) were not statistically significantly different between the interventions at either 
time-point.
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The maximum detrusor pressure measured at three, six, or 12 months (Analysis 1.3) 
was relatively stable and low in both groups without statistically significant differences 
between the groups. However, at 24 months, the maximum detrusor pressure sig-
nificantly increased in the participants who received an implantable stent, compared 
to the participants after sphincterotomy (MD 30.00 cmH2O, 95% CI 8.99 to 51.01, 
Analysis 1.3.4).
Renal function
The occurrence of vesico-ureteral reflux was not statistically significantly different 
between the groups at 12 and 24 months (Analysis 1.4).
Hydronephrosis using radiography was reported per renal unit, although we have 
strong indications that the reported number of evaluated renal units was incorrectly 
reported. The report describes an evaluation of 52 renal units in the sphincterotomy 
group and 69 renal units in the stent group. Further in the report, 59 renal units were 
evaluated in the stent group. We assumed 59 units was correct since this could be con-
firmed by the associated reported percentage. The occurrence of hydronephrosis was 
not statistically significantly different between the groups at 12 and 24 months (Analysis 
1.5). The confidence intervals were wide, reflecting few events and small groups.
The occurrence of urinary tract infections as a complication related to DSD was 
more common, but also not statistically significantly different between the groups at 
three, six, 12, and 24 months, neither in terms of positive urine culture (Analysis 1.6), 
nor in terms of symptomatic urinary tract infections (Analysis 1.7).
Secondary outcome measures
Quantification of symptoms
The participant-reported disappearance of autonomic dysreflexia symptoms was 
not statistically significantly different between groups at 24 months (Analysis 1.8). The 
catheterisation rates also were not statistically significantly different between groups at 
three, six, 12, and 24 months (Analysis 1.9).
Quality of life
The trial did not report which questionnaires it used to evaluate bladder emptying 
and quality of life with respect to the urological condition and if these questionnaires 
were validated. Exact data of the number of participants worrying about DSD, noticing 
bothersomeness with urination, the number who were hampered in their daily activi-
ties, and the participants reporting that the urological condition interfered with social 
life were lacking. We were therefore not able to analyse the effect of the intervention 
on quality of life.
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Measures of associated symptoms (objective or subjective)
Participants reported their bladder-emptying ability as “much better”, “somewhat bet-
ter”, “no change”, “somewhat worse”, and “much worse”. For the current review, “much 
better” and “somewhat better” defined improvement, while “no change”, “somewhat 
worse”, and “much worse” defined no improvement. No statistically significant differ-
ence of the improvement rate of the bladder-emptying ability was observed between 
groups at three, six, 12, and 24 months (Analysis 1.10).
The report stated that no alterations in erectile function or ejaculation were noted 
in men who underwent sphincterotomy or stent placement at any time. The report 
provided no data.
Surgical outcome measures
Surgical measures were reported in all 26 participants who underwent sphincterotomy 
and in 30 of 31 participants who underwent stent placement.
More participants after sphincterotomy (23/26, 88.5%) than after stent placement 
(19/30, 63.3%) were hospitalised for two days or longer after the surgical intervention, 
in favour of stent placement (RR 0.72, 95% CI 0.53 to 0.97, Analysis 1.11). There were no 
statistically significant differences between groups in the number of participants with 
bladder neck obstruction requiring treatment (Analysis 1.12).
Adverse effects
(See Table 7.2.)
There were no statistically significant differences between groups in outcomes of 
haemorrhaging (one-day postoperative bleeding as quantified by haemoglobin value, 
Analysis 1.13) or number of participants with urethral strictures requiring surgical treat-
ment (Analysis 1.14). Re-stenosis of the sphincter in two participants who underwent 
sphincterotomy required repeat sphincterotomy six months postoperatively.
Comparison 02: botulinum A toxin injection versus placebo
Two trials addressed this comparison.69,70
The extremely small trial from Dykstra & Sidi69 in five men with spinal cord injury 
compared sphincter injections with either a dose of BTX-A (n = 3) or normal saline as 
placebo (n = 2), applied once a week for a total of three weeks. The initial dose of BTX-
A was 140 U on a botulinum A toxin, with subsequent injections of 240 U. In the three 
participants allocated to the BTX-A treatment, an average decrease of 25 cmH2O was 
seen in the maximal urethral pressure, an average decrease of 125 mL was seen in their 
postvoid residual urine volume, and an average decrease of 30 cmH2O was found in 
the maximum bladder pressure during voiding. After completion of the study, partici-
pants who had received placebo were offered the opportunity to undergo the same 
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injections with BTX-A. The report mentions that in participants who received placebo 
injections, all outcomes were unchanged from baseline values until the subsequent 
injection with BTX-A once per week for three weeks. This resulted in similar responses 
to those of the other three participants who initially received BTX-A. The effects of the 
BTX-A injection lasted an average of 60 days in all five participants. All participants 
continued to use condom catheters after injection. Three participants had suffered 
from autonomic dysreflexia symptoms during voiding, of which all reported a notice-
able improvement in their autonomic dysreflexia symptoms after toxin injections. 
Unfortunately, the report presented no data on placebo treatment, and therefore we 
could not make quantitative comparison between active and placebo treatment.
Gallien et al.70 compared a single transperineal injection of BTX-A (Botox®, Allergan 
Inc.) into the external urethral sphincter with a single placebo (saline) transperineal 
injection into the external urethral sphincter in MS patients. In addition, participants 
in both groups were prescribed an alpha blocker (5 mg tablet slow-release alfuzosin 
twice a day) over four months. All results mentioned below in this comparison origi-
nate from Gallien et al.70 
Primary outcome measures
Urodynamic measurements
The postvoid residual urine volume measured using catheterisation at 30 days did 
not differ statistically significantly between groups (Analysis 2.1). However, the voiding 
volume at 30 days was statistically significantly larger in the BTX-A group (MD 69 mL, 
95% CI 11.87 to 126.13, Analysis 2.2).
At 30 days, the BTX-A group had a statistically significant lower pre-micturition 
detrusor pressure (MD -10.00 cmH2O, 95% CI -17.62 to -2.38, Analysis 2.3.2) and 
maximum detrusor pressure (MD -14.00 cmH2O, 95% CI -25.32 to -2.68, Analysis 2.3.3) 
compared to the placebo group. All other urodynamic outcomes at 30 days did not 
differ statistically significantly between groups: basal detrusor pressure (Analysis 2.3.1), 
maximal bladder capacity (Analysis 2.4), maximal urinary flow (Analysis 2.5), bladder 
compliance at functional bladder capacity (Analysis 2.6), and maximal and closure 
urethral pressure (Analysis 2.7).
Renal function
No data were available for analysis of any of the outcomes relating to renal function.
Secondary outcome measures
Quantification of symptoms
The occurrence of MS attacks was reported in both groups and did not differ statisti-




The International Prostate Symptoms Score (IPSS) was measured as a condition-specific 
quality of life questionnaire related to lower urinary tract symptoms. This IPSS score 
did not differ statistically significantly between groups (Analysis 2.9). The variables as-
sessing the quality of voiding (obstructive symptoms, urinary frequency, urgency, and 
incontinence) were assessed using 10 cm visual analogue scales (VAS). The VAS scores 
were not statistically significantly different between groups (Analysis 2.10).
Measures of associated symptoms (objective or subjective)
No data were available for analysis of any of the outcomes relating to symptoms as-
sociated with DSD.
Surgical outcome measures
The trials reported no relevant data regarding any surgical outcome measures.
Adverse effects
(See Table 7.2.)
Outcomes reported that related to the surgical intervention were the number of 
people with urinary tract infections, urinary leakage (incontinence), and faecal incon-
tinence. There were no statistically significant differences between groups (Analysis 
2.11). Serious adverse events and non-serious adverse events were reported, though 
exact data were not available.
Comparison 03: botulinum A toxin injection combined with non-surgical therapy
We identified one small trial67 comparing a single 200 U BTX-A injection combined 
with oral baclofen versus a single 200 U Chinese-manufactured BTX-A injection with-
out oral baclofen, in patients after spinal cord injury.
Primary outcome measures
Urodynamic measurements
The study measured the postvoid residual urine volume, though no data were avail-
able from the report to analyse the effect of intervention on postvoid residual urine 
volume.
Urodynamics were performed in both groups one month after the injections. The 
maximum uroflow rate (Analysis 3.1), maximal cystometric capacity (Analysis 3.2), and 
volume per voiding (Analysis 3.3) were not significantly different between groups. The 
bladder compliance was significantly higher (better) in the BTX-A group without oral 
baclofen group than in the BTX-A group with oral baclofen. Participants after BTX-A 
with baclofen had a lower (worse) compliance with a MD of -7.50 mL/cmH2O, 95% CI 
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-10.74 to -4.26 (Analysis 3.4), compared to participants after BTX-A without baclofen. 
The report does not describe at which bladder volume the compliance was calcu-
lated. This is important because the bladder compliance describes the relationship 
between change in bladder volume and change in detrusor pressure. Furthermore, 
this trial did not report the detrusor pressure, which is a shortcoming since it is an 
important urodynamic measure when evaluating renal function. Therefore, the value 
of compliance as an outcome in this report may be limited.
Renal function
No data were available for analysis of any of the outcomes relating to renal function.
Secondary outcome measures
Quantification of symptoms
No data were available for analysis of any of the outcomes that quantifies symptoms. 
The report describes the measurement of the urinary frequency per 24 hours, though 
no data were available.
Quality of life
The amelioration degree was not statistically significantly different between groups 
(Analysis 3.5). The report did not describe how the amelioration degree was mea-
sured. The IPSS was administered in men, and the Urogenital Distress Inventory (UDI) 
was administered in women, though no data were available from the report. We were 
therefore not able to analyse the effect of intervention regarding the quality of life.
Measures of associated symptoms (objective or subjective)
No data were available for analysis of any of the outcomes relating to associated 
symptoms of DSD.
Surgical outcome measures
No data were available for analysis of any of the outcomes relating to surgical outcome 
measures.
Adverse effects
Reported adverse events were haematuria and muscle weakness (Table 7.2). However, 
no data were available for analysis of any of the outcomes relating to adverse effects.
Chapter 7
158
Comparison 04: botulinum A toxin injection versus other surgical therapy
One very small trial68 addressed this comparison; participants with spinal cord lesions 
(due to traumatic spinal cord injury, MS, or congenital malformation) received either 
a single 100 U BTX-A injection (Botox®, Allergan Inc.) or a lidocaine injection into the 
external urethral sphincter via the transperineal route. Participants who had a negative 
result at the end of the trial (30 days) received the other treatment. The results pre-
sented below only include data from the first period, since only this information was 
available from the report.
Primary outcome measures
Urodynamic measurements
The postvoid residual urine volume measured by catheterisation was significantly 
lower (better) after seven days (MD -163 mL, 95% CI -309 to -17, Analysis 4.1.2) and 
30 days (MD -158 mL, 95% CI -278 to -39, Analysis 4.1.3) in favour of the group who 
received BTX-A injections. These differences were not quite statistically significantly 
different in the short-term (one day after treatment) (Analysis 4.1.1).
Reported urodynamic outcomes 30 days after injection were maximal detrusor 
pressure on voiding (Analysis 4.2), maximal urethral pressure (Analysis 4.3), and im-
provement in Blaivas classification of DSD (Analysis 4.4). None of these urodynamic 
outcomes were statistically significantly different between groups.
Renal function
No data were available for analysis for any of the outcomes relating to renal function.
Secondary outcome measures
Quantification of symptoms
No data were available for analysis of any of the outcomes that quantified symptoms 
of DSD.
Quality of life
The satisfaction score with treatment, using a question (“Do you find this treatment to 
be efficacious?”) with response options from 0 (no efficacy) to 10 (maximal efficacy), 
was measured 30 days after injection. This was statistically significantly higher (bet-
ter) in the participants who received BTX-A injections (MD 3.41, 95% CI 0.93 to 5.89, 
Analysis 4.5).
Measures of associated symptoms (objective or subjective)
The disappearance of symptoms of autonomic dysreflexia was not statistically signifi-
cantly different between groups (Analysis 4.6). The report described the assessment of 
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the participant’s personal opinion about the evolution of the voiding difficulties (time 
to induce voiding), but no data were available from the report for quantitative analysis. 
All participants in the BTX-A group reported an improvement in voiding difficulties, 
whereas the voiding difficulties remained unchanged in the lidocaine group.
Surgical outcome measures
At the end of the trial (30 days), one of five participants from the BTX-A group and all 
eight participants from the lidocaine group required another injection. The difference 
did not however reach statistical significance (Analysis 4.7).
Tolerance assessed by a quantitative tolerance score was not significantly different 
between groups (Analysis 4.8). Forty-six per cent of the participants reported that the 
BTX-A injection was efficacious for three months, and in 23% of the participants, the 
effect lasted longer than three months. The efficacy was shorter than three months in 
31% of participants.
Adverse effects
There were no events of haemorrhaging or infections related to the procedure in 
either group and no systematic side-effects. One participant in each group reported 
side-effects, involving faecal incontinence after lidocaine and transitory exacerbation 
of urinary incontinence for two weeks after BTX-A (Table 7.2).
DisCussion
summary of main results  
In patients with neurogenic bladder dysfunction, the first aim of any therapy is pro-
tection of the upper urinary tract.13 In patients with detrusor-sphincter dyssynergia 
(DSD), a high detrusor pressure during the voiding phase can result in a pathologic 
high-pressure bladder, which needs to be converted into a low-pressure reservoir. In 
patients for whom conservative treatment (i.e. clean intermittent self-catheterisation 
and pharmaceutical treatment (e.g. antimuscarinics)) is not possible or feasible, surgi-
cal treatment options should be considered. According to the European Association 
of Urology Guidelines,13 sphincterotomy is the standard surgical treatment for DSD. 
Since the introduction of sphincterotomy in 1958 as a treatment of obstruction at the 
level of the external urethral sphincter in people suffering from neurogenic bladder,82 
improvements in surgical care and the development of new surgical options have 
been developed. However, consensus on what defines optimal surgical management 
seems to be lacking. This was the background of the current systematic review.
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Only a limited number of small randomised controlled trials (RCTs) comparing a 
surgical approach with any other intervention in the treatment of functional bladder 
outlet obstruction (BOO) in adults with neurogenic bladder dysfunction was available. 
Also, the most recent included trial was performed no less than six years ago.67
Primary outcomes: urodynamic measurements
In the only trial comparing sphincterotomy with urethral stent placement,66 the 
maximum detrusor pressure was lower (mean difference (MD) of -30.00 cmH2O, 
95% confidence interval (CI) 8.99 to 51.01, Analysis 1.3.4) in the sphincterotomy group 
compared to the stent group, but only at two years.
Interestingly, this was due to an increase of maximum detrusor pressure in the stent 
group, rather than because of a decrease in the sphincterotomy group. Results for 
maximum detrusor pressure were inconclusive at three, six, and 12 months. Results for 
postvoid residual urine volume and cystometric bladder capacity were inconclusive 
and consistent with benefit of either sphincteric stent prosthesis or sphincterotomy at 
three, six, 12, and 24 months.
Four of five included trials assessed intraurethral botulinum A toxin (BTX-A) injections 
as a surgical option. Unfortunately, we could not combine these in a meta-analysis as 
the comparator treatment differed in these trials. Comparing a single intraurethral 100 
U BTX-A injection (Botox®, Allergan Inc.) with a placebo injection, while administering 
concomitant alfuzosin in multiple sclerosis (MS) patients,70 voiding volume was higher 
after BTX-A (MD of 69.00 mL, 95% CI 11.87 to 126.13, Analysis 2.2). Also, both pre-
micturition and maximal detrusor pressure were lower after BTX-A. A mean difference 
of -10.00 cmH2O, 95% CI -17.62 to -2.38 and -14.00 cmH2O, 95% CI -25.32 to -2.68, 
respectively, was found after 30 days (Analysis 2.3). However, postvoid residual urine 
volume as measured by catheterisation, basal detrusor pressure, maximal bladder 
capacity, maximal urinary flow, bladder compliance at functional bladder capacity, 
maximal urethral pressure, and closure urethral pressure at 30 days were inconclusive 
and consistent with benefit of either BTX-A or placebo injections. Cui et al.67compared 
200 U intraurethral BTX-A injection (Lanzhou Biotechnology, China) with or without 
concomitant oral baclofen in spinal cord injury patients. Bladder compliance was bet-
ter in patients who received BTX-A injections without oral baclofen, compared to the 
patients who received BTX-A injections with oral baclofen. Compared to the BTX-A 
group without baclofen, the BTX-A group with baclofen had a MD of -7.50 mL/cmH2O, 
95% CI -10.74 to -4.26 after one month (Analysis 3.4). Results for maximum uroflow 
rate, maximal cystometric capacity, and volume per voiding were all inconclusive and 
consistent with benefit of either BTX-A injection or BTX-A injection with the addition 
of oral baclofen. We believe that the relevance of bladder compliance as an outcome 
measure in this setting should be questioned. First, the authors did not report at which 
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bladder volume the compliance was calculated. Second, the trial authors did not pro-
vide data for comparison of detrusor pressure, which is a more important parameter 
for the effectiveness of treatment. Third, the trial authors did not provide a theoretical 
explanation of why particularly the addition of oral baclofen - which is supposed to act 
as an antispasticity agent - is not favoured in this trial.
The trial of de Sèze et al68 compared a single 100 U intraurethral BTX-A injection (Bo-
tox®, Allergan Inc.) with a single intraurethral lidocaine injection in participants with 
DSD of mixed aetiology (i.e. traumatic spinal cord injury, MS, or congenital malforma-
tion). Botulinum A toxin injections resulted in lower postvoid residual urine volumes 
with MDs of -163.00 mL, 95% CI -308.65 to -17.35 and -158.30 mL, 95% CI -277.57 to 
-39.03 after seven and 30 days, respectively (Analysis 4.1), though not yet after one 
day. Results at one month for maximal detrusor pressure on voiding, EUS activity in 
electromyography, and maximal urethral pressure were inconclusive and consistent 
with benefit of either BTX-A or lidocaine injections. In addition, participants were 
significantly more satisfied 30 days after BTX-A injections (Analysis 4.5).
Finally, Dykstra & Sidi69 performed a trial involving five men with spinal cord injury. 
These men were injected with either BTX-A (initial dose of 140 U onabotulinumtoxinA 
with subsequent injections of 240 U) or placebo (saline) once a week for three weeks 
at three or four sites in the external urethral sphincter. The placebo had no significant 
effect on DSD in the two participants allocated to the placebo treatment. Their urody-
namic parameters were unchanged from baseline values until subsequent injections 
with BTX-A once a week for three weeks. These subsequent injections resulted in 
similar responses to those of the three participants who were allocated to the BTX-A 
treatment.
However, it is unclear how relevant changes in urodynamic parameters, such as 
postvoid residual urine volumes, are to participants’ satisfaction with treatment and 
particularly whether beneficial urodynamic changes translate into reduced effect on 
damage to the kidneys, as none of the trials reported this crucial outcome.
Primary outcomes: renal function and urologic complications related to DSD
The remaining two primary outcome measures, renal function and urologic complica-
tions related to DSD, were only reported in the trial that compared sphincterotomy 
with stent placement. Results for renal function vesico-ureteric reflux and hydrone-
phrosis, Analysis 1.4; Analysis 1.5) at 12 and 24 months, and urologic complications 
related to DSD (e.g. urinary tract infection, Analysis 1.6; Analysis 1.7) at three, six, 12, 
and 24 months were inconclusive and consistent with benefit of either sphincteric 
stent prosthesis or sphincterotomy.
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Participant-reported outcomes and quality of life
Despite the major impact of neurogenic bladder dysfunction on quality of life (QoL), 
only two trials67,70 used questionnaires as a patient-reported outcome measure. Both 
used the International Prostate Symptom Score (IPSS), which is a seven-item symptom 
score originally developed for men with benign prostatic hyperplasia,83 the addition of 
a QoL question. Where Gallien et al.70 used this prostate symptom score in both male 
and female patients, Cui et al.67 used the Urogenital Distress Inventory (UDI)84 in female 
participants, which lacks a specific QoL question. Since both trials did not report the 
data of the QoL question of the IPSS separately, we were not able to draw any conclu-
sions regarding the improvement of QoL after intervention. Chancellor et al.66 reported 
surveying participants regarding the QoL with respect to the urogenital condition, but 
the lack of data and information regarding if and which questionnaires were used does 
not provide us with any meaningful data. In the trial of de Sèze,68 a treatment satisfac-
tion score was determined using a single question. However, this single question (“Do 
you find this treatment to be efficacious?”) may not be specific enough and can be 
interpreted as an improvement in symptoms as well as an improvement in QoL.
Duration of effect
The findings of the aforementioned trials evaluating BTX-A injections suggest that BTX-
A may be useful in the treatment of DSD in adults with neurogenic bladder dysfunction. 
The duration of effectiveness of BTX-A injections is however limited. Dykstra & Sidi69 
reported an effect of BTX-A of an average of 60 days after the third (last) injection, and 
de Sèze et al.68 reported BTX-A was efficacious for at least three months in the majority 
of participants (69%).
Adverse effects
See Table 7.2 on adverse effects.
Twenty-three per cent of participants needed more than one stent insertion proce-
dure, and 19% of participants required a stent explantation. This was in contrast to the 
adverse effects of sphincterotomy, where a repeat sphincterotomy after six months 
was required in only 8% of participants. Treatment for bladder neck obstruction was 
necessary in one out of five of all participants.
Concerning the adverse events in the BTX-A trials, haematuria was reported in two 
trials,67,69 but this was due to the cystoscopic injection and not necessarily due to the 
injected agent. More important are the effects of BTX-A on muscle weakness. This 
seem related to the dose of BTX-A used.
Two trials using more than 100 U BTX-A reported muscle weakness;67,69 this was in 
contrast to the two trials using 100 U (single dose) BTX-A, in which no muscle weakness 
was observed68 or reported.70 However, the last two trials reported both incontinence 
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for faeces68 and urine.68,70  The serious adverse events as reported by Gallien et al.70 
were not attributable to BTX-A.
quality of the evidence  
In general, the included trials were small, diversely designed, and reported outcomes 
were defined in different ways. Therefore, due to paucity of evidence, the results 
should be interpreted cautiously. The risk of selection bias and reporting bias (Figure 
7.3) is certainly present, mainly because of insufficient information to permit judge-
ment. Contacting trial authors resulted in additional information for one trial,69 though 
initially three of five trials did not provide enough information in their report.66,67,69 
These potential risks may be related to inadequate reporting common in older tri-
als,66,69 or to publication in a non-English language journal,67 rather than to method-
ological shortcomings.
Potential biases in the review process  
We applied no language or other restrictions in the search for trials. Despite the com-
prehensive search, we may still have missed unreported trials or trials only reported in 
conference abstracts, causing publication bias.
We added the following non-prespecified outcomes in the protocol to the review as 
secondary outcomes, since we judged these important during this review:
· The occurrence of autonomic dysreflexia symptoms and MS attacks as associated 
symptoms of neurogenic lower urinary tract dysfunction.
· The need for reinjection of intraurethral BTX-A.
· Participant-reported days of effect
This may have introduced unintentional outcome reporting bias in the review process 
with the possibility of biased and misleading interpretation of the results.85 However, 
we added these outcomes because of knowledge of studies that existed, not neces-
sarily because of knowledge of the results.
Agreements and disagreements with other studies or reviews  
We identified two systematic reviews that systematically reviewed surgical treatment 
options in the treatment of DSD.78,79
Mehta et al.78 conducted a systematic review and meta-analysis to assess the effect 
of intraurethral BTX-A injections on improving bladder emptying in patients with 
spinal cord injury. They pooled data from two RCTs68,69 and six uncontrolled trials, 
and concluded that BTX-A was effective in significantly reducing postvoid residual 
urine volume, detrusor pressure, and urethral pressure after one month. They made 
no statements about the clinical utility of BTX-A. Because this review included non-
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randomised controlled trials, the data used for meta-analysis were pre-intervention 
versus postintervention.
Naumann et al.79 conducted an evidence-based review of the safety and efficacy of 
BTX-A in the treatment of autonomic and urologic disorders and low back and head 
pain. The conclusions and recommendation of the safety and efficacy of BTX-A in the 
treatment of DSD were based on the quality of the trials.86 Gallien et al.70 received the 
highest classification based on the quality of the trial, and de Sèze et al.68 and Dykstra 
& Sidi69 received the second best classification. Based on these three trials, Naumann 
et al.79 recommended that BTX-A should be considered for DSD in people with spinal 
cord injury with a level B rating for recommendations.86 No effects of interventions 
were analysed.
Authors ConCLusions
implications for practice  
At present, there are insufficient data available to determine the optimal surgical treat-
ment of BOO in adults with neurogenic bladder dysfunction. Four out of five of the 
trials focused on BTX-A treatment. This review has found evidence of limited quality 
that BTX-A injection - either administered by itself or in combination with another 
treatment - confers benefit with regard to increasing voided urine volume, lowering 
detrusor pressure, and decreasing postvoid residual bladder urine volume. In addi-
tion, one small study found that it appears to lead to a higher satisfaction than lido-
caine injection. However, the necessity of regular reinjection of BTX-A is a significant 
drawback. A sphincterotomy might be a more effective treatment option for lowering 
bladder pressure in the long-term; however, results from one small study comparing 
sphincterotomy versus sphincteric stent prosthesis on urodynamic measures were 
inconclusive.
implications for research  
Unfortunately, this review failed to provide robust evidence in favour of any of the 
surgical treatment options, because of the limited availability of eligible trials, the vari-
ability in the interventions (e.g. dose and mode of injection of BTX-A) of the included 
trials, and particularly because of their small size (ranging from five to 86 participants). 
Also, the duration of follow-up of the included trials was limited, with an average of 
eight months.
Therefore, more and larger RCTs are needed to evaluate the most effective surgi-
cal intervention for functional BOO in adults with neurogenic bladder dysfunction. 
Furthermore, RCTs of specific surgical treatment options for DSD (i.e. urethral balloon 
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dilatation, intrathecal baclofen, pudendal nerve block, suprapubic catheterisation) 
are lacking. Randomised controlled trials assessing the effectiveness of BTX-A need 
to address the remaining uncertainty about the optimal dose and mode of injection, 
keeping in mind the possible dose-related adverse events.
Trials should use standardised terminology and outcomes in accordance with 
International Continence Society (ICS) standards2 and the Consolidated Standards of 
Reporting Trials (CONSORT) statement87 improve the quality of the reports and draw 
meaningful conclusions. In addition, further trials are advised to select outcomes that 
really matter to patients and practitioners, which is facilitated by the Core Outcome 
Measures in Effectiveness Trials (COMET) initiative.88 
The lack of trials assessing QoL from the patient’s point of view as an outcome is 
worrying, as the medical (technical) success does not necessarily correspond with the 
emotional judgement of success reported by the patient. Health-related QoL should 
receive much more attention in future trials. Furthermore, none of the included trials 
addressed socioeconomic outcomes. In future trials, the duration of effectiveness of 
BTX-A injections should be considered as a socioeconomic outcome.
This systematic review included only RCTs and quasi-RCTs. However, because of the 
limited availability of eligible trials, future reviews should consider including evidence 
from non-randomised trials for outcomes, although this will introduce bias.
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multidisciplinary guidelines in managing patients with neurogenic bladder 
dysfunction
Multidisciplinary evidence based clinical guidelines for management of patients with 
symptoms of neurogenic bladder in the Netherlands are provided. Information for 
Dutch clinical practitioners is provided about the incidence, definitions, diagnosis, 
therapy, and follow-up of neuro-urological disorders. 
These guidelines were made in collaboration with the Dutch associations of urolo-
gists (Nederlandse Vereniging voor Urologie), neurologists (Nederlandse Vereniging 
voor Neurologie),  rehabilitation physicians (Nederlandse Vereniging van Revalida-
tieartsen), Elderly Care Physicians and Social Geriatricians (Verenso), Continence 
Nurses and Carers (Continentie Verpleegkundigen & Verzorgenden), and patient 
support groups for people with paraplegia (Dwarslaesie Organisatie Nederland) and 
for people with congenital physical disabilities (BOSK). 
Neurogenic bladder dysfunction is a condition with many aspects. Comprehensive 
and specific diagnostics are needed to determine an individual treatment plan. Dur-
ing treatment the medical and physical condition of the patient needs to be taken 
into account. Furthermore, the patients’ expectations concerning social, physical and 
medical health occupy an important role. A considerable amount of different thera-
peutic options are available which needs to be personalized for each individual pa-
tient.  Equally important as treatment success is the requirement of lifelong guidance’s 
and follow-up. These Dutch guidelines serve to support both clinician and patient to 




Aanleiding voor het maken van de richtlijn
Elke schade aan de zenuwcontrole van de lage urinewegen kan leiden tot neurogeen 
blaaslijden. Een patiënt met neurogeen blaaslijden kan last hebben van onder andere 
urine incontinentie door onder- of overactieve blaas, infecties en steenvorming in 
de urinewegen en verslechtering van de nierfunctie. In de afgelopen vier decennia is 
de prognose bij patiënten met een neurogeen gestoorde blaas sterk verbeterd. Dit is 
deels het gevolg van maatregelen in de preventieve zorg zoals de introductie van inter-
mitterende katheterisatie en de controle en behandeling van de hoge drukblaas (LE: 3, 
Tabel 8.1).1,2  Het niet consequent toepassen van preventieve maatregelen kan leiden 
tot complicaties en verkort de levensverwachting. Het merendeel van de patiënten 
met neurogeen blaaslijden vereist dus levenslange zorg met als doel een optimale 
kwaliteit van leven en maximalisatie van de levensverwachting. De onduidelijkheid 
over de meest effectieve manier van diagnostiek en behandeling van neurogeen 
blaaslijden is echter blijven bestaan door het gebrek aan richtlijnen.
De “European Association of Urology (EAU) Guidelines Working Panel for NLUTD” heeft 
voor het eerst in de wereld richtlijnen betreffende neurogene blaas opgesteld en 
gepresenteerd tijdens het 23e jaarlijkse EAU congres in 2008.3 Deze richtlijnen bieden 
betrokken specialisten de gelegenheid hun behandeling van het neurogeen blaaslij-
den te toetsen aan die van experts. De EAU richtlijnen zijn weinig evidence based 
en alleen urologen zijn geconsulteerd bij de opstelling van het document. De hierbij 
gepresenteerde richtlijnen zijn deels gebaseerd op de EAU richtlijnen en opgesteld 
met de consensus van vier betrokken beroepsverenigingen. 
Tabel 8.1 Levels of Evidence
Level Type of evidence
1a Conclusie gebaseerd op meta-analyse of gerandomiseerde onderzoeken
1b Conclusie gebaseerd op minstens één gerandomiseerd onderzoek
2a Conclusie gebaseerd op één goed uitgevoerd gecontroleerd onderzoek zonder randomisatie
2b Conclusie gebaseerd op minimaal één ander soort goed uitgevoerd kwasi-experimenteel onderzoek
3 Conclusie gebaseerd op goed uitgevoerd niet-experimenteel onderzoek, zoals vergelijkende 
onderzoeken, correlatie onderzoeken en case reports
4 Conclusie gebaseerd op mening van deskundigen of klinische ervaringen  




Doelstelling van de richtlijn
Klinische richtlijnen zijn gedefinieerd als ‘systematisch ontwikkelde aanbevelingen 
bedoeld om hulpverleners en patiënten te helpen bij het nemen van beslissingen over 
de gewenste zorg bij concrete gezondheidsproblemen’. 4 
Deze richtlijn biedt ondersteuning bij het beantwoorden van de volgende vragen:
a) wat is neurogeen blaaslijden?
b) wanneer moet neurogeen blaaslijden worden vastgesteld?
c) met welke onderzoeken kan neurogeen blaaslijden worden aangetoond?
d) hoe moeten asymptomatische patiënten met neurogeen blaaslijden worden be-
handeld?
e) hoe moeten symptomatische patiënten met neurogeen blaaslijden worden be-
handeld?
f) is preventieve behandeling van neurogeen blaaslijden nodig?
g) wanneer is nader onderzoek naar neurogeen blaaslijden vereist?
h) wanneer moet naar tweede- en derdelijnszorg worden verwezen?
i) wat is het schema van lange termijn follow-up bij patiënten met hoog risico neuro-
geen blaaslijden?
j) welke adviezen aan verzorgers dienen te worden gegeven?
betrokken patiëntengroep
De richtlijn is relevant voor alle patiënten met bewezen of mogelijk neurogeen blaas-
lijden. Het betreft zowel klinische als ambulante patiënten. 
Voor wie is de richtlijn bedoeld?
Deze richtlijn is bedoeld voor:
· alle zorgverleners die betrokken zijn bij de zorg voor patiënten met een neurogene 
blaas, zoals huisartsen, verpleegkundigen, revalidatieartsen, neurologen, urologen 
en specialisten ouderengeneeskunde.
· patiënten met een neurogene blaas en hun familieleden en/of verzorgers
methode richtlijnontwikkeling
Deze richtlijn volgt de criteria zoals beschreven voor Evidence Based Medicine. Patiën-
ten met neurogeen blaaslijden krijgen weinig aandacht in medisch onderzoek. Het 
gevolg is dat literatuur met betrekking tot deze doelgroep schaars is en de beschikbare 
literatuur betreft zelden niveau 1 bewijs (gerandomiseerde trials). Desondanks heeft 
de werkgroep gemeend de bewijskracht indien mogelijk te scoren en te vermelden 
door gebruik te maken van “levels of evidence” (LE) en/of “grades of recommendati-
ons” (GR) gebaseerd op ‘expert opinion’ 5 (Tabel 8.2). 
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juridische betekenis van richtlijnen
Richtlijnen zijn geen juridische voorschriften, maar indien mogelijk op wetenschap-
pelijk bewijs gebaseerde inzichten om kwalitatief goede zorg te verlenen. Indien bear-
gumenteerd kan worden, kunnen zorgverleners op basis van hun autonomie afwijken 
van de richtlijn en toepassing hiervan is zijn of haar verantwoordelijkheid. De richtlijn 
is pas geldig indien geaccordeerd door de betrokken beroepsvereniging.
Wie hebben de richtlijn ontwikkeld?
De richtlijn is ontwikkeld door een multidisciplinair samengestelde werkgroep, waar-
bij het initiatief is genomen door de Nederlandse Vereniging voor Urologie. De Orde 
van Medisch Specialisten bood methodologische en financiële ondersteuning bij de 
richtlijnontwikkeling en bij het beoordelen en samenvatten van de wetenschappelijke 
evidentie.
Samenstelling van de werkgroep:
Dr. B. Blok, uroloog, voorzitter
Drs. M. de Beer, revalidatiearts
Dr. E. Birnie, epidemioloog
Dr. J. Heesakkers, uroloog
Prof. dr. R. Hintzen, neuroloog
Dr. L. de Kort, uroloog
Drs. H. van de Sande, specialist ouderengeneeskunde namens Verenso
Dr. J.R. Scheepe, kinderuroloog
Drs. T.A.M. Siepman, neuroloog
Mw. J. Bergman, Verpleegkundig Specialist Continentiezorg namens CV&V
Dhr. M. Klem, directeur BOSK
Mw. W. de Moes, namens Dwarslaesie Organisatie Nederland
Drs. E. Utomo, projectleider
Tabel 8.2 Gradering van aanbevelingen
Graad Aanbevelingen gebaseerd op
A Klinische onderzoeken van goede kwaliteit met specifieke aanbevelingen en minimaal één 
gerandomiseerd onderzoek
B Goed uitgevoerde klinische onderzoeken, maar zonder gerandomiseerde onderzoeken
C Geen gepaste klinische onderzoeken beschikbaar van goede kwaliteit 




sAmenVAttinG AAnbeVeLinGen en ConCLusies
Classificatie van neurogeen blaaslijden 
De functionele classificatie wordt aanbevolen. Deze classificatie is gebaseerd op 
symptomatologie tijdens de vullings- of mictiefase (GR: C).
Diagnostiek
Anamnese
· Een uitgebreide algemene anamnese moet worden verricht met de nadruk op hui-
dige klachten van urinewegen, darmstelsel, en seksuele en neurologische functies 
als klachten in het verleden (GR: C).
· Speciale aandacht moet worden besteed aan het bestaan  van alarmverschijnselen, 
zoals pijn, infectie, hematurie en koorts, toename van spasme en tekenen van 
autonome disregulatie, die verdere specifieke diagnostiek rechtvaardigen (GR: C).
· Het wordt geadviseerd om een mictiedagboek bij te houden omdat deze waarde-
volle informatie kan geven (GR: C).
Lichamelijk onderzoek
· De individuele beperkingen van de patiënt moeten worden meegewogen in de 
planning van nader onderzoek (GR: C).
· Alvorens diagnostische onderzoeken plaatsvinden, wordt geadviseerd de neuro-
logische status zo compleet mogelijk te omschrijven.  Alle sensaties en reflexen in 
het urogenitale gebied worden getest (GR: C). 
· Voor het vaststellen van de sensibiliteit bij dwarslaesie patiënten is de ASIA clas-
sificatie te prefereren.
D. Bij lichamelijk onderzoek moet extra aandacht worden gegeven aan aanwijzingen 
voor aangeboren afwijkingen die neurogene blaasklachten kunnen veroorzaken zoals 
spina bifida en scoliose (GR: C).
Aanvullend onderzoek
· Urinesediment, bloedonderzoek, residu na mictie en vrije uroflowmetrie en 
beeldvorming van de (hoge) urinewegen moeten aanvullend worden onderzocht.
Urodynamisch onderzoek
· Urodynamisch onderzoek is noodzakelijk om de eventuele disfunctie van de lage 
urinewegen vast te stellen (GR: B).
· Uroflowmetrie en meting van het residu na mictie moeten worden uitgevoerd 
voordat invasieve urodynamica worden verricht (GR: B).
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· Video-urodynamisch onderzoek is de gouden standaard van invasieve urodyna-
mica bij patiënten met neurogeen blaaslijden (GR: B).
· Specifieke uro-neurofysiologische onderzoeken worden alleen op indicatie ver-
richt (GR: B). 
behandeling
· Neurogeen blaaslijden wordt behandeld ter bescherming van de nierfunctie, 
verbetering van de urine incontinentie en optimalisatie van de kwaliteit van leven 
(LE: 3).
· Bij een te hoge detrusordruk moet deze worden verlaagd om schade aan de hoge 
urinewegen te voorkomen (GR: B).
Conservatieve behandeling
Geassisteerde blaasontlediging
· Elke methode van geassisteerd  legen van de blaas moet worden gebruikt met de 
grootste voorzichtigheid (GR: B).
· Gedragsmodificatie kan de continentie bevorderen (LE: 2b; GR: B).
Blaasrevalidatie
· Bekkenbodemfysiotherapie met biofeedback en blaasrevalidatie is mogelijk ef-
fectief gebleken in geselecteerde MS patiënten (LE 1b).
Elektrostimulatie
· Chronische nervus pudendus stimulatie geeft significante urodynamische verbete-
ringen (LE: 3). 
· Sacrale neuromodulatie is effectief gebleken bij dwarslaesiepatiënten, maar is wel 
afhankelijk van de onderliggende neurologische aandoening en of deze progres-
sief is (LE: 3). 
· Niet-chronische elektrische stimulatie kan gunstige effecten hebben op neurogene 
blaas (LE: 2b).
· Transcraniale magnetische stimulatie verbeterde mictiesymptomen bij MS en 
Parkinson patiënten (LE: 3).
Externe hulpmiddelen
· Een condoom katheter of incontinentiemateriaal kan de effecten van urine-






· De lange termijn werkzaamheid en veiligheid van anticholinerge therapie voor 
neurogene detrusor activiteit is goed gedocumenteerd (LE: 1a).
· Een combinatie van medicamenteuze therapieën kan worden overwogen om 
het behandelingsresultaat te maximaliseren, echter wees hierin terughoudend bij 
ouderen met comorbiditeit (LE: 2a; GR: B).
· Oxybutynine chloride en tolterodine tartraat zijn geaccepteerde en effectieve 
anticholinergica (LE: 1a).
Detrusor onderactiviteit
· Er bestaat geen bewijs voor de werking van medicijnen bij een onderactieve 
detrusor (LE: 2a).
Verlaging blaasuitgangsweerstand
· Alfa-blokkers zijn gedeeltelijk succesvol gebleken bij het verminderen van de 
urethrale weerstand (LE: 2a).
minimaal invasieve behandelingen
Katheterisatie
· Intermitterende katheterisatie (IC) is de standaard behandeling voor patiënten die 
niet in staat zijn om hun blaas spontaan en volledig te legen. Zij moeten echter 
lichamelijk en cognitief in staat zijn tot (zelf)katheterisatie (GR: A).
· Patiënten moeten goed worden geïnstrueerd in de techniek en de risico's van IC 
(GR: B).
· Aseptische IC is de methode van keuze (GR: B).
· De gewenste kathetergrootte is 12 tot 14 Charrière (GR: B).
· De gemiddelde frequentie van de IC is 4 tot 6 keer per dag (GR: B).
· Het gekatheriseerde blaasvolume moet lager blijven dan 400 ml (GR: B).
· Transurethrale en suprapubische verblijfskatheters dienen slechts in uitzonderlijke 
gevallen te worden gebruikt onder strikte controle. De katheter moet vaak worden 
vervangen.
· Siliconen katheters hebben de voorkeur en moet worden vervangen om de 6-12 
weken; (gecoate) latex katheters moeten worden vervangen om de 6 à 12 weken 
(GR: B).
Botulinetoxine A injecties in de blaas
· Botulinum toxine injecties in de detrusor is de meest effectieve minimaal invasieve 
behandeling om overactiviteit te verminderen bij neurogeen blaaslijden (GR: A), 
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voor onabotuline toxine A (Botox ®) worden 200 EH geadviseerd (GR: A) en voor 
abobotulinum toxine A (Dysport ®) 500 EH  (GR: A).
Intravesicale vanilloïden
· Intravesicale vanilloïden zorgen voor een tijdelijke afname van detrusor overactivi-
teit (LE: 1a).
Blaashals en urethrale behandelingen
· De blaasuitgangsweerstand kan worden verlaagd ter bescherming van de bovenste 
urinewegen door sfincterotomie of botulinum toxine A in de sfincter (GR: C). 
· Urethrale stents worden afgeraden vanwege de substantiële complicaties en 
risico’s op herhaaldelijke interventies (GR: B).
· Bij vesicoureterale reflux moet de intravesicale druk worden verlaagd (GR: B).
Chirurgische behandelingen
Overactieve detrusor
· Detrusormyectomie is een aanvaardbare optie voor de behandeling van een 
overactieve blaas wanneer een meer conservatieve aanpak heeft gefaald.  Het is 
beperkt invasief en heeft een minimale morbiditeit (GR: B); dit kan echter op de 
lange termijn leiden tot een verminderde blaascontractiliteit.
· Sacrale rhizotomie met sacrale anterior wortel stimulatie (SARS) in complete laesies 
en sacrale neuromodulatie in incomplete laesies zijn effectieve behandelingen in 
geselecteerde patiënten (GR: B).
· Blaasaugmentatie is een aanvaardbare optie voor het verminderen van detrusor-
druk wanneer minder invasieve ingrepen hebben gefaald.  Voor de behandeling 
van een ernstig verdikte of fibrotische blaaswand kan blaassubstitutie worden 
overwogen (GR: B).
Onderactieve blaas
· Sacrale neuromodulatie (bij incomplete laesies) kan bij geselecteerde patiënten 
een effectieve behandeling zijn (GR: B).
Urethrale sfincter insufficiëntie
· De artificiële urinaire sfincter (AUS) verdient de voorkeur bij patiënten met neuro-
geen blaaslijden  (GR: B). 
· De plaatsing van een urethrale sling is een geaccepteerde procedure bij onderac-





· Continente of incontinente stoma’s kunnen worden overwogen bij therapieresis-
tente patiënten.
· In geselecteerde patiënten (bijv. rolstoel gebonden patiënten) kan een katheteri-
seerbaar stoma waardevol zijn.
urineweginfecties bij neurogeen blaaslijden
De meeste kennis betreffende urineweginfecties (UWI) bij neurogene blaas is verkre-
gen uit studies bij patiënten met een dwarslaesie en niet direct toepasbaar op andere 
populaties, zoals MS, CVA of morbus Parkinson.
· Recidiverende UWI’s kunnen een teken zijn van een slechte techniek van zelfka-
theterisatie of een suboptimale behandeling van een onderliggend probleem, 
bijvoorbeeld een hoge drukblaas, residu na mictie of urinewegstenen. Het beves-
tigen of uitsluiten van deze oorzaken is noodzakelijk.
· Een asymptomatische bacteriurie moet niet worden behandeld bij patiënten met 
een dwarslaesie; ook niet bij intermitterende katheterisatie (GR: B).
· Gebruik van antibiotica bij recidiverende urineweginfecties kan leiden tot bacteri-
ele resistentie; gericht antibiotica gebruik wordt daarom geadviseerd (GR: C).
seksuele functie en vruchtbaarheid bij dwarslaesie
Erectiele disfunctie (ED)
· Orale PDE5Is zijn de eerstelijns behandeling voor ED bij mannen met een dwars-
laesie (GR: A). 
· Mechanische hulpmiddelen zoals een vacuümpompen en ringen kunnen effectief 
zijn maar zijn niet praktisch in het gebruik (GR: C).
· Intracaverneuze injecties met vasoactieve medicijnen (alleen of in combinatie) zijn 
de tweedelijns behandeling als orale medicatie niet heeft gewerkt (GR: A).
· Chirurgische peniele protheses kunnen worden gegeven aan geselecteerde pati-
enten die niet reageren op conservatieve behandelingen (GR: B).
Mannelijke vruchtbaarheid
· Spermawinning kan door middel van prostaatmassage, vibrostimulatie, transrec-
tale electro-ejaculatie of PESA (GR: B).
· Medisch geassisteerde voortplanting (IUI, IVF, ICSI) zijn geaccepteerde behande-
lingen bij dwarslaesiepatiënten (GR: B).
Vrouwelijke seksualiteit
· PDE5I’s kunnen gedeeltelijk de subjectieve seksuele problemen bij vrouwen met 
een dwarslaesie oplossen (GR: C).
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· Reflex lubricatie en orgasme kunnen worden opgewekt bij vrouwen met een 
dwarslaesie boven het sacrale ruggenmerg (GR: B).
· Orgasme en opwinding kunnen worden opgewekt bij vrouwen met schade aan 
de sacrale reflexboog door stimulatie van erogene zones boven het niveau van de 
laesie (GR: B).
Vrouwelijke vruchtbaarheid
· Het reproductieve vermogen van vrouwen wordt slechts tijdelijk beïnvloed door 
de dwarslaesie (GR: B).
· De zwangerschap heeft een normaal verloop maar er bestaat meer kans op compli-
caties zoals blaasproblemen, spasticiteit, doorligplekken door gewichtstoename 
en autonome dysreflexie tijdens zwangerschap en bevalling (GR: B).
kwaliteit van leven
· Een van de hoofddoelen is het verbeteren van de kwaliteit van leven (LE: A).
· Beschikbare instrumenten zijn: Qualiveen, een specifiek instrument voor dwars-
laesie en multiple sclerose patiënten, Visuele Analoge Schaal (VAS) voor de hinder. 
De Qualiveen is echter nog niet vertaald en gevalideerd in het Nederlands. Gene-
rieke (SF-36) of specifieke vragenlijsten voor incontinentie (UDI-6, IIQ-7, I-QOL) 
kunnen ook gebruikt worden (GR: B).
Follow-up
· Afhankelijk van de neurologische pathologie en de huidige toestand van het neu-
rogeen blaaslijden kan het controle interval variëren, maar bij patiënten met hoge 
blaasdrukken wordt geadviseerd eens in de 1 tot 2 jaar te controleren.




Het legen van de blaas door een katheter die na de procedure wordt verwijderd. De 
procedure gebeurt meestal met gelijkmatige intervallen, bijvoorbeeld vier maal per 
dag.
Aseptische iC
De katheters blijven tijdens de katheterisatie steriel, de genitaliën worden gedesin-





Voor de katheterisatie worden wegwerpkatheters gebruikt en de genitaliën worden 
tevoren gereinigd.
intermitterende zelf-katheterisatie
Intermitterende katheterisatie door de patiënt zelf.
Lower motor neuron laesie
Laesie ter hoogte van de segmenten S1-S2 of lager in het ruggenmerg, waarbij de 
motoneuronen van blaas en sfincter uitgevallen zijn.
upper motor neuron laesie
Laesie boven de segmenten S1-S2 in het ruggenmerg.
mictie, gebalanceerd
Bij patiënten met neurogeen blaaslijden (post-mictie residu <80 ml of <20% van het 
totale blaasvolume). Mictie met fysiologische detrusordruk en laag residu na mictie. 
De hoogte is afhankelijk van de urethrale weerstand en blaascontractiekracht.
mictie, getriggerd
Mictie, op gang wordt gebracht door te kloppen. Er ontstaat reflexmatig een blaascon-
tractie door stimulatie van drukreceptoren.
Detrusor lekdruk
De laagste waarde van de detrusordruk waarbij urine lekkage wordt gezien zonder een 




Patiënten met schade aan het zenuwstelsel hebben vaak last van een neurogene blaas. 
Er zijn ongeveer een half miljoen mensen met een neurogene blaas in Nederland. De 
bekendste oorzaken van neurogene blaas zijn dwarslaesie, multiple sclerose (MS), 
beroerte (CVA) en cauda equina syndroom (CES). Echter, ook minder voor de hand 
liggende aandoeningen die zenuwweefsel aantasten kunnen leiden tot een neuro-
gene blaas, zoals diabetes mellitus. Neurogeen blaaslijden komt ook vaak voor in 
verpleeghuizen, voorbeelden zijn eindstadia van MS en morbus Parkinson. Ook bij 
CVA-patiënten en dementerenden komt veelvuldig neurogeen blaaslijden voor.6
Neurogeen blaaslijden kan leiden tot verschillende soorten complicaties. Urine-
incontinentie treedt op door detrusoroveractiviteit (=overactieve blaas), overloop door 
acontractiele blaas (=verlamde blaas) en/of sfincterinsufficiëntie (sluitspier-insufficiën-
tie). Stoornissen in de blaaslediging kunnen leiden tot residu en retentie met als gevolg 
urineweginfecties met steenvorming. Een ernstige complicatie is nierschade door een 
hoge druk in de blaas in combinatie met of door opstijgende infecties. Verder kunnen 
verlies van kwaliteit van leven (KvL), hogere gezondheidszorgkosten ten gevolge van 
frequente ziekenhuisopnamen, minder arbeidsparticipatie en sociale isolatie optreden 
als gevolg van neurogene blaasfunctiestoornissen. Het merendeel van de patiënten 
met neurogeen blaaslijden vereist levenslange zorg om de kwaliteit van leven te be-
houden en de levensverwachting te maximaliseren. Patiënten na een CVA of patiënten 
met dementie kunnen (weer) onzindelijk worden. Zij hebben het besef van toiletgang 
niet meer (decorumverlies), maar dit hoeft niet altijd gepaard te gaan met over- of 
onderactiviteit van de blaas. Dit is dus een speciaal soort categorie patiënten. 
In de afgelopen jaren zijn er monodisciplinaire richtlijnen ontwikkeld voor de 
diagnostiek en behandeling van de neurogene blaas door de Europese Associatie 
voor de Urologie.7 Gezien de grote verschillen tussen de diverse Europese landen, de 
inrichting van het zorgstelsel, de beschikbaarheid van apparatuur en de financiering, 
kan deze richtlijn niet automatisch gebruikt worden voor de Nederlandse situatie. In 
Nederland zijn er helaas nog geen relevante mono- of multidisciplinaire richtlijnen 
beschikbaar. Dit initiatief tracht multidisciplinaire richtlijnen te ontwikkelen door 
middel van samenwerking van vier beroepsverenigingen, te weten de Nederlandse 
Vereniging voor Urologie (NVU), Nederlandse Vereniging voor Neurologie (NVVN), 
Vereniging voor Revalidatie Artsen (VRA) en Vereniging voor Specialisten Ouderenge-
neeskunde (Verenso). 
De noodzaak van een landelijke multidisciplinaire richtlijn werd bevestigd door 
een enquête onder Nederlandse urologen die werd gehouden bij de aanvang van 
het opstellen van deze richtlijn.8 Daaruit bleek dat er een zeer grote verscheidenheid 





Classificatie van neurogeen blaaslijden 
draagt bij tot beter begrip en behandeling 
van neurogeen blaaslijden. Diverse clas-
sificatiesystemen zijn voorgesteld voor de 
indeling van neurogeen blaaslijden.9-12  Een 
eenvoudig classificatie systeem is weerge-
geven in tabel 8.3 (LE: 4).13 Het is gebaseerd 
op symptomatologie tijdens de vullingsfase 
of tijdens de mictiefase.
Tijdens de vullingsfase kunnen deze symptomen veroorzaakt worden door disfunc-
tie van de blaas, de blaasuitgang of beide. De blaas kan bijvoorbeeld onwillekeurige 
contracties vertonen of een veranderde sensatie hebben. Een afwijking van de blaas-
uitgang kan zich presenteren als een intermitterend verlaagde uitgangsweerstand.
Het onvermogen om de blaas te legen tijdens de mictiefase kan eveneens komen 
door disfunctie van de blaas, de blaasuitgang of beide. De blaas kan bijvoorbeeld niet 
of onvoldoende contraheren; de blaasuitgang kan een anatomische obstructie heb-
ben of vertoont detrusor-sfincter dyssynergie (DSD). Bij DSD is de coördinatie tussen 
detrusor en sfincter verloren en dit kan resulteren in een onwillekeurig, onvolledig 
en regelmatig onderbroken mictie of zelfs in urine retentie. Aandoeningen, waarbij 
zowel de opslag als het legen van de blaas is aangedaan, kunnen ook eenvoudig met 
de voorgestelde classificatie worden ingedeeld. 
De functionele classificatie kan worden uitgebreid naar bijvoorbeeld een (video)
urodynamische classificatie onderverdeeld in blaas of blaasuitgangsactiviteit tijdens 
de vullings- of de mictiefase. Eveneens kunnen behandelingen op deze manier wor-
den ingedeeld. Een bepaalde therapie kan de vullings- of de mictiefase bevorderen. 
Het is een eenvoudige en informatieve indeling die naar eigen inzicht kan worden 
uitgebreid.
Gecombineerde problemen kunnen ook goed met de functionele classificatie wor-
den ingedeeld. Voorbeelden van gecombineerde problemen zijn: 
· verminderde blaascontractiliteit of blaasoveractiviteit gecombineerd met sfincter 
disfunctie
· blaasuitgangsobstructie gecombineerd met blaasoveractiviteit
· blaasuitgangsobstructie met een niet werkende sfincter
· blaasoveractiviteit met een verminderde blaascontractiliteit
Tabel 8.3 De functionele classificatie
Onvermogen tot opslag, veroorzaakt door:
• Blaas 
• Blaasuitgang 
• Combinatie van blaas en blaasuitgang  
Onvermvogen tot ledigen, veroorzaakt door:
• Blaas 
• Blaasuitgang 
• Combinatie van blaas en blaasuitgang  




Het tijdig stellen van een diagnose en classificeren van de blaasfunctie is van belang bij 
zowel het congenitale als het verworven neurogeen blaaslijden. Er kunnen namelijk 
onherstelbare veranderingen in de lage urinewegen optreden en het is belangrijk om 
de patiënt goed te evalueren en zo nodig te behandelen.14 Schade kan al zijn opge-
treden als neurologisch gerelateerde symptomen slechts in geringe mate aanwezig 
zijn (LE: 3).9,15  Tevens kan neurogeen blaaslijden het eerste symptoom zijn van een 
onderliggende neurologische aandoening (LE: 3).16,17
Diagnostiek naar neurogeen blaaslijden moet bestaan uit zowel neurologische als 
niet-neurologische onderzoeken (GR: C). Verder moet er navraag gedaan worden 
naar de voorgeschiedenis van de patiënt en lichamelijk onderzoek en urineonderzoek 
worden verricht (GR: C).
Anamnese
Een uitgebreide algemene en speciële anamnese is essentieel voor een goede evaluatie 
(Tabel 8.4). Navraag moet worden gedaan naar zowel huidige als vroegere symptomen en 
ziekten (LE: 4).18 Speciaal moet worden gevraagd naar het functioneren van het urogenitaal 
stelsel, defecatiepatroon, seksuele en neurologische functies. Aandacht moet worden 
gegeven aan mogelijke alarmsymptomen (zoals pijnklachten, infecties, hematurie, koorts, 
toename van spasme en tekenen van autonome disregulatie) die verder onderzoek vereisen. 
In de anamnese wordt gevraagd naar (GR: C):
· verworven of aangeboren neurologische afwijkingen
· neurologische symptomen (somatisch en sensorisch), inclusief luxerend moment, 
verloop en eventuele behandeling
· spasticiteit (alle suprasacrale laesies)
· autonome dysreflexie (laesie boven T6)





Een 24-uurs dagboek is een betrouwbaar en consistent diagnosticum bij vrouwen met 
urine incontinentie (LE: 3),20,21 dit is echter niet onderzocht bij patiënten met een neu-
rogene blaas. Desondanks wordt geadviseerd een mictiedagboek 2 tot 3 dagen bij te 
houden (GR: C). Indien een mictiedagboek nauwkeurig wordt bijgehouden, kan deze 
waardevolle informatie geven over de klachten die dagelijks worden ondervonden. Het 




Tabel 8.4 Anamnese bij neurogeen blaaslijden*
Voorgeschiedenis
• Kinderleeftijd – adolescentie – volwassen
• Erfelijke of familiaire risicofactoren
• Menarche (leeftijd); kan passen bij metabole afwijking
• Obstetrische voorgeschiedenis
• Geschiedenis van diabetes; soms kan correctie het neurologische probleem oplossen
• Specifieke ziekten, bijv. syfilis, Parkinson, multiple sclerose, encephalitis
• Traumata en operaties, vooral aan de wervelkolom en het centrale zenuwstelsel
Heden
• Medicatie
• Leefstijl (roken, alcohol en drugs); mogelijke invloed op urineren en defecatie
• Kwaliteit van leven
• Levensverwachting
Specifieke urologische voorgeschiedenis
• Begin van urologische klachten
• Verlichting na de mictie/gevoel van residu; mate van neurologische laesie bij het ontbreken van 
obstructieve uropathie
• Blaassensatie
• Start van de mictie (normaal, reflex, persen, Credé, katheteriseren)
• Onderbreking van de mictie (normaal, paradoxaal, passief)
• Enuresis
• Manier van mictie (zittend, staand, katheterisatie)
• Urineweginfecties
• Mictiedagboek; (semi)objectieve informatie over het aantal keren mictie, dag en nacht frequentie, 
geplaste volumina, incontinentie, urge episoden
Defecatie-anamnese
• Frequentie en fecale incontinentie/soiling
• Aandrang tot defecatie
• Defecatie patroon
• Rectale sensatie
• Start van defecatie (manuele rectale stimulatie of (micro)klysma)
Seksuele anamnese
• Genitale seksuele disfunctie symptomen
• Sensatie in genitaal gebied
• Specifiek man: erectie, (ontbreken van) orgasme, ejaculatie
• Specifiek vrouw: dyspareunie, (ontbreken van) orgasme, lubricatie
Neurologische anamnese
• Verkregen of congenitale neurologische aandoening
• Mentale status en begrip (ook via hetero-anamnese)
Neurologische symptomen (somatisch en sensorisch), met begin, beloop en eventueel behandeling
• Spasticiteit (alle suprasacrale laesies)
• Autonome dysreflexie (laesie boven niveau Th6)
• Mobiliteit en handfunctie
* Bors en Turner18 (LE: 4; GR: C) en  Stöhrer et al.19 (LE: 4; GR: C).
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De darmfunctie is vaak bij neurogene patiënten gestoord. Dit resulteert meestal in 
constipatie en in mindere mate in fecale incontinentie. Verder geeft persen bij gecon-
stipeerde patiënten overmatige belasting op de bekkenbodem, wat een verhoogde 
kans geeft op verzakkingsklachten en urine incontinentie.22 Darmontlediging moet 
daarom worden bevorderd, bijvoorbeeld door middel van laxantia, klysmata of darm-
spoelingen.22 Een landelijke richtlijn over obstipatie is beschikbaar en onderdeel van 
de richtlijnen palliatieve zorg van het Integraal Kankercentrum Midden-Nederland.23 
Lichamelijk onderzoek
Om het (lichamelijk) onderzoek zo goed mogelijk te laten verlopen, is het belangrijk 
om  aandacht te besteden aan mogelijke lichamelijke en geestelijke beperkingen. 
Dit kan worden gedaan door de neurologische status zo uitvoerig mogelijk in kaart 
te brengen (Tabel 8.5) (GR: C). De sensibiliteit en reflexen van het hele urogenitale 
gebied worden uitgebreid onderzocht evenals de anale sfincter en bij vrouwen de 
bekkenbodemspieren (Figuur 8.1).24,25 Bij patiënten met een dwarslaesie is voor het 
vaststellen van de sensibiliteit in de betreffende dermatomen zoals weergegeven in 
figuur 8.1 de ASIA classificatie26 te prefereren. Hierbij wordt in elk relevant dermatoom 
op een vast punt de tastzin en de pijnzin volgens vaste criteria gescoord. Bij een veran-
derd neurologisch beeld is het vervolgonderzoek dan betrouwbaarder. 
Uitgebreid lichamelijk onderzoek is van belang voor een betrouwbare interpretatie 
van de komende diagnostische onderzoeken. Voor het behandelplan is het belangrijk 
de mobiliteit en handfunctie van de patiënt goed te documenteren (GR: C). Verder 
moet gezocht worden naar aanwijzingen van aangeboren afwijkingen zoals voetafwij-
kingen, spina bifida occulta en scoliose (GR: C).
Tabel 8.5 Specifieke uro-neurologische onderzoeken*
• Sensaties S2-S5 (beide kanten)




- Knie en enkel reflexen
- Plantair respons (Babinski) 
• Anale sfincter tonus
- Aanwezigheid (verhoogd/normaal/verminderd/afwezig)
- Vrijwillige contracties van anale sfincter en heupmusculatuur  (verhoogd/normaal/verminderd/
afwezig)
• Specifiek mannen: prostaat palpatie
• Specifiek vrouwen: descensus (prolaps) van bekkenorganen




Autonome dysreflexie (AD) betreft een plotseling versterkte autonome reactie op 
potentieel pijnlijke stimuli onder het laesie niveau bij patiënten met een dwarslaesie 
of disfunctie van het myelum boven het niveau Th-6. Hypertensie komt hierbij vaak 
voor en kan levensbedreigend zijn indien onvoldoende behandeld 27-29 (LE: 3).
Aanvullend onderzoek
Aanvullend onderzoek moet worden uitgevoerd. Essentiële onderzoeken zijn:19
· Urinesediment
· Bloedonderzoek (o.a. kreatinine)
· Mictiedagboek
· Meting van urine residu na mictie, indien mogelijk ook vrije uroflowmetrie (zie: 
‘Urodynamische testen’)
· Indien van toepassing: kwantificatie van urineverlies door middel van padtest
· Beeldvorming hoge urinewegen (met name echografie)
urodynamisch onderzoek
Het urodynamische onderzoek (UDO) is de enige methode die objectief de (dis)func-
tie van de lage urinewegen kan weergeven. Het is essentieel om de status van de lage 
urinewegen te beschrijven bij patiënten met een neurogene blaas. Het onderzoek 
kan worden gebruikt in combinatie met aanvullende diagnostische toetsen om het 
type neurogeen blaaslijden te beschrijven (Tabel 8.6). Een kanttekening moet wor-
den gemaakt bij kwetsbare ouderen met neurogeen blaaslijden (bijvoorbeeld diep 
dementen) en patiënten met een slechte prognose. Een UDO voor deze doelgroep 



















Figuur 8.1 (a) dermatomen van de spinale zenuwen L2-S4; (b) urogenitale en andere reflexen van de 
caudale spinale zenuwen. Uit: Stöhrer et al.7
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De International Continence Society (ICS) heeft technische richtlijnen van het UDO 
beschreven en aanbevelingen gedaan voor het rapporteren van UDO resultaten  (LE: 4).19
Urodynamische testen
Vrije flowmetrie en bepaling van residu na mictie geven een eerste indruk van de mic-
tie (LE: 3).30,31 Als de conditie van de patiënt deze niet-invasieve onderzoeken toelaat 
moet dit gebeuren voordat het invasieve UDO wordt verricht.19
Vullingscystometrie betreft het eerste deel van het UDO en kwantificeert de cys-
tometrische capaciteit van de blaas; ook wel de blaascapaciteit. Vullingscystometrie 
als alleenstaand onderzoek heeft slechts een beperkte waarde (LE: 3).30 Tijdens dit 
onderzoek kunnen afwijkingen worden gezien zoals detrusoroveractiviteit, lage blaas-
compliantie (stugge blaas, waarbij toename van de blaasvulling resulteert in abnor-
male stijging van de blaasdruk), DSD, een incompetente urethrale sfincter, abnormale 
blaassensaties en andere sensaties (zoals autonome dysreflexie) en incontinentie (LE: 
3).30,32  
De detrusor leak point pressure (DLPP) of detrusor lekdruk is de laagste waarde 
van de detrusordruk waarbij urineverlies optreedt tijdens vullingsfase zonder dat er 
abdominale druk is of een detrusor contractie. Met de DLPP kan een schatting worden 
gemaakt van het risico voor de hoge urinewegen.33,34 Het is meer een screenende test 
vanwege de beperkte diagnostische waarde.19,35 Er zijn aanwijzingen dat een hoge 
DLPP (40 cm H2O of hoger) verder onderzoek vereist middels video urodynamisch 
onderzoek (VUDO) vanwege het risico op beschadiging van de hoge urinewegen (LE: 
3).33
De Valsalva leak point pressure (VLPP) of valsalva lekdruk is de laagste detrusordruk 
waarbij urineverlies optreedt zonder dat er een detrusorcontractie optreedt. De druk 
Tabel 8.6 Karakteristieke bevindingen bij neurogeen blaaslijden*
Vullingscystometrie
- toegenomen, afgenomen, of afwezig aandranggevoel
- vegetatieve niet-specifieke sensaties
- lage blaascompliantie
- (kleine of grote) blaascapaciteit
- detrusor overactiviteit; spontaan of opwekbaar
- incompetent urethraal sluitingsmechanisme (incontinentie)
Druk-flowcurve**
- verminderde detrusoractiviteit (hypocontractiele blaas) of acontractiele blaas
- blaasuitgangsobstructie
- detrusor/sfincter dyssynergie
* Gemodificeerd van Abrams et al 40.





die wordt opzettelijk veroorzaakt door te hoesten of de Valsalva manoeuvre. Het geeft 
een indruk van de ernst en soort stress urine incontinentie.19
Druk-flowcurven betreffen het tweede deel van het UDO en geven een indruk van 
de functie van de blaas en onderste urinewegen. Afwijkende bevindingen die tijdens 
dit onderzoek kunnen worden gezien zijn: detrusor onderactiviteit of acontractiliteit, 
DSD, obstructie door niet-relaxerende sfincter, te groot residu na mictie.
Video urodynamisch onderzoek (VUDO) combineert vulllingscystometrie en druk-
flowcurven met radiologische beeldvorming. Dezelfde afwijkingen kunnen worden 
gezien zoals eerder beschreven bij de vullingscystometie en druk-flowcurven, maar 
daarnaast geeft het extra informatie over de morfologie van de blaas en onderste urine-
wegen. In het bijzonder vesico-ureterale reflux (VUR) kan goed worden aangetoond. 
VUDO is momenteel het onderzoek dat de meest uitgebreide informatie geeft wat ge-
bruikt kan worden voor de evaluatie van neurogeen blaaslijden (LE: 3).19,36,37 VUDO is 
met name geïndiceerd bij verdenking van een hoge drukblaas, VUR, DSD, congenitale 
of verworven anatomische afwijkingen. In andere gevallen volstaat meestal een UDO. 
Elektromyografie (EMG) is een semi kwantitatieve meting van de bekkenbodemac-
tiviteit en kan worden gebruikt om DSD en verhoogde bekkenbodemcontracties 
te diagnosticeren. Gecombineerd met een VUDO kan meer accuraat DSD worden 
opgespoord (LE: 3).38
Ambulant urodynamisch onderzoek maakt het mogelijk de werking van de blaas te 
bestuderen tijdens normale blaasvulling. Het onderzoek vindt plaats in de eigen - en 
daarmee weinig stressvolle - omgeving tijdens normale dagelijkse bezigheden. Echter, 
onderzoek heeft aangetoond dat ambulant urodynamisch onderzoek niet nood-
zakelijk is bij dwarslaesie patiënten als standaard UDO adequaat wordt uitgevoerd. 
Ambulante urodynamica kunnen wel geïndiceerd zijn bij patiënten waarbij standaard 
urodynamica niet conclusief blijken te zijn.39
specifieke uro-neurofysiologische onderzoeken
Specifieke uro-neurofysiologische onderzoeken worden geadviseerd als onderdeel 
van de neurologische evaluatie van de patiënt. Electieve onderzoeken worden op 
specifieke indicatie verricht (GR: C)19:
· Elektromyografie van de bekkenbodemspieren, urethrale sfincter en/of anale 
sfincter
· Zenuwgeleidingsonderzoek van de nervus pudendus
· Meten van reflextijden van de bulbocarvernosus en anale reflexbogen
· Opgewekte potentialen van clitoris of glans penis 




De doelen van de behandeling van neurogeen blaaslijden zijn als volgt 41-44: behoud 
van nierfunctie, verbetering van de urine continentie, verbetering van de blaasont-
lediging en optimalisatie van de kwaliteit van leven (LE: 3). Hierbij zijn van belang de 
beperkingen van de patiënt, kosteneffectiviteit, technische complexiteit en mogelijke 
complicaties 44. Het behoud van de functie van de hoge urinewegen is van het groot-
ste belang bij patiënten met neurogeen blaaslijden.2,41-43,45-47 Vroeger was nierfalen een 
belangrijke doodsoorzaak bij chronische dwarslaesiepatiënten.2,46,47 Dit heeft geleid 
tot de gouden regel in de behandeling van neurogeen blaaslijden: garandeer dat 
de detrusordruk binnen een veilige limiet blijft tijdens de vullings- en mictiefase (LE: 
3).41-44  Als er bij vullingscystometrie een hoge detrusordruk wordt gezien moet wor-
den getracht deze druk te verlagen, zeker als deze aanwezig is vanaf geringe vulling 
en persisteert tot aan de maximale capaciteit. Persisterend hoge blaasdruk tijdens de 
vullingsfase is een belangrijke risicofactor voor beschadiging van de hoge urinewegen, 
een DLPP > 40 cmH2O wordt gezien als directe een oorzaak voor nierschade (LE: 3).33
De kwaliteit van leven is een belangrijke richtlijn waarop een therapiekeuze wordt 
gebaseerd. Ook is het ziektebeeld en leeftijd van belang bij de keuze van therapie.
Conservatieve behandeling
Geassisteerde blaasontlediging
Stimulatie van de sacrale of lumbale dermatomen bij patiënten met een suprasa-
crale dwarslaesie kan een reflex contractie van de detrusor opwekken (LE: 3).41,48 Dit 
reflexmatig opwekken van de mictie (bijvoorbeeld door suprapubisch kloppen) kan 
gebeuren onder strikte urodynamische controle vanwege de verhoogde morbiditeit 
die hiermee is geassocieerd (LE: 3; GR B).49-52
Blaascompressie technieken om urine uit te drijven (Credé manoeuvre) en mictie 
door gebruik te maken van buikpers (Valsalsva manoeuvre) zorgen voor hoge druk-
ken en zijn mogelijk schadelijk voor de hoge urinewegen en moeten daarom worden 
afgeraden (LE 3; GR: B).53,54 Verder kan een al verzwakte bekkenbodemfunctie door de 
passieve druk achteruitgaan en eventueel bestaande incontinentie verergeren.48
Gedragsmodificatie kan de continentie bevorderen door bijvoorbeeld direct te 
urineren bij aandrang, op de klok urineren (blaastraining) en leefstijlmodificatie (LE: 
2B; GR: B).55-58
Bekkenbodemfysiotherapie (BBFT) met eventueel biofeedback kan helpen bij 
geselecteerde patiënten met neurogene blaas.59-63 In een geblindeerde gerando-
miseerde studie met vrouwelijke MS patiënten bleek dat na BBFT met biofeedback 




pseudo-behandeling met biofeedback onderging (LE 1b).64 Derhalve kan BBFT met 
biofeedback bij MS patiënten worden geïndiceerd.
Urotherapie van de lage urinewegen, inclusief elektrostimulatie
Urotherapie
Urotherapie is een niet-farmacologische, niet-chirurgische behandeling gericht om de 
verstoorde blaasfunctie zo goed mogelijk te reguleren om zoveel mogelijk medische 
complicaties te beperken die negatieve effecten op de kwaliteit van leven kunnen 
hebben. Het terugkeren van de vrijwillige controle over de lage urinewegen en het 
verdwijnen van de disfunctie is beschreven bij patiënten met niet-neurogene blaas-
disfunctie. Dit gebeurt door gedragstherapie bij patiënten met urge incontinentie en 
biofeedback training bij stress incontinentie. Een recente gerandomiseerde gecon-
troleerde studie liet zien dat een uitgebreid urotherapie-programma van 12 maanden 
bij MS patiënten, de mictieklachten significant deed afnemen. Tevens was er een 
toename van de kwaliteit van leven, gemeten door niet gevalideerde vragenlijsten.65
Elektrostimulatie
Elektrische stimulatie van specifieke zenuwen of zenuwgebieden kan leiden tot een 
direct gewenst effect op blaasklachten. Verschillende vormen van elektrische stimula-
tie zullen worden besproken.
Chronische pudendus of sacrale elektrische stimulatie
Bij chronische elektrische stimulatie wordt gebruikt gemaakt van een implanteerbaar 
apparaat die elektrische pulsen stuurt naar zenuwen die de blaasfuncties regelen. Een 
proefstimulatie met apparaat buiten het lichaam perifere zenuw evaluatie (PNE) (1e fase) 
gaat voorafgaand aan de definitieve implantatie (2e fase). 
Chronische stimulatie van de nervus pudendus bij patiënten met een neurogene 
blaas gaf in een pilot studie significante subjectieve en urodynamische verbeteringen 
(LE: 3)66.
Bij sacrale neuromodulatie (SNS) worden de sacrale zenuwen elektrisch gestimuleerd. 
Bij dwarslaesie patiënten is SNS effectief gebleken (>50% verbeterd) bij een follow-up 
duur van 2,5 jaar (LE 3).67 De effectiviteit van SNS is afhankelijk van de onderliggende 
neurologische aandoening; met name of het een progressieve aandoening betreft of 
niet. MS patiënten hebben minder baat bij een SNS behandeling (LE: 3).68
Niet-chronische elektrische stimulatie
Bij niet-chronische elektrische stimulatie wordt gebruikt gemaakt van een tijdelijk 




Er werden therapeutische effecten gezien na stimulatie van de nervus tibialis posterior 
(PTNS) bij multiple sclerose (MS) patiënten.69 Echter, acute effecten tijdens urodyna-
misch onderzoek werden wisselend aangetoond in deze patiëntengroep (LE: 2b).70,71
Continue elektrische stimulatie van nervus dorsalis penis/clitoris (DPN) onderdrukt 
detrusor contracties en vergroot de blaascapaciteit bij patiënten met een dwarslaesie 
en MS (LE: 2b).72,73 De DPN kan ook conditioneel worden gestimuleerd. Zodra er een 
onwillekeurige detrusor contractie optreedt (gemeten door een toename van intra-
vesicale druk) wordt er elektrisch gestimuleerd zolang als deze detrusor contractie 
duurt. Conditionele elektrische stimulatie van de DPN onderdrukt effectief detrusor 
contracties en vergroot eveneens de blaascapaciteit van patiënten met een dwarslae-
sie en MS (LE: 2b).73-76
Transcutane elektrische stimulatie (TENS) van de sacrale dermatomen had geen tot 
minimaal effect op de urodynamische uitslagen, maar het leidde wel tot significant 
gunstige klinische effecten bij patiënten met neurogene detrusor overactiviteit (LE: 
2b).74,77
Neuromusculaire stimulatie met bekkenfysiotherapie kan bij MS patiënten ook een 
substantiële vermindering van blaasfunctiestoornissen geven  (LE: 2b).78
Repetitieve transcraniale magnetische stimulatie
Transcraniale magnetische stimulatie verbeterde mictiesymptomen bij patiënten 
met Parkinson en MS, hoewel het niet duidelijk is hoe lang en met welke parameters 
gestimuleerd moet worden (LE: 3).79,80
Externe hulpmiddelen
Opvangmateriaal kan het middel zijn om sociale continentie te verkrijgen.41,48 Con-
doomkatheters met opvangzak zijn een praktische methode bij de man. Ook kunnen 
incontinentieverbanden een oplossing bieden. In beide gevallen is het van belang 
goed toezicht te houden met het oog op het verhoogde risico op infectie48 en decu-
bitus.81
Een penisklem kan hoge druk in de blaas en op het urethrale weefsel veroorzaken 
en is daarom gecontraïndiceerd.82
medicamenteuze behandeling 
Er bestaat nog geen optimaal medicament tegen neurogene detrusor overactiviteit 
(NDO). Anticholinergica worden het meest voorgeschreven hoewel niet alle gere-
gistreerd zijn voor neurogene blaas (Tabel 8.7). Patiënten met neurogeen blaaslijden 
hebben meestal een hogere dosis anticholinergica nodig dan patiënten met idiopa-
thische detrusoroveractiviteit (LE: 1b; GR: A).83-88 Hogere doseringen zijn echter wel 




gezien de meerdere bijwerkingen en potentiële interacties. Vooral ouderen met 
co-morbiditeit zijn zeer kwetsbaar voor de bijwerkingen van polyfarmacie. Anticho-
linergica moeten zeer terughoudend in combinatie met elkaar worden gebruikt om 
stapeling van anticholinergische bijwerkingen te voorkomen.90 Anticholinergica kun-
nen ook intravesicaal worden toegediend  Dit kan een alternatief zijn bijvoorbeeld bij 
kinderen met neurogene blaas, die onvoldoende reageren op orale anticholinergica 
of bijwerkingen hebben.91,92 De bijwerkingen zijn minder bij intravesicale toediening 
maar kunnen nog steeds optreden.92 Een systematische review toonde aan dat na 
intravesicale toediening de maximale blaascapaciteit toenam en de blaasdruk afnam. 
Er is echter onvoldoende wetenschappelijk bewijs om deze therapie te adviseren.92
Keuze van anticholinergicum
Oxybutynine chloride (LE: 1a)84,85,88,89,93-96 en tolterodine tartraat (LE: 1a)97-99 zijn geac-
cepteerde en effectieve medicamenteuze behandelingen. Deze anticholinergica 
worden goed verdragen en zijn veilig, ook op lange termijn. Gezien het verschillende 
tolerantieprofiel kan een ander anticholinergicum worden voorgeschreven in het 
geval van bijwerkingen.87 Darifenacine,100,101 fesoterodine en solifenacine102 worden 
goed getolereerd en zijn effectief bij patiënten met overactieve blaas, maar er zijn 
slechts enkele onderzoeken uitgevoerd bij patiënten met neurogene blaasklachten.
Medicamenteuze behandeling van neurogene detrusor onderactiviteit
Er zijn geen medicamenten die bewezen effectief zijn in de behandeling van detrusor 
onderactiviteit (LE: 2a; GR: B).45 Het wordt niet aangeraden cholinerge medicatie, zoals 
bethanechol chloride en distigmine bromide, voor te schrijven voor dit doel (LE: 1a).109
Tabel 8.7 Anticholinergica voor de behandeling van neurogene detrusor overactiviteit
Geneesmiddel Referenties Opmerking LE GR
Oxybutynine Block et al.103, Granata et al.104 - 1b A
Trospium chloride Dykstra en Sidi.105, Wilson et al.106 - 1b A
Tolterodine Dykstra en Sidi105, Ströher en Pannek107 - 1b A
Propiverine Granata et al104, Ströher et al108 - 1b A
Darifenacine - Nog geen data - -
Solifenacine Van Rey et al102 - 3 C
Fesoterodine - Nog geen data - -
LE = level of evidence; GR = grade of recommendation.
Uit: Stöhrer et al. 7
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Medicamenteuze behandeling ter verlaging van de blaasuitgangsweerstand
Selectieve en niet-selectieve α-blokkers, zoals alfusozine en tamsulosine, hebben 
bewezen gedeeltelijk de blaasuitgangsweerstand te verlagen en residu na mictie te 




Intermitterend katheteriseren (IC) (zowel zelf-katheterisatie als gekatheteriseerd wor-
den door een ander)1,115 is de gouden standaard voor de behandeling van onderactief 
en overactief neurogeen blaaslijden onder de voorwaarden dat overactiviteit kan wor-
den gecontroleerd en de patiënt cognitief en lichamelijk in staat te katheteriseren.41,45
Steriele IC vermindert significant het risico op een urineweginfectie (UWI) en/of 
bacteriurie45,115,116 vergeleken met IC met behulp van een schone, niet-steriele katheter. 
In de dagelijkse praktijk is routinematig steriel IC echter niet haalbaar en aseptische IC 
of IC met behulp van een schone katheter is dan een goed alternatief.117,118 Aseptische 
IC geeft in vergelijking met ‘schone IC’ een significant kleiner risico op contaminatie.117
Inadequate instructies en onvolledige blaaslediging bij patiënten met neurogeen 
blaaslijden spelen een rol bij het risico op infectie.45,118 Gemiddeld wordt 4 tot 6 keer 
per dag gekatheteriseerd met een 12 of 14 Charrière katheter. Minder vaak kathete-
riseren verhoogt de kans op UWI’s omdat de urine langer in de blaas aanwezig is.118 
Vaker katheteriseren zorgt echter weer voor een toename van infecties.118 Het gekathe-
riseerde blaasvolume moet lager zijn dan 400 ml.
Transurethrale verblijfkatheters en – in mindere mate – suprapubische katheters 
moeten zoveel mogelijk worden vermeden omdat zij een risicofactor vormen op 
UWI’s en lange termijn complicaties.45,119-121 Indien verblijfkatheters toch moeten wor-
den gebruikt dan wordt de voorkeur gegeven aan siliconen boven latex katheters.122 In 
de praktijk verwisselt men één keer per 6 à 12 weken een siliconen katheter.123
Botulinetoxine A injecties in de blaas
Botulinetoxine A zorgt voor een langdurige (ongeveer 9 maanden), reversibele, che-
mische denervatie.124,125 Botulinetoxine A heeft bij een aantal kleine, gerandomiseerde, 
placebo-gecontroleerde onderzoeken bewezen effectief te zijn in de behandeling 
van neurogeen blaaslijden (LE: 1a).126,127 De injecties kunnen herhaaldelijk worden 
gegeven zonder dat het de effectiviteit doet afnemen.124,128,129 Sporadisch wordt er als 
bijwerking gegeneraliseerde spierzwakte gezien.124,128,130 Histologische onderzoeken 
hebben geen elektronen microscopische veranderingen in de blaaswand kunnen 
aantonen na injectie.131 In heel Europa, behalve in Zwitserland, is Botulinetoxine A 




gecontroleerd onderzoek (RCT) dat voor onabotuline toxine A (Botox®) injecties in 
de neurogene blaas 200 E en 300 E even effectief zijn en goed werd getolereerd. 
Echter 200 E onabotuline toxine A had minder bijwerkingen dan 300 E  (LE: 1b). Voor 
abobotulinum toxine A (Dysport®) geldt dat 500 E en 750 E even effectief met een 
vergelijkbaar bijwerkingsprofiel (LE: 1b).132 Op grond van deze RCT is registratie voor 
onabotuline toxine A aangevraagd en verwacht wordt dat deze in 2012 wordt toege-
kend. Aangezien Botulinetoxine A meerdere toepassingen heeft en ook voor andere 
indicaties wordt gebruikt, moet er altijd worden geïnformeerd of de patiënt hier recent 
mee is behandeld. Hoewel er geen consensus beschikbaar is over de tussentijd tussen 
twee verschillende behandelingen, wordt in praktijk minimaal 4 tot 6 weken gewacht 
tot de tweede injectie.
Intravesicale vanilloïden
De vanilloïden capsaicine en resiniferatoxine worden in de blaas als spoeling gegeven 
en desensitiseren de C-vezels met als effect een tijdelijke afname van detrusor overac-
tiviteit (LE: 1a).133-137  Resiniferatoine en capsaïcine hebben echter slechts een beperkte 
effectiviteit vergeleken met botulinetoxine A injecties in de musculus detrusor.138,139 
Deze middelen worden in Nederland nauwelijks gebruikt.
Blaashals en urethrale behandelingen
De blaasuitgangsweerstand kan worden verlaagd ter bescherming van de bovenste 
urinewegen. Dit kan worden bewerkstelligd door sfincterotomie140,141 of door middel 
van chemische denervatie van de sfincter met behulp van botulinetoxine A.105,142,143
Na sfincterotomie namen hydronefrose (70-90%), aantal recidiverende urine-
weginfecties (75%) en autonome dysreflexie (>90%) af.140 Tevens verbeterden de 
urodynamische parameters.140 Het is echter een onomkeerbare procedure waarbij de 
normale sfincter permanent wordt beschadigd en complicaties zoals bloedingen kun-
nen optreden.140,144 Het succespercentage van chemische denervatie van de sfincter 
met botuline toxine A varieert van 59-100%.144
Sfincterotomie en chemische denervatie van de sfincter zal tot incontinentie leiden 
maar kan worden gehanteerd door gebruik te maken van externe hulpmiddelen. In 
uitzonderlijke gevallen kan een semi-rigide penisprothese worden geplaatst indien de 
condoomkatheter niet op de penis kan blijven zitten.
Plaatsing van urethrale stents wordt afgeraden omdat deze procedure geassocieerd 
is met substantiële complicaties en risico’s op herhaaldelijke interventies.106,145 De 
blaasuitgangsweerstand verhogen door middel van bulkinjecties, urethrale stents of 




Neurogene detrusor overactiviteit en vesicoureterale reflux
Vesicoureterale reflux (VUR) moet worden behandeld door de intravesicale drukken 
te verlagen. Indien de reflux aanhoudt ondanks urodynamisch bewezen lage druk in 
de vulfase, kunnen bulkinjecties of een ureterreïmplantatie worden overwogen.104,147
Chirurgische behandelingen
Overactieve detrusor
Blaasaugmentatie (bijv. ileocystoplastiek) is geïndiceerd bij een overactieve detrusor 
wanneer andere behandelingen geen effect hebben gehad.107,148 (Figuur 8.2)
Alternatieve opties zijn autoaugmentatie (myomectomie)108, dorsale rhizotomie 
met of zonder “sacral anterior root stimulator” (SARS) (bij complete laesies)149,150 en 
neuromodulatie (bij incomplete laesies).151 Deze behandelingen blijken significant 
de kwaliteit van leven te verbeteren.149,152 Detrusor myectomie kan echter wel tot een 
verminderde contractiliteit leiden, en bijna de helft van de patiënten moet om deze 
reden zelf-katheteriseren.153
Onderactieve detrusor
Sacrale neuromodulatie (bij incomplete laesies)151 kan bij geselecteerde patiënten een 
effectieve behandeling zijn (LE: 2; GR: B).
Alle leasies  Incomplete laesie  Complete laesie 
  
Botuline toxine A  Neuromodulatie  Dorsale rhizotomie
   
 Autoaugmentatie (optioneel)     Neurostimulatie 
Clam-cytoplastiek 
Entero-cytoplastiek 
Figuur 8.2 Chirurgische behandeling van neurogene detrusor overactiviteit. 





De artificiële urinaire sfincter (AUS) verdient de voorkeur bij patiënten met neurogeen 
blaaslijden (LE: 2; GR: B).154 Echter, na implantatie van een AUS, is bijna de helft afhan-
kelijk van zelf-katheterisatie om de blaas volledig te legen.155-157 De ideale kandidaat 
voor een AUS is een patiënt die voor implantatie een goede blaasontlediging heeft.155
Een alternatieve en minimaal invasieve behandeling is de plaatsing van een midu-
rethrale sling bij de vrouw of para-urethrale ballon bij de blaashals bij de man (LE: 3, 
GR: B).158-160   Diverse soorten materialen zijn ontwikkeld voor een midurethrale sling.161 
Afhankelijk van de wens van de patiënt, ervaring van de operateur, de handfunctie, de 
mate van incontinentie en de blaasfunctie wordt de keuze gemaakt tussen een AUS of 
een andere methode.
Een voorwaarde van de behandeling van sfincter insufficiëntie is aanwezigheid van 
detrusor activiteit, of controle over de detrusor zonder significante vesicoureterale re-
flux. Het gelijktijdig uitvoeren van blaasaugmentatie en autologe fasciesling of implan-
tatie van een artificiële urinaire sfincter is een optie bij patiënten met neurologische 
afwijkingen.162
Urinedeviaties
Plaatsing van een continent163 of incontinente deviatie164-166 kan worden overwogen 
bij neurogeen blaaslijden. Het aanleggen van een stoma wordt meestal gezien als 
laatste optie bij therapieresistente patiënten. De nierfunctie wordt op deze manier 
beschermd en de incontinentie wordt verholpen. Een incontinent stoma (Bricker) is 
geïndiceerd bij patiënten die niet in staat zijn te katheteriseren. Een katheteriseerbaar 
stoma (appendicovesicostoma volgens Mitrofanoff of getapert ileum volgens Monti) 
kan een goed alternatief zijn bij mensen die in staat zijn te katheteriseren. Specifiek 
kan deze optie geïndiceerd zijn bij rolstoelgebonden vrouwelijke patiënten en bij 
mannen met een urethrale strictuur.
urineWeG inFeCties bij neuroGeen bLAAsLijDen
De meeste kennis betreffende urineweginfecties (UWI) bij neurogene blaas is verkre-
gen uit studies bij patiënten met een dwarslaesie en niet direct toepasbaar op andere 
populaties, zoals MS, CVA of morbus Parkinson. Bacteriurie zonder symptomatologie 
moet niet worden behandeld, ook niet bij intermitterende katheterisatie.167
recidiverende urineweginfecties
Recidiverende UWI’s kunnen een teken zijn van een slechte techniek van zelfkathete-
risatie of een suboptimale behandeling van een onderliggend probleem, bijvoorbeeld 
Chapter 8
202
een hoge drukblaas, residu na mictie of urinewegstenen. Het bevestigen of uitsluiten 
van deze oorzaken is noodzakelijk.167
Preventie
De beste preventie van UWI bij patiënten met neurogene blaas bestaat uit een 
evenwichtige behandeling van de disfunctie van de lage urinewegen. Hierbij is het 
belangrijk te streven naar een lage drukblaas tijdens de vulling en mictie en residuloze 
lediging van de blaas. Aseptische CIC wordt gebruikt met steriele gelubriceerde of 
hydrofiele katheters.168-170
Mictie op de klok en een minimale dagelijkse vloeistofinname van 30 ml/kg li-
chaamsgewicht worden gezien als ondersteunende factoren in de preventie van UWI.
Er is op diverse manieren geprobeerd om de UWI’s in de neurogene blaas te mini-
maliseren. Gerandomiseerd gecontroleerde studies geven wisselende resultaten over 
de meerwaarde cranberry extracten.171-173 Methenamine hippuraat174 en blaasspoelen 
zijn ineffectief gebleken.175 Het aminozuur L-methionine is mogelijk een belangrijk 
component in de profylaxe van recidiverende urineweginfecties. Het gunstige effect 
van L-methionine is te wijten aan een uitscheiding van zure valenties in de urine en 
het verlaagt de bacteriële cyto-adherentie.176,177 L-methionine kan worden toegepast 
bij neurogene blaaspatiënten als andere maatregelen en onderhoudsantibiotica niet 
werken.177 Er is weinig wetenschappelijk bewijs voor de preventieve werkzaamheid. 
De aanbevelingen over het gebruik van antibiotische profylaxe door de Neder-
landse Vereniging voor Urologie zijn beschreven in de richtlijn Bacteriële urinewegin-
fecties bij adolescenten en volwassenen.167 Een asymptomatische bacterurie moet niet 
worden behandeld. Er wordt geadviseerd bij drie of meer ongecompliceerde UWI’s 
binnen één jaar antibiotische profylaxe voor te schrijven om recidieven te beperken. 
Deze richtlijn is ook van toepassing op patiënten met neurogeen blaaslijden (LE 1b) 178, 
echter routinematig gebruik van profylaxe heeft een nadelige invloed op de resistentie 
ontwikkeling.179 Gericht gebruik wordt daarom geadviseerd. 
Er is geen indicatie om routinematig antibiotische profylaxe te geven bij katheterisa-
tie (ongeacht de duur) en bij het verwijderen van de katheter.
seksueLe FunCtie en VruChtbAArheiD bij DWArsLAesie
Neurologische ziektes en letsels hebben een evidente invloed op de seksuele gezond-
heid, echter richtlijnen voor de behandeling hiervan ontbreken nog.180 Periodieke 
controles met gevalideerde vragenlijsten kunnen helpen om het probleem inzichtelijk 





Medicamenteuze behandeling - Phosphodiesterase type 5 inhibitors (PDE5Is) 
Phosphodiesterase type 5 inhitors (PDE5Is) worden aanbevolen als eerstelijns behan-
deling bij mannen met een dwarslaesie en erectiele disfunctie (ED). De medicatie is 
veilig en effectief voor gebruik op de lange termijn (LE:1b).182-184  De meest voorko-
mende bijwerkingen zijn hoofdpijn en blozen. Mannen met een tetraplegie kunnen 
orthostatische hypotensie krijgen gedurende enkele uren na het gebruik van een 
PDE5I.
Ook bij patiënten met MS en de ziekte van Parkinson zijn tadalafil, vardenafil en 
sildenafil citraat effectieve en veilige lange termijnbehandelingen (LE: 1b).185-187
De grote meerderheid van de patiënten met neurogene erectiele disfunctie vereist 
een lange termijn behandeling voor ED. Echter, sommige patiënten nemen hun medi-
catie niet trouw in of stoppen de medicatie vanwege bijwerkingen.182 Daarnaast kun-
nen sommige patiënten met ernstig neurologisch letsel resistent zijn voor PDE5Is.187
Mechanische hulpmiddelen
Mechanische hulpmiddelen (vacuümpompen en penisringen) kunnen effectief 
zijn188,189 maar zijn vaak niet praktisch in het gebruik.
Intracaverneuze injecties
Patiënten die niet reageren op orale medicatie kunnen intracaverneuze injecties 
(ICI) met fentolamine/papaverine toegediend krijgen. Deze zijn zeer effectief bij de 
behandeling van ED bij mannen met een dwarslaesie, maar het gebruik vereist een 
nauwkeurige dosering met lage startdosis en enige voorzorgsmaatregelen. De be-
kendste complicaties bij intracaverneuze medicatie zijn priapisme en fibrose van de 
corpora cavernosa.
Een intracaverneuze injectie met vasoactieve medicatie is de eerste therapeutische 
optie bij patiënten die medicatie met nitraat gebruiken, bij medicatie met mogelijke 
interactie met PDE5Is, of bij patiënten voor wie PDE5Is ineffectief zijn.
Topische applicatie van middelen voor gladde spier relaxatie van de penis (pros-
taglandine) of intra-urethrale plaatsing van prostaglandine E1 (MUSE) blijken minder 
effectief te zijn bij dwarslaesie patiënten die lijden aan ED.190 
Peniele prothesen
Een peniele prothese kan effectief zijn bij de behandeling van ED bij mannen met 
een dwarslaesie en wordt aangeboden als alle conservatieve behandelingen hebben 
gefaald. Ernstige complicaties, waaronder infectie en prothese perforatie, komen voor 




In enkele klinieken wordt de ilioinguinale zenuw verbonden met de ipsilaterale nervus 
dorsalis penis (TOMAX procedure). Hierdoor kan de sensibiliteit aan de geopereerde 
zijde in de glans penis worden hersteld bij dwarslaesie en spina bifida patiënten met 
een lage laesie.194 Deze procedure is nog niet veelvuldig uitgevoerd, maar de resultaten 
zijn veelbelovend. Vijftien maanden na de ingreep waren alle mannen seksueel actief.
mannelijke vruchtbaarheid
Verminderde vruchtbaarheid bij mannen met een dwarslaesie is een veel voorko-
mend verschijnsel en komt door een combinatie van ED, anejaculatie en abnormaal 
semen. De precieze oorzaak van deze afgenomen vruchtbaarheid is niet bekend (LE: 
3).195  Vaak zijn geassisteerde reproductieve technieken (ART) noodzakelijk om tot een 
succesvolle bevruchting te komen.196
De kans op zwangerschap is lager dan in de algemene populatie. Sinds de introduc-
tie van medisch geassisteerde voortplantingstechnieken (met name intracytoplasmi-
sche sperma injectie (ICSI)) hebben mannen met een dwarslaesie een goede kans om 
biologische vaders te worden.196-198 Afhankelijk van de kwaliteit van het sperma kan er 
middels een beslisboom een behandelplan worden gemaakt.196
Er zijn diverse methodes beschreven om retrograad sperma goed op te vangen. 
Bij retrograde ejaculatie kan een ballonkatheter worden gebruikt om de blaashals af 
te sluiten en antegrade ejaculatie te verkrijgen.199 Er is meer vergelijkend onderzoek 
nodig om het effect van intracaverneuze injecties op de ejaculatie en het orgasme te 
evalueren en de effectiviteit en tolerantie bij lange termijn gebruik. Ook moet er wor-
den onderzocht of het vroege gebruik het herstel van spontane erecties verhoogt.182 
Prostaatmassage is veilig en eenvoudig uit te voeren om sperma te verkrijgen bij man-
nen met laesies boven Th10.200
De twee meest gebruikte mechanische methoden om sperma te verkrijgen zijn 
vibrostimulatie en transrectale electro-ejaculatie.201-203 Bij mannen met laesies boven 
Th10 wordt sperma beter verkregen middels vibrostimulatie.204-206 Als vibrostimulatie 
niet succesvol is, kan dit eventueel met midodrine worden gecombineerd. Electro-
ejaculatie is echter de tweede keus voor spermawinning als herhaalde pogingen met 
vibrostimulatie zijn mislukt.207 Bij intacte sensibiliteit moet electro-ejaculatie onder 
narcose plaatsvinden in verband met pijn bij deze behandeling.
Chirurgische procedures, zoals epididymale (PESA/MESA) of testiculaire (TESE) 
spermawinning, kunnen gebruikt worden als vibrostimulatie en electro ejaculatie niet 
hebben geholpen.208,209
Sperma kwaliteit en motiliteit




· Vibrostimulatie geeft ejaculaat met betere sperma-motiliteit dan verkregen door 
middel van electrostimulatie.202,210
· Antegraad sperma heeft een betere kwaliteit dan retrograad verkregen sperma.
· Electro-ejaculatie waarbij intermitterend met stroom wordt gestimuleerd produ-
ceert een grotere hoeveelheid antegraad sperma dan continue stimulatie.211
· Blaascontrole door intermitterende katheterisatie kan de sperma kwaliteit verbete-
ren, vergeleken met een verblijfskatheter, reflexmictie of blaasexpressie.212
· Sperma kwaliteit bij patiënten met een dwarslaesie verbetert door het opwerken 
in seminaal plasma.213
Er zijn geen relevante publicaties over vruchtbaarheid bij andere neurologische ziek-
ten. 
Vrouwelijke seksualiteit
Studies hebben aangetoond dat de meeste vrouwen (65–80%) seksueel actief blijven 
na een dwarslaesie, maar veel minder frequent dan voor het letsel. Daarbij geeft on-
geveer 25% van de vrouwen met een dwarslaesie aan minder tevreden te zijn met hun 
seksuele leven.214-216
Verder is aangetoond dat urine incontinentie de grootste blokkade voor seksuele 
activiteit is. Patiënten met een hoge dwarslaesie hebben vooral problemen met de 
positie en spasticiteit.
Met begeleiding kunnen vrouwen met een dwarslaesie zich seksueel aanpassen 
waardoor zij een positiever zelfbeeld krijgen, meer gevoel van eigenwaarde en het 
gevoel aantrekkelijk te zijn voor zichzelf en anderen.217-220
Het gebruik van specifieke medicatie voor seksuele disfunctie is geïndiceerd bij 
onvoldoende lubricatie. Sildenafil kan gedeeltelijk de subjectieve problemen met 
seksuele opwinding oplossen, terwijl manuele en mechanische stimulatie van de 
clitoris de genitale respons kan verhogen.221,222 Neurofysiologische studies hebben 
aangetoond dat vrouwen die Th11-L2 speldenprik sensaties beleven, ook psychogene 
genitale vasocongestie kunnen hebben. Reflex lubricatie en orgasme komen vaker 
voor bij vrouwen met een dwarslaesie waarbij de sacrale reflexboog intact is (S2-S5). 
Bij een complete laesie van de sacrale reflex, kunnen opwinding en orgasme worden 
opgewekt door stimulatie van andere erogene zones boven het niveau van de lae-
sies.223-225
Onderzoek heeft laten zien dat vrouwen met een dwarslaesie ontevreden zijn met 
de kwaliteit en de kwantiteit van seksueel gerelateerde revalidatie en dat zij minder 




Het reproductieve vermogen van vrouwen wordt slechts tijdelijk beïnvloed door de 
dwarslaesie. De menstruatie stopt gedurende kortere of langere tijd na de dwarslae-
sie.228 Niet bij iedereen treedt vervolgens cyclusherstel op. Circa 70% van de seksueel 
actieve vrouwen gebruikt een vorm van contraceptie na het letsel. Orale anticoncep-
tie wordt minder gebruikt na dan voor de dwarslaesie.215 Hoewel de zwangerschap 
doorgaans normaal verloopt, hebben vrouwen met een dwarslaesie meer kans op 
complicaties tijdens de zwangerschap en bevalling vergeleken met lichamelijk ge-
zonde vrouwen. Complicaties tijdens de bevalling zijn blaasproblemen, spasticiteit, 
doorligplekken door gewichtstoename en autonome dysreflexie.229,230 Obstetrisch 
gezien worden er in deze groep meer keizersneden uitgevoerd en is er een verhoogde 
incidentie van baby’s met een laag geboortegewicht.215 Epidurale anesthesie is effectief 
bij de meeste patiënten met autonome dysreflexie tijdens de bevalling.231,232
Er is zeer weinig gepubliceerd over de ervaringen van vrouwen in de menopauze na 
een dwarslaesie.233  Er zijn geen relevante publicaties over seksualiteit en vruchtbaar-
heid bij andere neurologische ziekten.
kWALiteit VAn LeVen
De kwaliteit van leven (KvL) is een zeer belangrijk aspect in de gehele behandeling 
van de patiënt met neurogeen blaaslijden.7 De wijze van behandeling van neurogeen 
blaaslijden kan sterk de gezondheid gerelateerde KvL beïnvloeden bij patiënten 
met een dwarslaesie.234 Behandelingen die de continentie verbeteren en gunstige 
urodynamische resultaten geven zijn gecorreleerd met een betere KvL.235 De KvL is 
een weergave van het coping mechanisme van het individu met de nieuwe levens-
situatie.236 De KvL kan worden beïnvloed door verschillende factoren, inclusief steun 
door familie, de mogelijkheid om aan te passen, productiviteit, eigenwaarde, financi-
ele stabiliteit, opleiding en de fysieke en sociale omgeving (LE: 3).237 Leeftijd, geslacht, 
ras en de acceptatie van de aandoening door de patiënt moeten ook in beschouwing 
worden genomen als de KvL wordt bepaald (LE: 3).238
bepaling van kwaliteit van leven
Er zijn specifieke KvL vragenlijsten voor neurogeen blaaslijden. De enige gevalideerde 
instrumenten zijn de algemene visuele analoge schaal (VAS) voor de symptoomlast 
en de Qualiveen welke een specifiek instrument is voor de KvL bij patiënten met 
een dwarslaesie en Multiple Sclerose. Qualiveen heeft een goed onderscheidend 
vermogen en is een valide evaluatie instrument235,239-241 en een verkorte versie is mo-




beschikbaar. Het International Consultation on Incontinence Modular Questionnaire 
(ICIQ)  Project ontwikkelt vragenlijsten met betrekking tot incontinentie volgens een 
modulair systeem.243 Een neurologische specifieke module is nog in ontwikkeling. 
Meer gebruikelijk is het bepalen van de KvL met behulp van incontinentie specifieke 
KvL vragenlijsten zoals de Incontinence Impact Questionnaire (IIQ)244,245, Urogenital 
Distress Inventory (UDI)244,245, Incontinence Quality of Life Instrument (I-QOL)246 of 
King’s Health Questionnaire (KHQ) 247. Of met behulp van algemene gezondheidsvra-
genlijsten zoals de Short Form 36 Health Survey Questionnaire (SF-36)248, Euro Quality 
of Life-5 Domains (EQ-5D)249, Short Form 6D Health Survey Questionnaire (SF-6D)250 
of de the Health Utilities Index 3 (HUI)251.
Verder kan de zogenaamde QALY (quality-adjusted life year) –metrie gebruikt wor-
den om de status van de patiënt uit te rekenen door de levensjaren doorgebracht in 
een specifieke gezondheidsstatus te wegen met een factor die staat voor een waarde 
die de maatschappij of patiënten geven aan die gezondheidsstatus (LE: 3).252
invloed van therapie op kwaliteit van leven
Geschikte therapieën dienen de symptomen, de urodynamische parameters, de 
functionele mogelijkheden en KvL te verbeteren, en secundaire complicaties te voor-
komen.240,253 Veranderingen in neurogene blaas klachten zijn een belangrijke factor in 
de KvL van de patiënt (LE:2a).254,255
FoLLoW-uP
Neurogeen blaaslijden is een instabiele ziekte en presenteert zich zeer variabel, zelfs 
binnen relatief korte tijd. Nauwkeurige follow-up en regelmatige controle worden 
daarom sterk aanbevolen.107 Afhankelijk van de neurologische pathologie en de 
huidige toestand van het neurogeen blaaslijden kan het controle interval variëren, 
maar bij patiënten met hoge blaasdrukken wordt geadviseerd eens in de 1 tot 2 jaar 
te controleren. Bij patiënten met MS of een acute dwarslaesie is het te adviseren dit 
interval te verkorten. In geval van een veilige blaas met lage drukken en gering residu 
hoeft regelmatige urodynamische controle niet worden verricht. Geïndividualiseerde 
follow-up is noodzakelijk om de KvL en levensverwachting te monitoren.
ConCLusie
Neurogeen blaaslijden is een ziektebeeld met veel aspecten. Uitgebreid onderzoek en 
specifieke diagnostiek zijn nodig voordat een individueel behandelplan kan worden 
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opgesteld. Gedurende de behandeling moet er rekening gehouden worden met de 
medische en fysieke conditie van de patiënt. Tevens zijn de verwachtingen van de pa-
tiënt ten aanzien van de toekomstige sociale, fysieke en medische situatie zeer belang-
rijk. De behandelend specialist kan kiezen uit een grote hoeveelheid therapeutische 
opties, elk met bepaalde voor- en nadelen. Ongeacht het succes van een ingestelde 
therapie, is een levenslange begeleiding essentieel voor het leven van de patiënt. Het 
doel van deze richtlijnen is de toestand van de neurogene blaas van een patiënt zo 
precies mogelijk te omschrijven. De hulpverlener kan met deze omschrijving, samen 
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Summary and general discussion
In this thesis traditional and patient reported outcome measures aimed to evaluate 
functional disorders of the pelvic floor are presented. 
trADitionAL outCome meAsures
Despite nowadays diagnostic and therapeutic advancements like magnetic resonance 
imaging and robot assistance, post-prostatectomy incontinence remains a major con-
cern for patients. The surgical armamentarium for stress urinary incontinence in men 
ranges from minimally invasive procedures to artificial urinary sphincter implantation. 
Multiple innovative devices have been introduced in this rapidly moving field over 
the recent years.1 These include the artificial urinary sphincter, bulking agent injec-
tion therapy, male slings, and balloon implantation. For severe or persistent urinary 
incontinence the artificial urinary sphincter is still the current standard of treatment. 
As the evidence for the use of these devices in daily practice is growing, the respec-
tive indications for the various surgical options are also evolving. In this respect pre-
intervention evaluation, including urodynamics to assess bladder storage, is important 
to understand the contributing components to the patient’s condition. This will also 
aid in the decision which intervention is best indicated for the individual patient in 
order to optimize treatment outcome. 
In Part I we reported on one of the backbones of diagnostics in functional urology, 
the urodynamic study. This traditional outcome investigation measures physiological 
parameters of the urinary bladder, sphincter, and urethra during filling and voiding. 
These urodynamic parameters are interpreted by the physician and assist to diagnose 
the cause and nature of bladder dysfunction. In Chapter 1, urodynamic changes after 
implantation of the Adjustable Continence Therapy (ProACT, Uromedica, Minne-
apolis, MN) were described. ProACT is a minimally invasive implant consisting of two 
volume-adjustable balloons.2 The balloons are placed paraurethrally just cranial from 
the pelvic floor. Each balloon is attached by a plastic tube to a titanium port placed 
subcutaneously in the scrotum allowing for separate volume adjustments using an 
isotonic solution of contrast medium after the initial implantation. The balloon volume 
is adjusted to create bilateral urethral compression until continence is achieved and 
the optimal balance between bladder emptying and dryness has been obtained. The 
implantation of ProACT in men with post-prostatectomy incontinence was consid-
ered successful if patients used none or one dry precautionary incontinence pad per 
day, and not successful if the patient reported one or more wet pads per day. Men 
who were successfully treated with ProACT (37 out of 49 men) showed an increased 
urethral resistance and reduced bladder contraction strength as compared to pre-
treatment urodynamic evaluation. Nonetheless, no signs of clinical obstruction were 
228
Summary and general discussion
found after successful implantation as patients did not develop significant post-void 
residue or symptomatic urinary tract infections during follow-up. Independent clini-
cal predictors for a non-successful ProACT implementation were a longer duration of 
urinary incontinence, more severe incontinence (i.e. the need to use more than five 
incontinence pads per day), and a smaller cystometric bladder capacity measured 
before ProACT implantation. These results suggest that ProACT implantation, which is 
a minimal invasive and reversible treatment, may be considered as a first-line surgical 
option in a ‘step up’ approach for the treatment of post-prostatectomy incontinence 
after conservative treatment has failed.3 It should at least be considered before opting 
for more invasive operative techniques, like the artificial urinary sphincter, especially 
for patients with less severe incontinence. Although more studies are required before 
clinical algorithms can be constructed, our results indicate that urodynamic mea-
surements may be useful to guide the choice for an individually tailored treatment 
modality. It is clear that, these adjustable balloons are not an option for all men and 
that potentially subgroups may best benefit from implantation. The ultimate role 
of adjustable balloons will depend on their generalized availability and a rational 
treatment paradigm, which incorporates their use in appropriately selected patients. 
Undoubtedly, the treatment of male urinary incontinence remains a clinical problem 
because of the lack of a solution that is universally successful. 
PAtient rePorteD outCome meAsures (Proms)
Urinary incontinence is a symptom of inadequate storage indicating bladder dysfunc-
tion. The standardisation sub-committee of the International Continence Society defined 
it as “the complaint of any involuntary loss of urine”. 4 This definition is suitable for 
epidemiological studies, but when assessing the prevalence of bothersome inconti-
nence the definition of ‘‘involuntary loss of urine that is a social or hygienic problem’’ 
seems more useful.5 There is not a single and precise definition for incontinence which 
frequently limits the comparison of results derived from various studies in this field. 
This also applies to any measure of severity which is further complicated by subjectiv-
ity and dependence on self-report by the individual. While urinary incontinence is not 
a life-threatening condition, it certainly has the potential to have a negative impact on 
the psychological health of the patients. Furthermore, it hinders aspects of daily living, 
thereby having a detrimental effect on quality of life.6  Measures incorporating the 
patient’s perspective are called patient reported outcome measures (PROMs), which 
are originating from patients themselves, reporting their health condition, including 
symptoms, functional status and health-related quality of life (HRQL). Especially in 
conditions involving pelvic floor dysfunction, PROMs should be considered as impor-
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tant measures of outcome when considering natural history and therapeutic efficacy. 
Validated PROMs for adequate assessment are, however, not generally available for 
patients and physicians, and were lacking in Dutch, which is the native language of the 
vast majority of people in the Netherlands.
Therefore, in Part II, commonly used English PROMs for assessing symptom distress 
and HRQOL of pelvic floor dysfunction, including urogenital functional disorders, 
were translated and adapted to Dutch after which their measurement properties 
were tested. The translation into Dutch followed standardized forward-backward 
procedures: three independent forward translations, and a backward translation by 
a native speaker.7 Subsequently each Dutch PROM was pilot tested with interviews 
during which potential problems were explored and discussed through guidance of 
a checklist. Hereafter, the final versions of the questionnaires were designed. Patients 
with symptoms of pelvic floor dysfunction were requested to complete the question-
naires at inclusion; 1-week after inclusion; and 6 months after inclusion together with 
a single self-reported health transition question of the RAND-36.8-10 By following the 
quality criteria as proposed by the EMGO Institute for Health and Care Research11 we 
were able to perform a standardized assessment of the measurement properties of the 
following disease specific PROMs:
· the Urogenital Distress Inventory (UDI-6) and Incontinence Impact Questionnaire 
(IIQ-7) short forms (Chapter 2) to assess urinary incontinence,
· the Pelvic Floor Distress Inventory (PFDI-20) and Pelvic Floor Impact Questionnaire 
(PFIQ-7) short form (Chapter 3) to assess pelvic floor dysfunction,
· the Fecal Incontinence Quality of Life Questionnaire (FIQL) and the Fecal Inconti-
nence Severity Index (FISI) (Chapter 4) to assess fecal incontinence,
· the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire 
short form (PISQ-12) (Chapter 5) to assess prolapse and sexuality,
· the 5-item International Index of Erectile Function (IIEF-5) (Chapter 6) to assess 
erectile dysfunction. 
All above translated PROMs had adequate internal consistency and thus proved to be 
reliable and valid instruments for assessing symptom distress and HRQOL of pelvic 
floor dysfunction. The UDI-6, IIQ-7, PFDI-20, and PFIQ-7 also showed to be respon-
sive meaning that they have the ability to detect changes over time. The PFDI-20 and 
PFIQ-7 showed adequate interpretability; indicating that a qualitative meaning to the 
quantitative scores can be assigned.  In addition, we validated the UDI-6 and IIQ-7 in 
male patients by revising the gender-specific items of the IIQ-7, as these were originally 
constructed and validated in women.  
Demonstrating reliability and validity is essential in determining whether a specific 
PROM will be useful in the evaluation of a health-care intervention. Reliability and 
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validity are more accurately described as continuous rather than dichotomous psy-
chometric indices. For this reason, claiming that an instrument is “completely reliable” 
or “completely valid” is inaccurate. Reliability and validity are separate psychometric 
properties. Measures can be highly reliable but still not able to measure what they are 
purported to measure. Thus, reliability is necessary but not sufficient for a measure 
to be valid.  Similarly, saying an instrument has been “validated” conveys no informa-
tion other than that its performance or psychometric properties have been evaluated. 
However, as this is an accustomed way to summarize the findings in PROM-based 
research we have formulated our conclusions concordantly. Although information 
about the reliability and validity of an instrument is critical, these properties must 
be considered in the context of the setting in which the instrument will be used. A 
good example is the IIEF-5 which is supposed to complement clinical judgment and 
diagnostic assessment, but not to replace patient history taking (Chapter 6).  
In the field of functional urology linguistically adapted and psychometrically 
adequate PROMS are valuable as treatment success is dependent on the patient’s 
perspective on their quality of life and their ability to function. Validated PROMs 
should thus form a key part of treatment evaluation and development, both within as 
well as outside of the context of clinical trials, in addition to the traditional outcome 
measures such as surgical complications and morbidity rates. Furthermore, PROMs 
could be useful for clinicians in daily practice as well, for instance in understanding 
the long-term results of intervention on HRQOL or the impact of pelvic floor dysfunc-
tion for the individual patient over time, which may very well fluctuate.  Systematized 
information about the self-perceived severity of pelvic floor dysfunction could be 
especially relevant with respect to the decision whether to proceed or not to proceed 
with more invasive treatments strategies. Unfortunately, physicians are often reluctant 
to routinely use PROMs because of the concerns of additional workload. Also, some 
clinicians believe that they already understand their patients’ problems by adequate 
history taking and that they are not in need of the additional information derived by 
PROMs for patient management.12 On the other hand, patients generally welcome 
systems that routinely use PROMs if used well and not misdirect the focus of the clini-
cal encounter, it not only focuses on factors that have value to clinicians, and as long 
as it is not too much of an inconvenience.12 To overcome the barriers for routine use, 
PROMS should preferably be short and easy to use and interpret, both for patients as 
well as physicians. Secure electronic forms through interactive applications are prob-
ably essential before successful implementation of PROMs in daily practice can be 
considered.
Also needed before general implementation of the Dutch measures is validation 
in other clinical settings. Our studies were all conducted in a tertiary urology and 
gynaecology care centre, where we expect patients to have more severe symptoms of 
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functional disorders of the pelvic floor. The extent to which the results of our studies 
can thus be generalized may be limited. Firstly, in primary care practice there is a higher 
prevalence of community-dwelling older adults with symptoms of urogenital dysfunc-
tion. A Dutch survey study13 among 255 women of 55 years and up found that 64% 
were not known by their general physician (GP) as suffering from at least one episode 
of involuntary loss of urine a month. These women’s main reasons for not consulting a 
GP were: not regarding incontinence as a serious problem (73%), having found a way 
to cope on their own (57%), considering urinary incontinence as a normal sequel of 
aging (47%), and having low expectations of treatment (24%). In addition, mentioning 
the symptoms to a professional may not be enough as there are reports of GPs not 
responding to these complaints, either by ignoring the statement of symptoms or by 
providing a dismissive explanation. Patients tend to interpret a lack of response from 
the doctor as an indication that no treatment is available. In a study of management of 
incontinence in general practice, 30% of the women who had told their doctor about 
their symptoms perceived that they were offered no help.14 It is probable that many 
primary health care providers lack confidence in managing urinary incontinence, 
and that this contributes to under treatment in those seeking help. Validated PROMs 
might actually help GPs in the interpretation of the severity of functional disorders 
of the pelvic floor and subsequent need for further therapy or referral. Educational 
outreach regarding pelvic floor disorders and the Urogynecology specialty would 
likely improve patient access to care.15 The adoption of PROMs in primary care, how-
ever, poses specific challenges that are related to the specific characteristics of the 
patient population. For instance, primary care patients show a wide range of disease, 
including many early undifferentiated stages and conditions which may be mild and 
temporary. Therefore, disease-specific measures may be less preferable over generic 
measures in this setting, as the latter can be used across diseases to address a broad set 
of domains of general health.16,17  
eViDenCe bAseD meDiCine in FunCtionAL uroLoGy
Part III focuses on evidence based medicine (EBM) in the clinical research of neuro-
genic bladder dysfunction. In this specific disease the first aim of urological treatment is 
protection of the upper urinary tract.18 In patients with detrusor-sphincter dyssynergia 
(DSD), a high detrusor pressure during filling may result in a pathologic high-pressure 
bladder, which needs to be converted into a low-pressure reservoir. Surgical treat-
ment can be considered in patients for whom conservative treatment failed or is not 
possible. Since the introduction of endoscopic sphincterotomy in 1958 as a treatment 
of functional obstruction at the level of the external urethral sphincter in neurogenic 
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bladder 19 new surgical options have been developed. In Chapter 7 the effectiveness of 
different surgical therapies for the treatment of functional bladder outlet obstruction 
due to DSD in patients with neurogenic bladder was assessed. The wide variety of sur-
gical treatments available for curing or improving bladder outlet obstruction in adults 
with neurogenic bladder dysfunction indicates a lack of consensus for what is optimal 
treatment. We conducted a Cochrane systematic review to help identify optimal prac-
tice in patients with DSD, and to highlight where there is need for further research.  The 
Cochrane Collaboration is to develop systematic reviews of the strongest evidence 
available about healthcare interventions, with editorial teams overseeing the prepara-
tion and maintenance of the reviews.20 We used explicit methods aimed at minimizing 
bias in order to produce more reliable findings that can be used to inform decision-
making. In our review we identified limited quality of evidence for intraurethral Botu-
linum toxin A injections in improving urodynamic outcomes related to the function of 
the bladder and urethra 30 days after injection. Nonetheless this review did not find 
enough evidence to identify the most effective surgical treatment for DSD.  It is often 
thought that due to focusing exclusively on randomized controlled trials (RCTs) a large 
swath of the published literature is excluded from their purview. Nevertheless, Alper 
et al. determined how often clinical conclusions derived from Cochrane Reviews have 
uncertain validity due to review conduct and reporting deficiencies. They concluded 
that Cochrane Reviews provide high-quality assessment and synthesis of evidence, 
with fewer than 1% of Cochrane Reviews having limitations which hinder the summary 
of best current evidence for clinical decision-making.21 However, in daily practice an 
intervention may nevertheless be considered as an adequate patient management 
strategy, despite scientifically proven efficacy within placebo-controlled studies. This 
is especially the case in interventions with low risks and low costs. 
Finally, in Chapter 8 multidisciplinary evidence based clinical guidelines for manage-
ment of patients with symptoms of neurogenic bladder in the Netherlands are pro-
vided. With these guidelines, we provided information for Dutch clinical practitioners 
about the incidence, definitions, diagnosis, therapy, and follow-up of neuro-urological 
disorders. The multidisciplinary guidelines serve the clinician to make decisions about 
appropriate health care. These guidelines were made in collaboration with the Dutch 
associations of urologists (Nederlandse Vereniging voor Urologie), neurologists (Ned-
erlandse Vereniging voor Neurologie),  rehabilitation physicians (Nederlandse Vereni-
ging van Revalidatieartsen), Elderly Care Physicians and Social Geriatricians (Verenso), 
Continence Nurses and Carers (Continentie Verpleegkundigen & Verzorgenden), and 
patient support groups for people with paraplegia (Dwarslaesie Organisatie Neder-
land) and for people with congenital physical disabilities (BOSK). 
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FinAL ConCLusion
This thesis has yielded significant results regarding the evaluation of functional disor-
ders of the pelvic floor in both men and women, using traditional outcome measures 
along with PROMs, namely:
· Successful ProACT implantation resulted in greater urethral resistance during void-
ing and reduced bladder contraction strength. 
· Independent predictors of unsuccessful clinical outcome after ProACT implanta-
tion include a longer duration of incontinence, the use of 5 or more incontinence 
pads a day, and a smaller cystometric bladder capacity.
· The Dutch short-form measures UDI-6 and IIQ-7  to assess urinary incontinence, the 
PFDI-20 and PFIQ-7 to assess pelvic floor dysfunction, the FIQL and FISI to assess fe-
cal incontinence, the PISQ-12 to assess prolapse and sexuality, and the IIEF-5 to assess 
erectile dysfunction, all had adequate internal consistency and thus proved to be 
reliable and valid instruments for assessing symptom distress and HRQOL of pelvic 
floor dysfunction.
· Using the Cochrane methodology, evidence of limited quality was found that in-
traurethral Botulinum toxin A injections improve some urodynamic measures after 
30 days in the treatment of functional bladder outlet obstruction in adults with 
neurogenic bladder dysfunction.
· Our Dutch multidisciplinary guidelines “Neurogene blaas” provide an overview 
of the available evidence for adequate diagnosis, treatment, and follow-up of 
patients suffering from neurogenic bladder.
As PROMs are designed to provide relevant insight in the self-perceived impact of 
pelvic floor dysfunction on the HRQOL of the individual patient, which cannot be 
captured with objective medical testing, we believe both should be correspond-
ingly weighted when determining and providing good medical care.  Along with the 
presented evidence-based management strategies in this thesis, we can contribute 
to shared decision making, as this is defined as: ‘an approach where clinicians and 
patients share the best available evidence when faced with the task of making deci-
sions, and where patients are supported to consider options, to achieve informed 
preferences’. 22
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In dit proefschrift worden traditionele en patiënt gerapporteerde uitkomstmaten 
gepresenteerd. Deze uitkomstmaten hebben als doel om functionele klachten van de 
bekkenbodem te evalueren. 
trADitioneLe uitkomstmAten
Urine incontinentie na operatieve prostaatverwijdering (prostatectomie) blijft ondanks 
de hedendaagse diagnostische en therapeutische innovaties, zoals de MRI-scanner 
(magnetic resonance imaging) en robot geassisteerde ingrepen, een belangrijke zorg 
voor patiënten. Tot op heden is de kunstmatige sfincter prothese de standaard behan-
deling voor ernstige of aanhoudende urine incontinentie. In de afgelopen jaren zijn 
op het gebied meerdere vooruitstrevende behandelingen geïntroduceerd.1 Hieron-
der vallen onder andere de kunstmatige sfincter prothese, bulkinjecties, plaatsing van 
bandjes (male sling) en sluitspierballonnen (Adjustable Continence Therapy: ProACT). 
Gezien er steeds meer wetenschappelijk bewijs is voor het gebruik en effectiviteit van 
deze behandelingen, worden de verschillende indicaties ook steeds specifieker. Om 
die reden is evaluatie vóór de interventie belangrijk, zoals urodynamisch onderzoek 
welke een beeld geeft van de gezondheidstoestand van de patiënt. Dit zal tevens 
helpen in de besluitvorming welke interventie het beste past bij de individuele patiënt 
om tot een zo goed mogelijk behandelingsresultaat te komen.
In het eerste deel van dit proefschrift wordt een van de belangrijkste diagnostische 
onderzoeken binnen de functionele urologie belicht: het urodynamisch onderzoek. 
Dit functie onderzoek van de lage urinewegen levert fysiologische waarden (traditio-
nele uitkomstmaten) op van de urine blaas, sluitspier (‘sfincter’) en plasbuis (‘urethra’) 
tijdens blaasvulling en –lediging. Deze waarden worden door de arts geïnterpreteerd 
en hebben als doel om de oorzaak en de aard van de blaasdisfunctie te diagnostice-
ren. In hoofdstuk 1 worden de urodynamische veranderingen na implantatie van de 
sluitspierballonnen ProACT beschreven. ProACT is een minimaal invasieve implantaat 
die bestaat uit twee ballonnen geplaatst aan weerszijden van de plasbuis vlak bij de 
blaas.2 Het volume van de ballonnen zijn na implantatie aan te passen. Dit wordt 
gedaan via een slangetje met een ventiel dat aan het ballonnetje zit. Dit ventiel wordt 
onderhuids in de balzak geplaatst en is dan goed bereikbaar voor het bijvullen. Door 
het volume van de ballon aan te passen wordt er bilaterale compressie gegeven op 
de urethra tot een optimum tussen blaaslediging en continentie is bereikt. De implan-
tatie van ProACT bij incontinente mannen na prostaatverwijdering was succesvol als 
de patiënt geen of één droge incontinentie inlegger (‘voor de zekerheid’) gebruikte. 
De behandeling werd als niet succesvol bevonden als de patiënt aangaf minimaal 
één natte inlegger te hebben per dag. De mannen in ons onderzoek die succesvol 
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werden behandeld met ProACT (37 van de 49 mannen), hadden bij het urodynamisch 
onderzoek ná implantatie een toegenomen urethrale weerstand en een afgenomen 
blaascontractiekracht vergeleken met urodynamisch onderzoek vóór implantatie. Dit 
leidde echter niet tot klinische blaasobstructie, daar de patiënten geen significante 
residu na mictie of symptomatische urineweginfecties doormaakten gedurende fol-
low-up. Onafhankelijke factoren van niet-succesvolle ProACT implantatie waren een 
langere duur van urine incontinentie, ernstigere incontinentie (d.w.z. meer dan vijf 
incontinentie inleggers per dag) en een kleinere cystometrische blaascapaciteit voor 
implantatie. Deze resultaten wekken de suggestie dat ProACT implantatie – wat im-
mers een minimaal invasieve en reversibele behandeling is – een eerste chirurgische 
optie is in de behandeling van incontinentie na prostaatverwijdering als conservatieve 
behandelingen hebben gefaald.3 Het zou op zijn minst moeten worden overwogen 
alvorens er gekozen wordt voor meer invasieve operatieve technieken zoals de 
kunstmatige sfincter prothese, zeker voor patiënten met een minder ernstige vorm van 
incontinentie. Er zijn uiteraard meer onderzoeken nodig voordat klinische algoritmen 
kunnen worden ontworpen, maar onze resultaten laten zien dat dergelijke traditio-
nele uitkomstwaarden belangrijk zijn voor het maken van een individuele keuze van 
de te vervolgen behandelstrategie. Het is duidelijke dat de aanpasbare ballonnen niet 
een optie zijn voor alle mannen en er hier gekeken moet worden naar de subgroepen 
die er het beste mee geholpen worden. De toekomstige rol die ProACT ballonnen 
gaan krijgen hangt af van de uiteindelijke bruikbaarheid die mede bepaald wordt door 
toepassing in correct geselecteerde patiëntengroepen. Ongetwijfeld blijft de behan-
deling van urine incontinentie bij mannen een klinisch probleem doordat er nog geen 
universele succesvolle oplossing voorhanden is. 
PAtiënt-GerAPPorteerDe uitkomstmAten
Urine incontinentie is een symptoom van inadequate urine opslag door de blaas en 
daarom een teken van blaasdysfunctie. De standardisation sub-committee of the Inter-
national Continence Society (ICS) definieert de klacht als “elke vorm van onvrijwillige 
urine verlies”.4 Dit is een definitie die voornamelijk geschikt lijkt te zijn voor gebruik 
in epidemiologisch onderzoek. De definitie “onvrijwillig urineverlies dat tot een so-
ciaal of hygiënisch probleem leidt” legt meer de nadruk op de hinder en is daardoor 
geschikter als er gekeken wordt naar de prevalentie van de hinder van incontinen-
tieklachten.5 Een enkele en precieze definitie voor incontinentie ontbreekt en dit 
zorgt ervoor dat de resultaten van verschillende onderzoeken niet goed onderling te 
vergelijken zijn. Dit is ook het geval bij uitkomstmaten over de ernst of hinder van in-




is geen levensbedreigende aandoening, maar het heeft zeker een negatieve impact 
op de psychische gezondheid van patiënten. Het hindert aspecten van het dagelijkse 
leven en heeft daardoor een nadelig effect op de kwaliteit van leven.6 
Uitkomstmaten die het perspectief van de patiënt meenemen worden patiënt-
gerapporteerde uitkomstmaten (patient reported outcome measures: PROMs) ge-
noemd. Dit zijn uitkomstmaten die door de patiënten zelf worden gerapporteerd 
waarin zij hun gezondheidstoestand aangeven zoals symptomen, functionele status 
en gezondheidsafhankelijke kwaliteit van leven (health-related quality of life: HROQL). 
PROMs zijn belangrijke maten in het beoordelen van de therapeutische effectiviteit, 
zeker in het geval van aandoeningen die de bekkenbodem betreffen. Gevalideerde 
Nederlandstalige PROMs voor gebruik bij patiënten met bekkenbodemproblematiek 
waren echter niet voldoende voorhanden. Om die reden zijn in het tweede deel 
van dit proefschrift veelgebruikte Engelstalige bekkenbodemvragenlijsten vertaald 
en aangepast voor de Nederlandse taal. Van deze Nederlandse PROMs hebben we 
de psychometrische eigenschappen getest. De cross-culturele vertaling naar het 
Nederlands is volgens richtlijnen uitgevoerd: drie onafhankelijke heen-vertalingen 
(vanuit het Engels naar het Nederlands) en een terug-vertaling (vanuit het Nederlands 
weer naar het Engels) door personen met de doeltaal als moedertaal.7 Daaropvolgend 
werd elke Nederlandse PROM getest (‘pilot test’): patiënten vulden de vragenlijsten in 
en werden achteraf geïnterviewd ondersteund door een checklist over de betekenis 
van de vragen en antwoorden om potentiele problemen op te sporen. Na de pilot 
test waren de vragenlijsten klaar voor gebruik. Patiënten met bekkenbodemklachten 
werden gevraagd om de vragenlijsten in te vullen op drie verschillende momenten: 
op de dag van inclusie, 1 week na inclusie en 6 maanden na inclusie. Bij de laatste vra-
genlijst was een gezondheidsverandering item toegevoegd van de RAND-36.8-10 Door 
gebruik te maken van de kwaliteitscriteria zoals opgesteld door het EMGO instituut11 
hebben we de psychometrische eigenschappen getest van de door ons vertaalde 
ziekte-specifieke PROMs: 
· De korte versie van de Urogenital Distress Inventory (UDI-6) en Incontinence Impact 
Questionnaire (IIQ-7) (Hoofdstuk 2) om urine incontinentieklachten te evalueren,
· De korte versie van de Pelvic Floor Distress Inventory (PFDI-20) en Pelvic Floor Impact 
Questionnaire (PFIQ-7) (Hoofdstuk 3) om bekkenbodemklachten te evalueren,
· de Fecal Incontinence Quality of Life Questionnaire (FIQL) en de Fecal Incontinence 
Severity Index (FISI) (Hoofdstuk 4) om klachten van ontlastingsincontinentie te 
evalueren,
· de korte versie van de Pelvic Organ Prolapse/Urinary Incontinence Sexual Function 




· de 5-item International Index of Erectile Function (IIEF-5) (Hoofdstuk 6) om erectie-
klachten te evalueren.
Alle hierboven genoemde PROMs hadden een adequate interne consistentie en zijn 
daarom betrouwbare en valide instrumenten om de hinder van symptomen van bek-
kenbodemklachten en de HRQOL te evalueren. De UDI-6, IIQ-7, PFDI-20 en PFIQ-7 
bleken ook responsief te zijn, dat wil zeggen dat deze vragenlijsten werkelijke veran-
deringen konden meten over de tijd. De PFDI-20 en PFIQ-7 hadden een adequate 
interpreteerbaarheid: een kwalitatieve betekenis aan een kwantitatieve score kon 
worden toegerekend. De UDI-6 en IIQ-7 die oorspronkelijk ontwikkeld en gevali-
deerd zijn voor gebruik bij vrouwen hebben we ook kunnen valideren voor gebruik 
bij mannen door een geslacht specifieke vraag te reviseren. 
Om een PROM te kunnen gebruiken als evaluatie instrument in de gezondheidszorg 
dient deze betrouwbaar en valide te zijn. Betrouwbaarheid en validiteit zijn continue 
en eigenlijk nooit dichotome variabelen. Om die reden is het incorrect om te zeggen 
dat een instrument ‘volledig betrouwbaar’ of ‘volledig valide’ is. Betrouwbaarheid en 
validiteit zijn aparte psychometrische eigenschappen. Instrumenten zouden zeer be-
trouwbaar kunnen zijn en tegelijk niet meten wat het beoogt te meten. Daardoor is de 
eigenschap betrouwbaarheid noodzakelijk, doch niet op zichzelf staand voldoende 
om valide te zijn. Eveneens, concluderen dat een instrument is ‘gevalideerd’ zegt niets 
meer dan dat het gebruik of de psychometrische eigenschappen zijn geëvalueerd. 
Omdat dit echter een gebruikelijke manier is van het samenvatten van bevindingen 
in PROM-gerelateerd onderzoek, hebben we eveneens onze conclusies op deze 
manier gesteld. Informatie over de betrouwbaarheid en validiteit van een instrument 
is belangrijk, maar deze eigenschappen moeten wel worden beoordeel in de context 
waarin deze wordt gebruikt. Een goed voorbeeld is de IIEF-5 die vooral bedoeld is om 
het klinische oordeel te ondersteunen en als hulpmiddel voor diagnostiek, niet om de 
anamnese te vervangen (zie ook Hoofdstuk 6). 
Op het gebied van functionele urologie zijn taalkundig aangepaste en psycho-
metrisch adequate PROMs waardevol daar het behandelsucces afhankelijk is van 
het perspectief van de patiënt op hun kwaliteit van leven en mogelijkheden in het 
dagelijkse functioneren. Gevalideerde PROMs zouden daarom een sleutelrol moeten 
vervullen in de ontwikkeling en evaluatie van behandelingen, naast de traditionele 
uitkomstmaten zoals urodynamische waarden, chirurgische complicaties en mor-
biditeit aantallen. PROMs kunnen clinici in de dagelijkse praktijk ondersteunen om 
bijvoorbeeld de lange termijn resultaten van een interventie op de impact of HRQOL 
te beoordelen over de tijd, aangezien deze doorgaans fluctueren. Het systematisch 
verzamelen van informatie over subjectieve bekkenbodemklachten is vooral relevant 
zodra de keuze wordt gemaakt door te gaan met meer invasieve behandelingen. 




er gedacht wordt dat dit extra werk met zich meebrengt. Ook zijn er artsen die menen 
dat ze al voldoende hebben aan de anamnese om te begrijpen welke hinder patiënten 
ondervinden en hier geen PROMs voor nodig hebben.12 Aan de andere kant, patiënten 
staan doorgaans wel open voor een systematiek waarin routinematig PROMs worden 
gebruikt mits deze niet de aandacht verschuift van het klinische bezoek, niet alleen 
aandacht vestigt op items die voor de arts zelf interessant zijn en als het niet teveel 
moeite kost.12 Om dergelijke barrières te doorbreken zouden PROMs dus kort en 
makkelijk in te vullen zijn. In de toekomst zijn beveiligde elektronische vragenlijsten 
middels interactieve programma’s en toepassingen vermoedelijk een vereiste voor 
succesvolle implementatie van PROMs in de dagelijkse praktijk. 
Een ander punt waar naar gekeken dient te worden alvorens de Nederlandse vra-
genlijsten kunnen worden geïmplementeerd is de toepasbaarheid in andere klinische 
settings. Onze studies werden allemaal verricht in een derdelijns urogynaecologische 
centrum waar patiënten over het algemeen ernstigere symptomen hebben van bek-
kenbodemklachten. De mate waarin de resultaten van onze studies doorgetrokken 
mogen worden naar de algehele populatie is dus beperkt. Allereerst in de eerstelijns-
zorg is een hogere prevalentie van thuiswonende ouderen met urogenitale klachten. 
Een Nederlands onderzoek liet zien dat 64% van de 255 deelnemende vrouwen 
van 55 jaar en ouder nooit hun klachten van urine incontinentie (minimaal één keer 
per maand onvrijwillig urineverlies) hadden besproken bij hun eigen huisarts.13 De 
hoofdredenen hiervan waren: het gevoel hebben dat incontinentie niet een serieuze 
klacht is (73%), zelf een manier hadden bedacht hoe hiermee om te gaan (57%), urine 
incontinentie beschouwen als een normaal verloop bij het ouder worden (47%) en 
weinig verwachten van een behandeling (24%). Het benoemen van deze klachten 
aan een professional blijkt echter niet altijd afdoende te zijn; er zijn huisartsen die 
niet reageren als een patiënt deze klacht meldt door deze klacht te negeren of door 
een afwijzende reactie. Patiënten nemen dan aan dat het uitblijven van een reactie 
van een arts een aanwijzing is dat er geen behandeling voorhanden is. In een ander 
onderzoek werd aangetoond dat 30% van de vrouwen die het probleem bij hun arts 
neerlegden geen hulp aangeboden kregen.14 Mogelijk weten eerstelijns hulpverleners 
geen raad hoe om te gaan met klachten van urine incontinentie en dit draagt weer bij 
aan de onderbehandeling van patiënten die wél hulp zoeken. Gevalideerde PROMs 
zouden huisartsen goed kunnen helpen bij het interpreteren van de ernst van de 
functionele bekkenbodemklachten. Dit faciliteert op zijn beurt de beslissing van de 
te ondernemen vervolgstappen bijvoorbeeld door te verwijzen naar een specialist. 
Door educatie te geven aan huisartsen over bekkenbodemklachten zou de toegang 
van de zorg voor de patiënt kunnen verbeteren.15 
Alvorens PROMs in de eerste lijn kunnen worden toegepast moet er rekening ge-
houden worden met de specifieke karakteristieken van de patiëntenpopulatie in de 
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eerste lijn. Patiënten uit de eerste lijn hebben namelijk een breder scala aan klachten 
en aandoeningen die vaak ook nog in een vroeg ongedifferentieerd stadium worden 
gepresenteerd. Sommige klachten hiervan zijn slechts mild van aard en tijdelijk van 
duur. Algemene gezondheidsvragenlijsten hebben om deze reden waarschijnlijk de 
voorkeur boven ziekte-specifieke vragenlijsten, daar deze verschillende domeinen 
bevraagt over de algehele breedte van de gezondheid.16,17
eViDenCe bAseD meDiCine in De FunCtioneLe uroLoGie
In het derde deel van dit proefschrift wordt er aandacht geschonken aan het we-
tenschappelijke bewijs (evidence based medicine: EBM) in klinisch onderzoek van 
neurogeen blaaslijden. Bij neurogeen blaaslijden is bescherming van de hogere urine-
wegen het hoofddoel van urologische behandeling.18 Patiënten met detrusor-sfincter 
dyssynergie (DSD) kunnen hoge blaasdrukken ontwikkelen wat tot een pathologische 
hoge drukblaas kan leiden. In dat geval moet de blaas omgevormd worden naar een 
lage druk reservoir. Als conservatieve behandeling tekortschiet moeten chirurgische 
opties worden overwogen. Sinds de introductie van endoscopische sfincterotomie in 
195819 als behandeling van functionele obstructie ter hoogte van de externe sfincter 
bij neurogeen blaaslijden, zijn er diverse nieuwe chirurgische opties ontwikkeld. In 
Hoofdstuk 7 hebben we gekeken naar de effectiviteit van diverse chirurgische thera-
pieën voor de behandeling van functionele blaasobstructie door DSD bij patiënten 
met neurogeen blaaslijden. Er bestaat geen consensus over de vraag wat de optimale 
chirurgische behandeling is van neurogeen blaaslijden door de grote verscheiden-
heid in mogelijkheden. Wij hebben daarom een Cochrane systematische review 
verricht om de optimale behandeling te identificeren voor patiënten met DSD. De 
Cochrane Collaboration is een internationale, onafhankelijke, non-profit organisatie 
met als missie zorgverleners, beleidsmakers en patiënten te helpen bij het nemen van 
beslissingen over gezondheidszorg.  Zij doet dit door het maken van systematische 
samenvattingen van al het beschikbare wetenschappelijke onderzoek betreffende het 
effect (of het ontbreken daarvan) van gezondheidszorginterventies.20 Door gebruik 
te maken van de Cochrane methodiek verkleinden we het risico op bias waardoor 
we zoveel mogelijk betrouwbare conclusies konden trekken. In ons review vonden 
we bewijs van beperkte kwaliteit voor de behandeling middels intra-urethrale Bo-
tulinum toxine A injecties. Urodynamische uitkomsten gerelateerd aan de blaas- en 
urethrafunctie verbeterden 30 dagen na injectie. Desalniettemin is er niet voldoende 





Er wordt vaak gedacht dat door alleen gerandomiseerd gecontroleerd onderzoek te 
includeren in Cochrane reviews er een heleboel gepubliceerde data die wel zouden 
kunnen bijdragen worden uitgesloten. Echter, Alper e.a. hebben onderzocht hoe 
vaak conclusies getrokken uit Cochrane reviews een twijfelachtige validiteit hadden 
als gevolg van de manier van het uitvoeren van de review (review conduct en reporting 
deficiencies). Zij concludeerden dat Cochrane reviews van hoge kwaliteit zijn met in 
minder dan 1% van de gevallen beperkingen die het beste bewijs voor het nemen van 
klinische beslissingen in de weg zaten.21 Echter in de dagelijkse gang van zaken kan 
iets toch worden gezien als een adequate behandeloptie zonder dat dit wetenschap-
pelijke wordt ondersteund door onderzoek naar de effectiviteit middels placebo 
gecontroleerd bewijs. Dit is vooral het geval bij interventies met lage risico’s en lage 
kosten. 
Tenslotte, in Hoofdstuk 8 staan multidisciplinaire wetenschappelijk ondersteunde 
richtlijnen voor de behandeling van patiënten met klachten neurogene blaas in 
Nederland. Met deze richtlijnen bieden we informatie voor behandelaren over de 
incidentie, definities, diagnose, behandelingen en follow-up van neuro urologische 
aandoeningen. De richtlijnen hebben als doel om de clinicus te ondersteunen in het 
maken van beslissingen op dit gebied. De werkgroep bestond uit leden van de Ne-
derlandse Vereniging van de Urologie, de Nederlandse Vereniging voor Neurologie, 
de Nederlandse Vereniging van Revalidatieartsen, Verenso, V&VN Continentie Ver-
pleegkundigen & Verzorgenden en de patiëntenorganisaties Dwarslaesie Organisatie 
Nederland en Organisatie BOSK.
ConCLusie
Dit proefschrift verschaft belangrijke resultaten met betrekking tot de evaluatie van 
functionele stoornissen van de bekkenbodem bij zowel mannen als vrouwen. Hier is 
gebruik gemaakt van traditionele uitkomstmaten evenals PROMs. De conclusies die 
kunnen worden getrokken uit dit proefschrift zijn:
· Succesvolle ProACT-implantatie resulteerde in een toegenomen urethrale weer-
stand tijdens mictie en een afgenomen blaasconcentratiekracht.
· Onafhankelijke voorspellers voor een succesvolle ProACT-implantatie zijn een 
langere incontinentieduur, het gebruik van vijf of meer incontinentie verbanden 
per dag en een kleinere cystometrische blaascapaciteit.
· De gepresenteerde Nederlandse korte vragenlijsten UDI-6 en IIQ-7 voor de be-
oordeling van urine-incontinentie, de PFDI-20 en PFIQ-7 voor de beoordeling van 
bekkenbodemklachten, de FIQL en FISI voor de beoordeling van ontlastingsincon-
tinentie, de PISQ-12 voor de beoordeling van prolaps en seksualiteit en de IIEF-5 
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voor de beoordeling van erectieklachten, hadden allemaal een adequate interne 
consistentie en zijn derhalve betrouwbare en geldige (valide) instrumenten voor 
het beoordelen van symptomen en HRQOL van bekkenbodemklachten.
· Er is bewijs van beperkte kwaliteit dat intra-urethrale Botulinum toxine A injecties 
voor de behandeling van functionele blaas obstructie na 30 dagen een aantal uro-
dynamische waarden verbeterden bij volwassenen met neurogene blaasklachten.
· De Nederlandse multidisciplinaire richtlijnen "Neurogene blaas" geven een 
overzicht van het beschikbare bewijs voor adequate diagnose, behandeling en 
follow-up van patiënten met klachten van neurogene blaaslijden.
Daar PROMs het inzicht geven in de HRQOL van bekkenbodemklachten en tradi-
tionele onderzoeksmethoden dit niet doen, zijn wij van mening dat beide soorten 
uitkomstmaten naar ratio moeten worden toegepast voor adequate gezondheidszorg. 
Samen met de gepresenteerde EBM strategieën uit dit proefschrift leveren we een be-
langrijk aandeel aan gezamenlijke besluitvorming (shared decision making). Dit laatste 
is namelijk gedefinieerd als een gezamenlijk proces van zorgverlener en patiënt over 
gezondheids- en behandelingsdoelen welke worden gesteld op basis van weten-
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UDI-6: Urogenitale Klachten Lijst 
 
 
In hoeverre heeft u van het volgende last: 
 
(Kruis één vakje per regel aan) Helemaal niet Een beetje Redelijk wat Zeer veel 
 
1. Vaak plassen 
    
    
    
 
2. Urineverlies dat verband houdt 











3. Urineverlies dat verband houdt 
met lichamelijke activiteit, 
































    
 
6. Pijn of ongemak in de 
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u 
IIQ-7: vragenlijst impact van incontinentie 
 
Sommige mensen vinden dat ongewild urineverlies invloed kan hebben op hun activiteiten, 
relaties en gevoelens. De onderstaande vragen gaan over facetten van uw leven die misschien zijn 
beïnvloed of veranderd door uw probleem. 
 
Kruis bij elke vraag het antwoord aan, dat het best omschrijft in hoeverre uw activiteiten, relaties 
en gevoelens zijn beïnvloed door urineverlies. 
 
Heeft urineverlies invloed gehad op uw…. 
 
(Kruis één vakje per regel aan) Helemaal niet Een beetje Redelijk wat Zeer veel 
 
1. vermogen om huishoudelijke 
taken te doen (koken, 
schoonmaken, de was doen)? 
    
    
    
 
2. lichamelijke activiteiten zoals 























4. vermogen om langer dan 30 
minuten van uw huis met de auto 






















6. emotionele gezondheid 
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PFDI-20: inventaris van bekkenbodemproblemen 
 
 
Wilt u alstublieft alle vragen van onderstaande lijst beantwoorden? Er wordt gevraagd of u 
bepaalde darm, blaas of bekkenbodem symptomen heeft, en zo ja, in hoeverre u daar last van 
heeft.  
 




• Indien u gewoonlijk GEEN drukkend gevoel in de onderbuik heeft, zet dan een X in het vakje bij 
“Nee” en ga door met de volgende vraag. 
• Indien u gewoonlijk WEL een drukkend gevoel heeft in de onderbuik, zet dan een X in het vakje bij 
“ja” én geef aan in hoeverre u daar last van heeft. Ga daarna door met de volgende vraag. 
 
 
1. Heeft u gewoonlijk een drukkend gevoel in de onderbuik? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
2. Heeft u doorgaans een zwaar of verdoofd gevoel in het bekkengebied? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
3. Heeft u gewoonlijk een uitstulping of komt er iets naar buiten, dat u kunt zien of voelen in 
het gebied van uw vagina? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
4. Moet u doorgaans op de vagina of rond de endeldarm drukken om ontlasting te hebben of 
om het af te kunnen maken? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
5. Heeft u gewoonlijk het gevoel dat u uw blaas niet volledig leeg plast? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 







Ga naar vraag 6  
op de volgende pagina 
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6. Heeft u ooit met uw vingers op een uitstulping moeten drukken in het gebied van de vagina 
om te kunnen plassen of om het plassen af te kunnen maken? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
7. Heeft u het gevoel dat u teveel moet persen om ontlasting te kunnen hebben? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
8. Heeft u het gevoel dat uw darmen nog niet helemaal leeg zijn na de ontlasting? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
9. Heeft u gewoonlijk ongecontroleerd ontlastingverlies als uw ontlasting goed gevormd is? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
10. Heeft u gewoonlijk ongecontroleerd ontlastingverlies als uw ontlasting dun is? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
11. Heeft u gewoonlijk ongecontroleerde winderigheid uit uw endeldarm? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
12. Heeft u doorgaans pijn tijdens de ontlasting?  
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
13. Ervaart u een sterk aandranggevoel en moet u zich haasten naar het toilet voor de 
ontlasting? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
14. Komt een deel van uw darmen wel eens door de anus en stulpt die uit tijdens of na de 
ontlasting? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 




Ga naar vraag 15  




Utomo et al. Int Urogynecol J. 2014 Apr;25(4):531-44. 
15. Moet u gewoonlijk vaak plassen? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
16. Heeft u doorgaans urineverlies dat verband houdt met een gevoel van aandrang; oftewel een 
sterk gevoel dat u naar het toilet moet gaan? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
17. Heeft u gewoonlijk urineverlies dat verband houdt met  hoesten, niezen of lachen? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
18. Heeft u doorgaans kleine hoeveelheden urineverlies (druppels)? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
19. Heeft u gewoonlijk moeite uw blaas te legen? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
20. Heeft u doorgaans pijn of ongemak in de onderbuik of rond het kruis? 
 nee   ja 
 Zo ja, in hoeverre heeft u daar last van? 
 helemaal niet   een beetje    redelijk wat   vrij veel 
 
 
Einde van vragenlijst PFDI-20 
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PFIQ-7: vragenlijst impact bekkenbodemklachten 
 
 
Sommige vrouwen vinden dat blaas, darm of vaginale klachten invloed kunnen hebben 
op hun activiteiten, relaties en gevoelens.  
 
Zet achter elke vraag een X bij het antwoord dat het best beschrijft in hoeverre uw 
activiteiten, relaties en gevoelens zijn beïnvloed door uw blaas, darm of vaginale klachten 
of aandoeningen in de afgelopen 3 maanden.  
 
Mogelijk heeft u wel of geen klachten in elk van deze drie gebieden, maar vult u 
alstublieft altijd een antwoord in, in alle drie de kolommen bij elke vraag.  
Indien u geen klachten heeft in deze gebieden dan zou het juiste antwoord “Helemaal niet” 
zijn in de bijbehorende kolom van de vraag. 
 
In hoeverre beïnvloeden klachten 
of aandoeningen gerelateerd aan, 
uw:  
 
Blaas of urine 
 
Darm of endeldarm 
 
Vagina of bekken 
 
1. vermogen om huishoudelijke 
taken te doen (koken, 

















2. vermogen om lichamelijke 
activiteiten uit te voeren, zoals 




































4. vermogen om te reizen met de 
auto of bus op een afstand van 




































6. emotionele gezondheid 






































FIQL: Ontlasting (fecale) Incontinentie 
Kwaliteit van Leven Schaal 
 
 
1. Hoe zou u over het algemeen uw gezondheid noemen: 























De volgende uitspraken gaan over ongewild ontlastingverlies.  
Wilt u voor elk van onderstaande uitspraken aangeven, hoe vaak dit een probleem voor u is? 
Als één van onderstaande uitspraken een probleem voor u is vanwege een andere reden dan ongewenst 
ontlastingverlies, kruis dan het hokje “niet van toepassing” (n.v.t.) aan. 
 
2. Als gevolg van ongewenst ontlastingverlies: 




a. Ben ik bang om uit te gaan.      
b. Vermijd ik bezoek aan vrienden.      
c. Vermijd ik een nacht ergens anders te slapen 
dan thuis.      
d. Vind ik het lastig uit te gaan en dingen te doen, 
zoals naar de bioscoop of naar de kerk gaan.      
e. Eet ik minder voordat ik uitga.       
f. Probeer ik zoveel mogelijk in de buurt van een 
toilet te blijven als ik van huis ben.      
g. Is het belangrijk dat ik mijn dagelijkse 
activiteiten afstem op mijn ontlastingpatroon.      
h. Vermijd ik reizen.      
i. Maak ik mij zorgen dat ik niet op tijd het toilet 
haal.      
j. Heb ik het gevoel geen controle over mijn 
darmen te hebben.      
k. Kan ik mijn ontlasting niet lang genoeg 
ophouden voordat ik bij het toilet ben.      
l. Verlies ik ontlasting zonder dat ik dit merk.      
m. Probeer ik ongelukjes te voorkomen door in de 
buurt te blijven van een toilet.      









De volgende uitspraken gaan over ongewild ontlastingverlies.  
Wilt u voor elk van onderstaande uitspraken aangeven in hoeverre u het hiermee eens of oneens bent? 
Als één van onderstaande uitspraken een probleem voor u is vanwege een andere reden dan ongewenst 
ontlastingverlies, kruis dan het hokje “niet van toepassing” (n.v.t.) aan. 
 
3. Als gevolg van ongewenst ontlastingverlies: 










a. Schaam ik mij.      
b. Kan ik veel dingen niet doen, die ik 
wil doen.      
c. Maak ik mij zorgen om ongelukjes 
met ontlasting.      
d. Voel ik mij somber.      
e. Maak ik mij zorgen dat anderen mij 
naar ontlasting vinden ruiken.      
f. Heb ik het gevoel dat ik geen 
gezond persoon ben.      
g. Geniet ik minder van het leven.      
h. Heb ik minder vaak seks dan ik 
zou willen.      
i. Voel ik mij anders dan andere 
mensen.      
j. Ben ik me constant bewust van de 
kans op ongelukjes.      
k. Ben ik bang om seks te hebben.      
l. Vermijd ik reizen met het vliegtuig 
of de trein.      
m. Vermijd ik uit eten gaan.      
n. Als ik naar een onbekende plek ga, 
zoek ik altijd eerst uit waar het toilet 
is. 
     
 
4. Heeft u zich in de afgelopen maand zo verdrietig, ontmoedigd, hopeloos gevoeld, of heeft u 
zoveel problemen gehad dat u zich afvroeg of het allemaal nog wel zin had? 





tot het punt dat 














genoeg om me 
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Wilt u voor elk van de onderstaande vormen van ongewenst ontlastingverlies aangeven hoe vaak 
u er gemiddeld last van had, ongeacht de hoeveelheid. 
 
Denk aan uw klachten van de afgelopen maand.  
 
(Kruis één vakje per regel aan) 2 of meer 
keer per dag 
1 keer per 
dag 
2 of meer 
keer per 
week 
1 keer per 
week 

































































Einde van vragenlijst FISI 
262
Vragenlijsten
’t Hoen et al. Int Urogynecol J. 2015 Sep;26(9):1293-303. 
Einde van vragenlijst PISQ-12
 
PISQ-12: vragenlijst over bekkenbodemverzakking/ 
urine-incontinentie en seksueel functioneren 
 
 
Hieronder vindt u een lijst met vragen over u en uw partners seksleven. Alle informatie is strikt 
vertrouwelijk. Uw vertrouwelijke antwoorden zullen uitsluitend worden gebruikt om artsen te 
helpen begrijpen wat voor patiënten belangrijk is voor hun seksleven. 
 
Bij het beantwoorden van de vragen moet u denken aan uw seksleven in de afgelopen zes maanden. 
(Kruis één vakje per regel aan) Altijd Gewoonlijk Soms Zelden Nooit 
 
1. Hoe vaak heeft u behoefte aan seks?  
Dit gevoel kan inhouden zin in seks hebben, plannen om 














2. Komt u tot een hoogtepunt (heeft u een 














3. Voelt u zich seksueel opgewonden wanneer u 














4. Hoe tevreden bent u over de afwisseling van 











































7. Beperkt de angst voor urine- of 














8. Vermijdt u geslachtsgemeenschap vanwege een 
uitstulping in de vagina (bijvoorbeeld de blaas, 













9. Wanneer u seks heeft met uw partner, ervaart u 
dan negatieve emotionele reacties zoals angst, 













10. Heeft uw partner een probleem met erecties 














11. Heeft uw partner een probleem met voortijdig 














12. Hoe intens zijn uw orgasmen de afgelopen 6 
maanden, in vergelijking met orgasmen die u in 
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IIEF-5: Seksuele gezondheidsinventaris voor mannen 
 
 
Seksuele gezondheid is een belangrijk onderdeel van het lichamelijke en geestelijk welbevinden van een 
individu. Erectiestoornissen zijn veel voorkomende seksuele klachten. Er zijn veel verschillende 
mogelijkheden om erectiestoornissen te behandelen. Deze vragenlijst is ontwikkeld om u en uw arts te 
helpen ontdekken of u misschien last heeft van erectiestoornissen en om eventueel 
behandelingsmogelijkheden te bespreken. 
 
In de afgelopen zes maanden:     
 
1. Hoe beoordeelt u uw vertrouwen om een erectie te krijgen en te behouden? 
(Omcirkel het juiste antwoord) 
 
 Erg laag Laag Gemiddeld Hoog Erg hoog 
      
2. Als u erecties had met seksuele stimulatie*, hoe vaak waren uw erecties hard genoeg voor penetratie? 





Een paar keer (veel 
minder dan de helft van 
het aantal keer) 
Soms 
(ongeveer de helft 
van het aantal keer) 
Meestal 
(veel meer dan de helft 
van het aantal keer) 
Bijna altijd/altijd 
      
3. Tijdens de gemeenschap**, hoe vaak was u in staat om uw erectie te behouden nadat u bij uw 
partner naar binnen was gegaan (gepenetreerd)? 





Een paar keer (veel 
minder dan de helft van 
het aantal keer) 
Soms 
(ongeveer de helft 
van het aantal keer) 
Meestal 
(veel meer dan de helft 
van het aantal keer) 
Bijna altijd/altijd 
      
4. Tijdens de gemeenschap**, hoe moeilijk was het om uw erectie te behouden tot het volbrengen van de 
geslachtsdaad? 




Heel erg moeilijk Erg moeilijk Moeilijk Een beetje moeilijk Niet moeilijk 
      
5. Wanneer u gemeenschap** had, hoe vaak was het bevredigend voor u? 





Een paar keer (veel 
minder dan de helft van 
het aantal keer) 
Soms 
(ongeveer de helft 
van het aantal keer) 
Meestal 
(veel meer dan de helft 
van het aantal keer) 
Bijna altijd/altijd 
      
*) Seksuele activiteit: Hieronder verstaan we bijv. erotisch spel met een partner, erotische afbeeldingen bekijken, etc. 























Met dit laatste hoofdstuk van het proefschrift is een eind gekomen aan mijn promotie-
traject. Een traject dat niet succesvol afgesloten had kunnen worden zonder de bij-
drage en steun van vele betrokkenen. Een aantal mensen wil ik hierbij in het bijzonder 
bedanken. 
Een speciaal woord van dank gaat uit naar alle patiënten die deel uit hebben ge-
maakt van mijn onderzoeken. Veel dank voor hun bereidheid om alle vragenlijsten in 
te vullen. Zonder hen hadden de onderzoeken in dit proefschrift niet tot stand kunnen 
komen. 
Allereerst dank aan mijn twee co-promotoren, dr. B.F.M. Blok en dr. I.J. Korfage. Beste 
Bertil, bedankt voor je sterke klinische blik, je gedrevenheid en begeleiding. Je wist 
me met je optimisme en creativiteit altijd weer de goede richting te wijzen wanneer 
ik even vastliep in de diverse projecten. Beste Ida, dank voor je snelle, enthousiaste, 
maar altijd kritische noten bij mijn manuscripten. Jouw grote kennis over vragenlijsten 
en methodologie zijn van enorme waarde geweest voor dit proefschrift. 
Mijn promotor, Prof.dr. C.H. Bangma. Beste Chris, hartelijk dank voor je begeleiding 
gedurende de afgelopen jaren. Ik heb veel gehad aan je betrokkenheid en kritische 
blik, en vond het heel plezierig dat ik altijd bij je terecht kon voor overleg of een vraag.
Beste leden van de leescommissie en promotiecommissie, dank voor jullie kritische 
beoordeling van mijn proefschrift en jullie bereidheid om te opponeren. Een speciaal 
woord van dank aan Prof.dr.ir. R. van Mastrigt. Beste Ron, ik heb met veel plezier met 
je samengewerkt en veel van je geleerd over de urodynamica. Ik heb het heel erg 
gewaardeerd dat je me altijd hebt betrokken bij de ‘Furore’ groep. En de onderzoeken 
met de Dino kar zal ik nooit meer vergeten. 
Dank aan alle co-auteurs voor hun expertise en inbreng. In het bijzonder Jan Groen 
en Sandra de Zeeuw: dank dat jullie op zo’n enthousiaste manier jullie kennis met mij 
hebben gedeeld. Zonder jullie had ik de urodynamica nooit begrepen. Naast de fijne 
samenwerking was het ook altijd erg gezellig om bij jullie te buurten in het Furore lab 
op de 16e verdieping van het faculteitsgebouw. 
Dank aan alle mede arts-onderzoekers. Een speciaal woord voor mijn oud-kamer-
genoten voor hun steun en gezelligheid: Suzanne, Jos, Telma, Leonard en Jolanda. In 
het bijzonder Lionne: dank voor al je hulp met mijn laatste loodjes van mijn promotie! 
Uiteraard niet te vergeten alle andere oud-collega onderzoekers en A(N)IOSen, dank 
voor de afleiding en gezelligheid tijdens de lunches, borrels en sportieve uitdagingen. 
Ik kijk met veel plezier terug op o.a. de Alpe d’HuZes en (externe) lunches zoals bij 
“Ivy” (nu FG). Lisette (’t Hoen), oorspronkelijk gestart als mijn opvolger maar inmid-
dels alweer een tijd mijn voorganger, dank voor het voorzetten van de studies. Ik heb 
plezier beleefd aan je opgewekte werkwijze! Lieve Lisette (Elzinga-Tinke), we leerden 
elkaar kennen als collega’s maar werden al snel vriendinnen. Dank voor je steun tij-
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dens mijn onderzoeksperiode, maar zeker ook de jaren daarbuiten. Zometeen zijn 
we beiden mamma en huisarts! Ik kan me hier alleen maar ontzettend op verheugen. 
Lieve Frank en Femke, ontzettend bedankt voor de fantastische begeleiding in mijn 
laatste jaar als huisarts-in-opleiding en ook de warme en fijne periode die na mijn 
afstuderen volgde als jullie collega huisarts. Onder jullie supervisie heb ik mij op een 
veilige manier in alle aspecten van het ‘huisarts zijn’ kunnen ontwikkelen. Dit proef-
schrift is echter geen vrijbrief om alle patiënten met urogynaecologische klachten op 
mijn spreekuur te plaatsen hoor Fem! Ook dank aan alle lieve collega’s van het Me-
disch Centrum Oostvoorne voor de gezellige momenten van overleg, met altijd veel 
humor maar zo nodig ook een luisterend oor. Door al deze aspecten rij ik meerdere 
keren per week met veel plezier richting Oostvoorne.
Lieve vriendinnen en vrienden - you know who you are - dank aan jullie allemaal 
voor jullie interesse en steun, maar bovenal voor de afleiding die jullie me gaven 
tijdens de momenten dat we samen waren. Het relativerende effect van een gezellig 
samenkomen is voor mij van groot belang geweest om de moed erin te houden en dit 
proefschrift af te ronden. De laatste tijd heb ik onze dates omwille van ‘die promotie’ 
soms moeten verzetten of afzeggen; dank voor jullie geduld en begrip hiervoor! Lieve 
Reshmi, al sinds groep 5 zijn wij vriendinnen. Ook als we elkaar even een tijdje niet 
hebben gezien blijft een half woord voor ons genoeg! Wat mooi dat we nu, 25 jaar 
later, allebei onze doctorstitel hebben behaald. Dank je dat je me zo goed kent en 
aanvoelt. Ik sta vandaag steviger in mijn schoenen met jou naast mij! 
Lieve (schoon)familieleden, dank voor al jullie interesse in mijn verhalen over mijn 
onderzoek en opleiding. Ook heel veel dank voor jullie begrip wanneer ik door kli-
nisch verantwoordelijkheden, werk of een wetenschappelijke deadline moest afzeg-
gen voor familiebijeenkomsten. 
Lieve Joop en Wietske, pa en ma, Femke en Robert, jullie zijn de beste schoonfamilie 
die ik me maar had kunnen wensen! Ontzettend veel dank voor al jullie ondersteuning 
op juist al die verschillende fronten buiten mijn werk. 
Lieve Flora en Chin Kie, mijn lieve ouders, ontzettend bedankt voor jullie onvoor-
waardelijke steun, interesse, liefde en bezorgdheid! Jullie onuitputtelijke behulpzaam-
heid om mij te ondersteunen en voor mij klaar te staan hebben mij enorm gesterkt. Liz, 
mijn lieve zusje: natuurlijk sta jij naast mij! Ontzettend bedankt voor je interesse, steun 
en luisterend oor. Misschien iets vanzelfsprekend daar we zo close zijn als zusjes, maar 
extra fijn dat je als mede-promovendus het wel en wee van een onderzoeker begrijpt. 
Ik ben ontzettend trots op jou. Het is voor mij een geruststellende gedachte dat je 
tijdens mijn verdediging aan mijn zijde staat. Binnenkort aan jou de beurt!
En last but alles behalve least, liefste Ad, bestaat er eigenlijk een overtreffende trap 
van duizendmaal dank? Ik ben je immens dankbaar voor al je hulp en steun in mijn 
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- Classical Methods for Data-analysis
-  2 day course Dutch Cochrane Center Development of 
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- Department Journal Club
- Department “refereeravond”
- Department “promovendi-avond”
- Department Campbell Club
- Department “heilig onderwijsuur”
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-  Speaker podium presentation: Invasive versus non-invasive 
evaluation of successful Pro-ACT treatment in post radical 
prostatectomy stress urinary incontinence 41st annual meeting of 
the International Continence Society (ICS), Glasgow UK, 2011
-  Speaker poster presentation: Evaluation of ProACT treatment 
in male stress urinary incontinence after radical prostatectomy: 
invasive and non-invasive urodynamics       27th Annual European 






-  Voorjaarsvergadering Nederlandse Vereniging voor Urologie 
Speaker: Invasieve en niet-invasieve urodynamica van 
ProACT behandeling bij stress urine-incontinentie na radicale 
prostatectomie
-  Externe refereeravond Erasmus MC 
Speaker: Evaluatie van ProACT behandeling bij mannen met 
stress urine incontinentie na radicale prostatectomie: invasieve 
en non-invasieve urodynamica
-  Voorjaarsvergadering Nederlandse Vereniging voor Urologie 
peaker: Validatie van twee veelgebruikte vragenlijsten: 
Nederlandse Urogenital Distress Inventory (UDI-6) en 
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-  PKV (“Practicum Klinische Vaardigheden”) medical interns topic: 
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“From where I stand, 
the sun is shining all over the place.”
